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SUMMARY 
 
Keywords: Streptococcus agalactiae, genetic lineages, capsular switching 
 
Streptococcus agalactiae (group B streptococci, GBS) is primarily a colonizing 
agent of the genitourinary and gastrointestinal tracts of a significant proportion of the 
human population. It is, however, well established as a leading cause of bacterial sepsis 
and meningitis in neonates and is increasingly associated with invasive infections in 
adults. 
While vertical transmission is commonly accepted to be the cause of early-onset 
disease, the source of bacterial strains causing infection in the late-onset period is less 
well understood. Administration of intrapartum antimicrobial prophylaxis to colonized 
women has resulted in a striking decline in early-onset and maternal GBS disease, but 
late-onset infections have mostly remained unchanged. Moreover, antimicrobial 
prophylaxis raised concerns as to selection and emergence of GBS resistant strains and 
alternative prevention strategies have focused on the development of vaccines that hold 
promising, although still preliminary results. 
The aim of the work presented in this thesis was to characterize the population 
structure of GBS in Portugal, and to assess the genetic diversity of isolates recovered 
from vaginal colonization and invasive disease in different age groups, to contribute to 
the global epidemiology of GBS and our understanding of GBS population biology. To 
this end a set of common techniques was chosen, including serotyping, antimicrobial 
susceptibility testing, pulsed field gel electrophoresis (PFGE), multilocus sequence 
typing (MLST) and surface protein gene profiling. In combination, these methods 
allowed the identification of the main genetic lineages circulating in Portugal and 
Barcelona, providing the means for an appropriate comparison of both.  
These studies started with the comparison of 64 isolates recovered from invasive 
infections in newborns in the Lisbon area with 269 isolates colonizing women in the 
third trimester of pregnancy, from the same period. The genetic lineages defined by 
both PFGE and MLST identified very diverse populations with reported differences in 
the prevalence of serotypes and clones in carriage and invasive disease. A major finding 
concerned the identification of an unusually high proportion of ST24 isolates among 
serotype Ia, further strengthened by the independent study of another population (212 
neonatal isolates) from the Barcelona area. Despite the geographic distance, both studies 
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from Barcelona and Lisbon revealed extensive similarity in terms of clonal structure 
and genetic lineages. The high prevalence in both the studies of a particular lineage 
serotype Ia, defined by ST24 and the surface protein gene bca, highlighted the 
importance of local dynamics, indicating that genetic evolution of GBS presents with a 
geographic structure and may depend on local factors. 
The subsequent analysis of 225 isolates recovered from non-pregnant adults in 
Portugal revealed a GBS population dominated by a more diverse clonal composition 
when compared to that of neonates, consistent with the broader spectrum of disease 
presentation in these patients and consequent multiplicity of genetic lineages. Invasive 
disease in this population increased with age and was more frequent among men. The 
dominance of serotype Ia in this population, regardless of age, highlighted the 
importance of this serotype in GBS pathogenesis as a leading cause of invasive 
infections in adults, not reported elsewhere but already noted among neonatal infections 
in the Iberian Peninsula. Furthermore, the high prevalence of ST24 in all these studies, 
as opposed to rare descriptions elsewhere, suggested that this lineage had enhanced 
invasiveness and was probably expanding as a regionally successful clone that may 
disseminate more globally. 
Macrolide resistance rates in Portugal did not show significant trends, even if 
macrolides have been used in intrapartum prophylaxis increasing the selective pressure 
on GBS. Macrolide resistance is disseminated in Portugal by both a multiclonal 
mechanism resulting from the spread of resistance genes throughout most serotypes and 
genetic backgrounds, as well as by clonal expansion of particular lineages, such as the 
serotype V ST1/alp3. 
One of the main purposes of the analysis of a significant number of GBS isolates 
was their classification into lineages sharing the same genetic background, which would 
allow the inference of genetic relationships between strains and their contextualization 
in the global epidemiology of GBS. However, the associations of phenotype-genotype 
or between different genetic traits were never absolute, highlighting the role of 
horizontal genetic transfer in the evolution of GBS. Capsular switching was anticipated 
to occur frequently within GBS, even though this species is not recognized to be 
naturally competent for the acquisition of foreign DNA. Substantial evidence provided 
by the epidemiological studies performed on the Portuguese GBS collections drove the 
search for capsular transformants within these populations. The results obtained 
confirmed the existence of capsular switching in GBS, but questioned the high 
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frequency of these events estimated from previous studies. Serotyping errors probably 
justified the overrepresentation of capsular switching in epidemiological studies. The 
mechanism for these genetic transfer events involved the replacement of the whole 
capsular locus instead of the previously proposed genetic transfer of only the serotype-
specific genes. 
Globally, the results presented in this thesis suggest that GBS has an apparent 
remarkably stable, both temporally and geographically, clonal structure. Against this, 
background diversification is ongoing and can depend on local factors. Capsular 
switching is likely contributing to diversification, however not as frequently as initially 
thought and may impact on the vaccine formulations currently under development. 
Despite increasing information on maternal colonization and invasive disease, a better 
understanding of colonization in adults and natural reservoirs of GBS is required for the 
appropriate management of the GBS infections. 
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RESUMO 
 
Palavras-chave: Streptococcus agalactiae, linhagens genéticas, transformação capsular  
 
Streptococcus agalactiae (estreptococos do grupo B, GBS) é maioritariamente 
um agente colonizador dos tratos genito-urinário e gastrointestinal de uma proporção 
significativa da população humana. É, no entanto, reconhecido como uma das principais 
causas de sépsis e meningite bacteriana em recém-nascidos, e crescentemente associado 
a infecções invasivas em adultos. 
Enquanto a transmissão vertical é normalmente aceite como causa do 
aparecimento precoce da doença, a origem das estirpes bacterianas que causam infecção 
no período tardio é menos bem compreendida. A administração de profilaxia 
antimicrobiana intraparto a mulheres colonizadas resultou num declínio acentuado das 
infecções por GBS de início precoce e materna, mas as infecções de início tardio, na sua 
maioria, mantiveram-se inalteradas. Mais ainda, a profilaxia antimicrobiana levantou 
preocupações quanto à selecção e ao aparecimento de estirpes de GBS resistentes e as 
estratégias alternativas de prevenção têm-se focado no desenvolvimento de vacinas com 
resultados promissores, embora ainda preliminares. 
O objectivo do trabalho apresentado nesta tese foi caracterizar a estrutura da 
população de GBS em Portugal e avaliar a diversidade genética das estirpes isoladas de 
colonização vaginal e doença invasiva em diferentes faixas etárias, de forma a 
contribuir para a epidemiologia global de GBS e para a compreensão da biologia 
populacional de GBS. Para atingir esse objectivo foi escolhido um conjunto de técnicas, 
incluindo a serotipagem, testes de susceptibilidade a antimicrobianos, electroforese em 
gel de campo pulsado (PFGE), “multilocus sequence typing” (MLST) e determinação 
de perfis de proteínas de superfície. Em combinação, estes métodos permitiram a 
identificação das principais linhagens genéticas que circulam em Portugal e Barcelona, 
fornecendo meios para uma comparação apropriada de ambas. 
Estes estudos começaram com a comparação de 64 estirpes isoladas de infecções 
invasivas em recém-nascidos na região de Lisboa com 269 estirpes de colonização em 
mulheres no terceiro trimestre de gravidez, no mesmo período. As linhagens genéticas 
definidas por PFGE e MLST identificaram populações muito diversificadas, com 
diferenças descritas na prevalência dos serótipos e clones, em colonização e doença 
invasiva. Uma constatação importante diz respeito à identificação de um número 
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excepcionalmente elevado de estirpes ST24 no serótipo Ia, reforçado pelo estudo 
independente de outra população (212 estirpes neonatais) da área de Barcelona. Apesar 
da distância geográfica, ambos os estudos de Barcelona e Lisboa revelaram uma enorme 
semelhança em termos da estrutura clonal e linhagens genéticas. A elevada prevalência 
em ambos os estudos de uma linhagem particular do serótipo Ia, definida pelo ST24 e 
pelo gene que codifica a proteína de superfície bca, salientaram a importância de 
dinâmicas locais, indicando que a evolução genética de GBS apresenta uma estrutura 
geográfica e pode depender de factores locais 
A análise subsequente de 225 estirpes isoladas de adultos, exceptuando grávidas, 
em Portugal revelou uma população de GBS dominada por uma composição clonal 
mais diversificada quando comparada com a de recém-nascidos, consistente com o 
espectro mais alargado de manifestações de doença nestes indivíduos e consequente 
multiplicidade de linhagens genéticas. A doença invasiva nesta população aumentou 
com a idade, sendo mais frequente entre os homens. A predominância do serótipo Ia 
nessa população, independentemente da idade, destacou a importância deste serótipo na 
patogénese da GBS como uma das principais causas de infecções invasivas em adultos, 
não relatada noutros locais mas já identificada nas infecções neonatais na Península 
Ibérica. Além disso, a elevada prevalência de ST24 em todos estes estudos, por 
oposição a raras descrições noutros locais, sugerem que esta linhagem tem maior 
capacidade invasiva e está provavelmente em expansão como um clone bem-sucedido a 
nível regional que pode disseminar mais globalmente. 
As taxas de resistência aos macrólidos em Portugal não apresentaram tendências 
significativas, ainda que os macrólidos sejam usados na profilaxia intraparto, 
aumentando a pressão selectiva sobre GBS. A resistência aos macrólidos está 
disseminada em Portugal, tanto por um mecanismo multiclonal que resulta na dispersão 
de genes de resistência na maior parte serótipos e clones, como pela expansão clonal de 
linhagens específicas, tais como a do serótipo V ST1/alp3. 
Um dos principais objectivos da análise de um número significativo de estirpes 
de GBS era a sua classificação em linhagens com o mesmo património genético, o que 
permitiria a inferência de relações genéticas entre estirpes, e a sua contextualização na 
epidemiologia global de GBS. Contudo, as associações fenótipo-genótipo ou entre 
características genéticas diferentes nunca foram absolutas, salientando o papel da 
transferência genética horizontal na evolução de GBS. Foi proposto que a 
transformação capsular ocorre frequentemente em GBS, apesar de esta espécie não ser 
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reconhecida como naturalmente competente para a aquisição de DNA exógeno. 
Evidências substanciais fornecidas pelos estudos epidemiológicos realizados nas 
colecções portuguesas de GBS levaram à pesquisa de transformantes capsular nessas 
populações. Os resultados obtidos confirmaram a existência de transformação capsular 
em GBS, mas questionaram a elevada frequência destes eventos, estimada em estudos 
anteriores. Erros de serotipagem provavelmente justificam a elevada representação de 
transformação capsular em estudos epidemiológicos. O mecanismo na base destes 
eventos de transferência genética envolveu a substituição de todo o locus capsular em 
vez da transferência genética de apenas os genes específicos do serótipo, proposta 
anteriormente. 
Globalmente, os resultados apresentados nesta tese sugerem que os GBS 
possuem uma estrutura clonal, extremamente estável, tanto geográfica como 
temporalmente. Por oposição, a diversificação do património genético é permanente e 
pode depender de factores locais. A transformação capsular provavelmente contribui 
para esta diversificação, porém não tão frequentemente quanto inicialmente se pensava 
e pode ter um impacto na formulação das vacinas actualmente em desenvolvimento. 
Apesar do aumento da informação sobre a colonização materna e a doença invasiva, 
uma melhor compreensão da colonização em adultos e dos reservatórios naturais de 
GBS é necessária para uma abordagem mais fundamentada das infecções por GBS. 
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THESIS OUTLINE 
 
The purpose of the work presented in this thesis was to obtain insights on 
different aspects of the molecular epidemiology of Streptococcus agalactiae with 
particular emphasis on invasive infections. 
Chapter 1 puts the problems addressed in the thesis into context, by briefly 
reviewing essential aspects of S. agalactiae disease and colonization, as well as of the 
impact of preventive strategies. The contribution of virulence factors and antimicrobial 
resistance on GBS epidemiology, the importance of surveillance and characterization of 
the isolates, as well as the major findings in recent years on the structure of the GBS 
population are also reviewed in this chapter. 
Chapters 2 to 5 address the phenotypic and genotypic characterization of the 
GBS isolated from colonization in pregnant women and invasive infections in newborns 
and non-pregnant adults.  
Chapters 2 and 3 present a detailed description of the epidemiology of GBS 
isolates recovered from invasive infections in newborns and colonization in pregnant 
women in Portugal, and of neonatal invasive infections in Barcelona, Spain, 
respectively. The small number of isolates recovered from invasive infections in 
neonates in Portugal was complemented by the study of homologous isolates from 
Barcelona, Spain, with the aim of evaluating if the GBS clonal structure in stable in the 
Iberian Peninsula. 
Chapters 4 and 5 provide a detailed description of the clonal structure of the 
GBS populations causing invasive infections in non-pregnant adults in Portugal. 
Chapter 4 addresses the analysis of two temporally and geographically clustered cases 
of GBS meningitis in adults, rare events that were thoroughly investigated as to their 
circumstances in the context of GBS invasive disease in Portugal. Chapter 5 consists in 
the characterization of the isolates recovered from invasive disease in non-pregnant 
adults in Portugal, in order to assess the main genetic lineages responsible for these 
infections, and to compare them to those involved in neonatal invasive infections. 
Chapter 6 provides unambiguous evidence for the existence of capsular 
switching in GBS, by recombinational events that imply the exchange of the entire 
capsular locus rather than switching restricted to capsule-specific genes, as previously 
proposed in the literature.  
xii 
Chapter 7 presents an integrated discussion of the major findings of the thesis, 
highlighting unsolved questions that could be addressed in the future follow-up of these 
investigations. 
 
Chapters 2-6 can be read independently. They are reproductions of the following 
publications: 
Chapter 2: Martins, E. R., M. A. Pessanha, M. Ramirez, J. Melo-Cristino, and the 
Portuguese Group for the Study of Streptococcal Infections. 2007. Analysis of group B 
streptococcal isolates from infants and pregnant women in Portugal revealing two 
lineages with enhanced invasiveness. J Clin Microbiol 45: 3224-9. 
 
Chapter 3: Martins, E. R., A. Andreu, P. Correia, T. Juncosa, J. Bosch, M. Ramirez, 
and J. Melo-Cristino. 2011. Group B streptococci causing neonatal infections in 
Barcelona are a stable clonal population: 18-year surveillance. J Clin Microbiol 49: 
2911-2918. 
 
Chapter 4: Martins, E. R., C. Florindo, F. Martins, I. Aldir, M. J. Borrego, L. Brum, M. 
Ramirez, and J. Melo-Cristino. 2007. Streptococcus agalactiae serotype Ib as an agent 
of meningitis in two adult nonpregnant women. J Clin Microbiol 45: 3850-2. 
 
Chapter 5: E. R. Martins, J. Melo-Cristino, M. Ramirez, and the Portuguese Group for 
the Study of Streptococcal Infections. 2011. Dominance of serotype Ia among group B 
streptococci causing invasive infections in non-pregnant adults in Portugal. (Submitted 
to Journal of Clinical Microbiology) 
 
Chapter 6: Martins, E. R., J. Melo-Cristino, and M. Ramirez. 2010. Evidence for rare 
capsular switching in Streptococcus agalactiae. J Bacteriol 192: 1361-9. 
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 1.  Streptococcus agalactiae  
Streptococcus agalactiae is a Gram-positive bacterium, historically associated to 
bovine mastitis and dairy sources under the designation of Streptococcus mastiditis 
(101). It was first identified as group B streptococci (GBS) in 1933, when Rebecca 
Lancefield published her studies on serological differentiation of streptococci (101). 
GBS was later proposed as an occasional causative agent of puerperal infections (100), 
and in 1938 it was recognized as an important human pathogen responsible for multiple 
infections (63). It was not until the 1970s that GBS was acknowledged as a leading 
cause of neonatal invasive infections (21) and since the 1990s it has also been 
increasingly associated with invasive infections in non-pregnant adults (54). Despite its 
unquestionable importance as a human pathogen, GBS is, however, mainly a colonizing 
agent of the gastrointestinal and genitourinary tracts of a significant proportion of the 
human population (156). 
 
 
1.1 Group B streptococcal disease 
 
Neonatal infections 
The onset of GBS infections takes place very early in infancy, usually within the 
first week of life, in which case it is designated of early-onset disease (EOD). Late-
onset disease (LOD) develops between one week and three months of age (156). 
Maternal carriage is a major risk factor for neonatal GBS disease, which is influenced 
by the degree of bacterial colonization; women with heavy colonization are more likely 
to have symptomatically infected infants and heavily colonized infants are more likely 
to develop invasive disease (106).  
Whereas EOD and LOD can differ in clinical presentation, mode of transmission 
and risk factors for disease, the most frequent clinical presentations of invasive disease 
in neonates are pneumonia, bacteraemia and meningitis. The majority of EOD cases 
occur within the first 24 hours after birth (156). The onset of disease is associated with 
the presence of GBS in the genital tract of the mother, and transmission is thought to 
occur vertically due to an ascending infection during the course of pregnancy or passage 
through the birth canal (156). Even though perinatal transmission can occur across 
intact membranes, both premature and prolonged rupture of membranes increase the 
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risk of GBS acquisition (157). Aspiration of contaminated amniotic fluid then leads to 
colonization of the airways of the neonate and is rapidly followed by the development 
of pneumonia. Breaching of the pulmonary mucosal barrier leads to the entry of GBS 
into the bloodstream and to the development of severe sepsis in some infants (85, 156).  
More than half reported cases of neonatal GBS disease now occur during the 
late-onset period (25). The pathogenesis of LOD is less well understood, although some 
cases also suggest a maternal source, probably reflecting acquisition of the 
microorganism during passage through the birth canal (156). Ingestion of contaminated 
breast milk has also been proposed as a possible maternal source for LOD (10). Even 
though nearly 50% of mothers of infants with LOD were found to carry the same GBS 
serotype as that causing infection in their infants, the source of infection in other infants 
is unclear (156). Nosocomial and horizontal transmission by hospital and community 
sources are probably involved in some cases of LOD, but the risk factors are not well 
understood (71). LOD presents with meningitis and bacteraemia without a focus as 
predominant clinical syndromes; osteoarticular infections, urinary tract infections, and 
pneumonia are less frequent (157). Meningitis develops when the entry of bacteria into 
the bloodstream is followed by the invasion of the cerebrospinal fluid. Severe long-term 
sequelae such as blindness, deafness and global developmental delay occur in a 
significant number of neonatal meningitis survivors (50).  
 
 
 
        FIGURE 1.1 Stages of neonatal GBS infection. Adapted from (44). 
 
 
Infections in pregnancy 
Pregnant women are at a higher risk of disease because GBS vaginal 
colonization is a risk factor for maternal peripartum infection (96). The clinical 
presentations of disease among pregnant women are diverse, and include urinary tract 
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infection (usually asymptomatic bacteriuria), endometritis, intra-amniotic infection 
(chorioamnionitis), wound infections associated with caesarean delivery or episiotomy, 
and, less frequently, puerperal sepsis and meningitis (96, 157). GBS can cause stillbirth 
in some instances, and evidence points to a causative role of these microorganisms in 
pre-term delivery (96, 147). An active, laboratory-based surveillance study for GBS 
infections in the United States revealed that invasive infections among pregnant women 
accounted for 6.3% of all adult cases of invasive infection (155). 
  
Infections in non-pregnant adults 
In the past two decades GBS has been increasingly associated with invasive 
disease in non-pregnant adults (9, 130, 144, 160). Such infections increase with age, 
occur more frequently among nursing facility residents than in the community, and are 
considered responsible for substantial morbidity and mortality, with case-fatality rates 
of nearly 25% (53, 76). Most cases occur in individuals with significant underlying 
conditions; diabetes mellitus being is the most frequent co-morbidity, typically present 
in approximately 30% of non-pregnant adults with GBS disease (54, 82). Other risk 
factors have been detailed in recent years and include liver cirrhosis, heart and 
neurologic disease, cancer and immunosuppressive conditions (82).  
The clinical spectrum of GBS disease in adults is broad, including more 
frequently bacteraemia with or without sepsis, skin and soft tissue, osteoarticular and 
urinary tract infections (53). Less frequent clinical presentations include meningitis and 
endocarditis that are, however associated with significantly higher morbidity and 
mortality (43, 152). The possible emergence of GBS as a respiratory pathogen 
associated with cystic fibrosis has also been proposed in a recent report (52). Recurrent 
GBS infection was identified among adults, and suggested to be mostly caused by 
relapse, but an association of relapse with persistent carriage or poor clinical 
management of primary infection was not determined (74). Nosocomial disease is also 
raising concerns as more than 20% of patients with GBS invasive infection are thought 
to have acquired the bacteria from hospital settings (82).  
The diversity of clinical presentations and poor outcome of invasive disease in 
adults are in support for the complexity of the pathogenesis of GBS infections. GBS 
invasive infections are more frequent in the elderly, probably reflecting the impact of 
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risk factors that increase with age such as co-morbidities, altered integrity of anatomical 
barriers and immune senescence (49).  
 
 
1.2 Colonization and Transmission 
The gastrointestinal tract serves as the natural reservoir for GBS and is likely to 
be the source of vaginal and rectal colonization. Approximately 10-30% of pregnant 
women are colonized with GBS in the vagina or rectum (147), although the colonization 
can be transient, chronic or intermittent (72). As maternal GBS carriage in the 
gastrointestinal and/or genital tracts is a prerequisite for EOD, the different prevalence 
of maternal GBS colonization could help choose preventive strategies. In most 
European countries, the prevalence of GBS carriage among pregnant women varies 
between 6.5 and 36%, with most countries reporting colonization rates of 15-20% (6, 
174).  
Even though colonization among non-pregnant adults is less well known, 
vaginal and rectal colonization of healthy young and elderly adults have been reported 
at levels (20-34%) similar to those observed during pregnancy (13, 51, 123). GBS was 
also found to be likely transmitted between sex partners during pregnancy (61), yet 
multiple transmission modes may exist (123). An increasing number of studies also 
suggest that limited interspecies GBS transmission is likely to occur between humans 
and their livestock (125, 139, 163), further proposing a framework for GBS as a 
possible zoonotic infection, which can have significant public health implications (125). 
 
 
1.3 Prevention strategies - advantages and drawbacks 
Although prevention of GBS neonatal infections by intrapartum antibiotic 
prophylaxis (IAP) was suggested as early as the mid 1960s, and a selective screen for 
carriage in pregnant women was proposed a few years later (73), it was not until 1996 
that guidelines for the prevention of GBS neonatal infections were published in the 
United States (27). These guidelines identified the candidates for IAP according to 
either a screening-based or a risk-based strategy (27), and this approach led to a 65% 
decrease in the incidence of EOD in the United States (155). A later update of the 
national guidelines in 2002 replaced the recommendation for either of these alternatives 
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by the recommendation for the universal culture-based screening of all pregnant women 
for GBS vaginal colonization at 35 to 37 weeks of gestation, and the administration of 
IAP to carriers (28). As expected, an additional reduction in the incidence of EOD was 
shown by active population-based surveillance after the guidelines were issued (26, 
144). 
However, the screening approach for the prevention of GBS neonatal disease 
has proved challenging. Efforts to reduce missed opportunities of prevention should 
include the appropriate clinical management of women whose GBS colonization status 
is unknown, particularly those at risk of preterm delivery; and the identification of 
factors that contribute for false negative screening results (180, 181).  
While in the United States the incidences of EOD and LOD have been closely 
monitored in the last decades, the same did not happen in Europe, with most countries 
lacking nationwide or local protocols for surveillance and prevention of neonatal GBS 
disease. By 1999, only 4 out of 29 European countries had available national guidelines 
for the prevention of neonatal GBS infections (174). Later, as more countries set up 
prevention protocols, decreasing incidences of EOD were reported (39). Since 2004 
Portugal relies on a protocol for screening and prevention of GBS perinatal disease 
issued by the neonatology section of the Portuguese Society of Paediatrics (2), due to 
the lack of guidelines from national health authorities. Subsequently, a study based on 
voluntary report of GBS neonatal disease in Portugal described a reduction in the 
incidence of disease of nearly 40%, as well as of the case-fatality rates (135), similarly 
to what had been observed in other European countries (4, 8, 59, 110, 186). 
Despite the fact that universal screening policies and IAP have reduced 
significantly the high morbidity and mortality rates associated with EOD, while also 
contributing for the prevention of invasive infections in pregnant women (155), several 
problems remain regarding the management and prevention of GBS neonatal infections. 
First, this strategy does not prevent LOD, although more than half of reported cases of 
neonatal GBS disease now occur during the late-onset period (25), with some countries 
actually describing increasing incidences of LOD (138). It has been suggested that IAP 
might delay GBS disease onset, rather than prevent it, resulting in increased rates of 
LOD (25). Secondly, the widespread use of antibiotics in intrapartum prophylaxis may 
lead to potentially adverse or unintended effects of GBS prevention efforts, including 
allergic or anaphylactic reactions to the antimicrobials used in IAP, emergence of GBS 
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strains resistant to standard therapies, and increasing incidence of neonatal infections 
caused by pathogens other than GBS (153).  
Penicillin is the agent of choice for IAP because of effective transplacental 
crossing, narrow-spectrum of antimicrobial activity and low cost (6). Although GBS is 
considered universally susceptible to penicillin, recent studies from Japan (89) and the 
United States (36) reported reduced penicillin susceptibility in a limited number of both 
non-invasive and invasive isolates, respectively. These isolates showed increased 
minimum inhibitory concentrations (MICs) to penicillin, mostly associated to mutations 
in a penicillin-binding protein (PBP-2x), yet the clinical significance of these findings is 
unknown. 
Additionally, the emerging frequency of GBS resistance to erythromycin and 
clindamycin, antibiotics frequently given to pregnant women with documented 
penicillin allergy, has been reported worldwide (6, 24, 158). In support of these 
findings, the 2002 guidelines issued from the Centres for Disease Control and 
Prevention (CDC) recommended susceptibility testing of isolates from IAP candidates 
with penicillin allergy (28). Additionally, increasing resistance rates to erythromycin 
and clindamycin in both invasive and non-invasive infections among non-pregnant 
adults have also been described in recent years (9, 24, 83).  
Concern has been raised that the use of IAP for prevention of GBS disease could 
result in increasing incidence of early-onset infections due to microorganisms other than 
GBS (154), particularly antimicrobial resistant Escherichia coli (90). However, a direct 
assessment of causality between IAP exposure and risk of non-GBS neonatal sepsis has 
not been established (133), nor has the association between IAP and early-onset sepsis 
due to ampicillin-resistant E. coli (90).  
Whereas the improved use of IAP has resulted in a substantial reduction in 
early-onset GBS disease, it does not prevent late-onset neonatal infections, nor does it 
address GBS disease in non-pregnant adults (153). New strategies, such as the 
development of vaccines against GBS, continue to hold the most promise for further 
prevention of GBS disease. GBS vaccines will be discussed in section 4. 
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2. Virulence factors 
Although GBS usually resides as a commensal microorganism in genital and 
gastrointestinal tracts, it does have the ability to access several other niches such as the 
intrauterine compartment and multiple organs. This indicates that GBS has a survival 
advantage by being efficiently able to adapt to different host environments during the 
course of infection (146). The development of GBS disease reflects successful bacterial 
colonization and the capacity to penetrate host physical barriers and requires appropriate 
expression and regulation of surface-associated and secreted virulence factors that 
mediate host-cell interactions, including adherence to host epithelial surfaces, invasion 
across epithelial and endothelial barriers, and interference with innate immune clearance 
mechanisms (116). Table 1.1 summarizes some key virulence factors of GBS, detailing 
their proposed pathogenic mechanisms, critical for its ability to cause disease. 
This section will address briefly the GBS virulence factors that contribute for the 
epidemiological characterization of GBS isolates.  
  
TABLE 1.1 Main virulence factors of GBS. Adapted from (44, 108, 137, 146).  
a
 PMN - polymorphonuclear (leukocytes) 
b
 ECM - extracellular matrix 
c GPI - glycosylphosphatidylinositol
Virulence factor Genes Molecular or cellular action Proposed contribution to pathogenesis 
Polysaccharide capsule  cpsA-L  
 neuA-D 
Impairs complement C3 deposition and activation 
Masks pro-inflammatory cell wall components 
Decreases immune recognition, perhaps through 
molecular mimicry of host sialic acid epitopes 
Blocks opsonophagocytic clearance, preventing the 
recognition of GBS through molecular mimicry of host-
cell surface glycoconjugates 
Delays neutrophil recruitment   
β-Haemolysin/cytolysin   cylE Forms pores in cell membranes 
Induces  inflammatory response and apoptosis  
Triggers cytokine release 
 
Direct tissue injury 
Penetration of epithelial barriers 
Induction of sepsis syndrome 
Phagocytic resistance  
Impairs cardiac and liver function 
Hyaluronate lyase   hylB Cleaves hyaluronan  Promotes spread through host tissues during infection 
Impairment of leukocyte trafficking 
C5a peptidase  
 
 scpB Cleaves human  complement C5a 
Binds fibronectin 
 
Inhibits PMNa recruitment 
Epithelial adherence and invasion by binding to ECMb 
fibronectin  
CAMP factor   cfb Forms pores in host-cell membrane 
Binds to GPIc anchored proteins  
Binds to IgG, IgM 
Direct tissue injury 
Impairment of antibody function 
C protein (α and β components) bca (α) 
bac (β) 
Binds epithelial cells 
Blocks intracellular killing by neutrophils  
Non-immune binding  of IgA 
Epithelial cell adherence 
Epithelial cell invasion 
Resistance to phagocytic clearance 
Alpha-like protein (Alp) family bca, eps, rib, 
alp2, alp3 
Binds epithelial cells 
Suffers antigenic variation as evasion mechanism of 
antibody detection 
Epithelial cell adherence 
Epithelial cell invasion 
Fibrinogen binding proteins A and B  fbsA 
 fbsB 
Binds ECM fibrinogen through repetitive structure 
motifs 
 
ECM attachment 
Epithelial adherence 
Promotes entry of GBS into host cells 
Pili PI-1  
PI-2a or PI-2b 
Promotes resistance to antimicrobial peptides by an 
unknown mechanism 
Promotes adherence of GBS to host cells 
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2.1 Capsule 
The majority of GBS isolates recovered from human infections is encapsulated. 
The capsule is a major virulence determinant of GBS, being responsible for resistance 
to opsonophagocitic killing and phagocytosis, as well as for the inhibition of 
complement system clearance (44). 
GBS capsular polysaccharides (CPS) are predominantly composed of repeating 
units containing four elements: glucose, galactose, N-acetylglucosamine and sialic acid, 
the terminal sugar on the side chain of all serotypes. Serotypes VI and VIII are an 
exception to this composition by lacking the N-acetylglucosamine and serotype VIII has 
an additional ramnose residue (112). The biochemical and immunological properties of 
the GBS polysaccharide have been extensively studied. In 1987, the role of the GBS 
capsule in virulence was evaluated in a rat model of neonatal infection, by showing that 
a non-capsulated mutant of GBS presented significantly reduced virulence as compared 
to the encapsulated strain (150). The importance of the capsular sialic acid for bacterial 
evasion of host mechanisms was also demonstrated when an encapsulated strain lost its 
virulence after removal of the sialic acid in a neonatal rat model of lethal GBS infection 
(188). 
According to the chemical composition, structure, and serological properties, the 
GBS capsular polysaccharides are classified into nine distinct serotypes: Ia, Ib and II-
VIII (112). The polysaccharide capsule is encoded in a gene cluster consisting of a 
central group of genes that encode serotype-specific glycosyltransferases and 
polymerases, which are flanked by genes conserved across all serotypes. The genes 
upstream of the serotype-specific region encode enzymes that synthesize and activate 
sialic acid, and the genes downstream are hypothesized to function in export of the 
polysaccharide capsule (32). The capsule gene clusters of all nine GBS serotypes have 
been described (Figure 1.2) and shown to be both structurally and genetically closely 
related. Nevertheless, the amino acid sequences of proteins having similar functions in 
different capsular types were found to exhibit significant heterogeneity (31, 128).  
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FIGURE 1.2 Capsule gene clusters of the nine GBS serotypes. The colours inside each arrow indicate the 
degree of similarity of the amino acid sequence to those encoded by other open reading frames (ORFs). 
Black arrows indicate ORFs with higher BLAST homology to species other than GBS. A gap was 
introduced between genes cpsH-cpsI and cpsJ-cpsK to permit an alignment of corresponding open 
reading frames. Adapted from (31, 128). 
 
 
A detailed examination of the capsule biosynthesis clusters provided evidence 
for horizontal transfer of capsular genes that may have occurred by intra- and inter-
species recombination events, contributing to the genetic diversity of the CPS gene 
clusters. Furthermore, changes at the capsular locus were proposed to be driven by the 
equilibrium between the selective pressure imposed by host immunity, that lead to 
capsular variation, and the conservation of structural elements of a particular capsular 
polysaccharide that might be required for pathogenicity (18, 31). 
  
 
2.2 Surface proteins 
Surface proteins of GBS are likely to play important roles during different stages 
of infection, holding promise as vaccine components. Moreover, surface proteins are 
also interesting for the analysis of some major problems in medical microbiology, such 
as adherence to epithelial cells, interactions with human extracellular matrix or plasma 
proteins, and escape from the host immunity response (108). 
 
 
 
 
Ia 
Ib 
II 
III 
IV 
V 
VI 
VII 
VIII 
P Q 
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C protein (α and β components) 
Historically, the C protein was the first surface protein antigen identified in 
GBS. The subsequent characterization of this protein revealed that it was composed of 
two protein components: the trypsin-resistant α protein and the trypsin-sensitive β 
protein, both capable of eliciting protective immunity (131). The α-C component 
mediates invasion of human epithelial cells, by promoting adherence and internalization 
in epithelial cells (168). The β-C component is a cell-surface receptor which binds the 
Fc portion of human immunoglobulin A (IgA), interfering with opsonophagocytosis and 
effective clearance (136). The two components of the C-protein are independently 
expressed on the bacterial cell surface; a particular strain may express either or both α 
and β antigens, yet the reason why they are often expressed together remains elusive 
(108). Furthermore, the phenotypic detection of the α or β protein antigens was 
considered of limited interest because a significant number of GBS strains does not 
express either one of them on their surface (84).  
Later, sequencing of the α protein gene bca revealed the presence of a large 
region composed of tandem repeating units, identical at the nucleotide level, and 
defining protective epitopes at the surface of GBS (132). The detection of yet another 
gene in the same genomic locus of bca resulted in the identification of the Rib protein, 
having an overall similar structure and sequence with the α protein (184), and leading to 
the recognition of a novel family of bacterial surface proteins, the alpha-like protein 
(Alp) family. 
 
Alpha-like protein (Alp) family 
The Alp family consists of surface associated proteins of similar structure 
containing repetitive sequences that express protective epitopes. Four members of the 
Alp family were initially identified: the α, Rib, Alp2, and Alp3 proteins, and two more 
members, Eps and Alp4 proteins were later included (34). Genetic and immunological 
evidence indicates that the different Alp proteins are encoded by allelic genes, mutually 
exclusive, implying that a GBS strain expresses only one member of the family (97). 
Partial sequencing of the Alp family members revealed that these proteins have 
very stable sequences, varying very little in sequence between strains, except for the 
number of repeats (91). In spite of their stability, these proteins appear to have a 
chimeric structure, suggesting that the genes can recombine with each other and/or other 
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genes, and the current proteins known may have been selected for conferring superior 
fitness (108). 
For all members of the Alp protein family, the proteins were shown to vary in 
size among different clinical isolates, with the size of the protein being proportional to 
the number of repeats it contains (97). GBS suffers deletions in the repetitive region of 
the alpha-like proteins by a mechanism of antigenic variation that may provide a means 
for GBS to evade host immunity. Strains with fewer repetitions are though to have a 
selective advantage by escaping antibody mediated immunity due to the loss of 
protective epitopes that result in less antibody binding (67, 111). The average number of 
tandem repeats of the rib gene in invasive GBS recovered from neonates was shown to 
be smaller than that from adults, implying a distinct contribution of immunity toward 
this age-related variation (79). On the other hand, naturally occurring variants of Alp 
containing multiple repeats suggest that longer proteins enhance virulence in humans, 
probably due to an increased ability to colonize particular niches (68, 70).  
Being so, the average number of repeats in an Alp family protein represents the 
net result of the two conflicting selective pressures, on one hand bacterial virulence that 
favours proteins with many repeats, and on the other hand, host immunity that promotes 
selection of variants with fewer repeats. While immune selection results in rapid 
contraction of the repeat region, release from such selective pressure would allow 
expansion of the repeat region, which may be required for spread to a new host (108). 
 
 
2.3 Pili 
The presence of pilus-like structures in GBS was first described in 2005 (104). 
The genes encoding pili in GBS are located within two distinct loci in different regions 
of the genome, designated pilus-islands 1 and 2 (PI-1 and PI-2), the later presenting two 
distinct variants, PI-2a and PI-2b (149).  
Pili are composed of three subunits: a backbone protein, the bona fide pilin, and 
two ancillary proteins, a pilus associated adhesin and a component that anchors the pili 
to the cell wall. Both the polymerization and attachment of the pili to the peptidoglycan 
cell wall occur by sortase-dependent mechanisms (46). 
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FIGURE 1.3 Schematic representation of PI-1, PI-2a and PI-2b. The upper panel shows PI-1 and the 
same region in a pilus-negative GBS strain. Adapted from (169). 
 
 
Even though PI-1 is not present in all GBS strains, PI-2 is ubiquitously 
expressed. The sequences of the all three pilus-islands appear to be remarkably well 
conserved, with PI-2a being the only island to show some extent of variability (126). 
Nevertheless, and considering the variability observed in other pathogenic bacteria, it 
has been suggested that the expression of pili may be regulated in order to have a 
transient expression at the bacterial surface, thus avoiding the selective pressure of the 
host immune system. Another possible explanation is that the main environmental 
niches that GBS occupies in humans (lower gastrointestinal tract and vaginal mucosa) 
are relatively inert from an immunological standpoint, not providing a sufficient 
immune pressure to drive significant variability (126).  
While a specific function for pili has not been identified, these structures have 
been recognized to play a role in adherence, invasion and translocation of epithelial 
cells (94, 117, 143), and also as important for biofilm formation, all functions possibly 
conditioning tissue-tropism (119, 148).  
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3 Antimicrobial resistance in GBS 
 
3.1 β-lactams 
Penicillin and other β-lactam antibiotics covalently bind to and inactivate the 
bacterial proteins (penicillin-binding proteins, PBPs) involved in the formation of 
peptidoglycan by crosslinking its subunits in the bacterial cell wall. While in 
Streptococcus pneumoniae penicillin resistance involves the stepwise accumulation of 
mutations in the PBPs or, more frequently, the acquisition of foreign DNA that alters 
the PBP genes; in GBS, both invasive and colonizing isolates are considered universally 
susceptible to penicillin and ampicillin, and these are the first choice antibiotics for 
intrapartum prophylaxis as well as for treatment of GBS infections in all age groups 
(36). However, two recent studies have described reduced penicillin susceptibility in 
isolates recovered from both non-invasive and invasive infections. These isolates had 
mutations in a penicillin-binding protein (PBP-2x) resulting in increased MICs to 
penicillin (36, 89). While these findings raise concerns as to the possibility of 
emergence of penicillin resistance in GBS, their clinical impact is yet to be defined and, 
since these isolates have got to be found in significant numbers, they remain anecdotal 
cases. 
 
 
3.2 Macrolides 
Macrolides inhibit bacterial protein synthesis by binding to a specific location of 
the 50S subunit of the bacterial ribosome, thereby preventing its association to tRNA. 
Resistance to macrolides and related antibiotics in GBS presents as resistance to 
erythromycin alone or to both erythromycin and clindamycin, and occurs mainly by two 
mechanisms. The first involves target-site modification by a methylase encoded by an 
erm (erythromycin ribosome methylase) gene. The methylation of 23S rRNA at the 
erythromycin-binding nucleotide target alters the binding site for antibiotics on the 
ribosomes, thereby conferring broad-spectrum resistance to macrolides, lincosamides 
and streptogramin B (MLSB phenotype). Expression of MLSB resistance is either 
constitutive (cMLSB) or inducible (iMLSB). Inducible resistance occurs when the 
presence of an inducer antibiotic is necessary to allow the proper translation of the 
mRNA encoding the methylase. By opposition, in constitutive expression, the 
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methylase is produced even in the absence of an inducer antibiotic (105). In the second 
mechanism a membrane-bound pump, encoded by a mef (macrolide efflux) gene, is 
responsible for the active efflux of the antibiotic, causing resistance to 14- and 15-
membered ring macrolides while retaining susceptibility to lincosamides and 
streptogramin B (M phenotype) (105).  
In GBS the spread of genes belonging to the erm(B) class (23, 24, 58, 60, 64, 83, 
158) and, less frequently, to the erm(TR) subset of the erm(A) class (38) account for the 
vast majority of macrolide resistance. Moreover, most of these studies report an 
association between the erm(B) gene and cMLSB phenotype, while others describe also 
the association of iMLSB and the erm(TR) gene (24, 151). An additional erm gene, the 
erm(T), which had only been described in Streptococcus bovis, was recently found 
among iMLSB GBS strains (41). Among the isolates presenting the M phenotype, the 
mef(A) and mef(E) genes are responsible for macrolide resistance (24, 127). Despite the 
fact that antimicrobial resistance varies according to the geographical location, there has 
long been a wide consensus as to the association of serotype V and erythromycin 
resistance (24, 182). 
In Canada, a GBS isolate that was susceptible to erythromycin but resistant to 
clindamycin was shown to carry the lin(B) (or lnuB) gene, responsible for lincosamide 
nucleotidylation and previously described in Enterococcus faecium to confer resistance 
to lincosamides only (38). This resistance determinant was later found in Korea and 
suggested to be co-localized in the same mobile genetic element as the erm(B) gene 
(158). In contrast, GBS strains from New Zealand were found to be simultaneously 
resistant to lincosamide and streptogramin A, giving rise to the proposal of a new LSA 
phenotype (118). The presence of the LSA phenotype in different GBS clones suggested 
a horizontal source of the resistance determinants, although a conjugative transfer of 
resistance traits could not be detected. Additionally, no known genes conferring 
resistance to lincosamides or streptogramin A antibiotics were found (118). This 
phenotype has also been detected in Taiwan (183) and Korea (177). 
 
 
3.3 Tetracycline 
Tetracycline inhibits bacterial protein synthesis by preventing the association of 
tRNA with the bacterial ribosome (30). In GBS, resistance to this antibiotic is nearly 
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ubiquitous and is most frequently due to a protein encoded by tet(M) or tet(O), which 
protects the ribosome from the action the tetracycline. Less common tet(K) or tet(L) 
genes encode a tetracycline efflux pump (30).  
Whereas tet(M) is the most frequent tetracycline resistance determinant among 
GBS isolates recovered from human infections, tet(O) is common among those bacteria 
isolated from bovines (42, 47). Other unusual ribosomal protection genes tet(T) and 
tet(W) have also been found among GBS isolates from human infections (151).  
Tetracycline is not usually used for the treatment of streptococcal infections. 
However, surveillance of tetracycline resistance is important because the genetic 
elements carrying tet genes are often the same that carry genes encoding resistance to 
macrolides, lincosamides and chloramphenicol (30). An association between the 
macrolide resistance gene erm(B) and either the presence of tet(M) in human or tet(O) 
in bovine isolates was found, supporting the importance of horizontal gene transfer for 
antimicrobial resistance evolution in GBS (47). Even though many studies have found 
an association between tet and erm genes pointing to their carriage by the same 
transposons and also suggesting the epidemic spread of resistant clones (64, 145, 151), 
in others tetracycline resistance was not linked to erythromycin resistance, indicating an 
independent dissemination of resistance (35). 
 
 
3.4 Quinolones 
The quinolones target DNA gyrase and topoisomerase IV, which are involved in 
the supercoiling of bacterial DNA that is essential to cellular processes such as DNA 
replication and transcription. Resistance to fluoroquinolones arises mainly due to target 
gene modification by mutation, yet the acquisition of a single mutation does not usually 
confer significant fluoroquinolone resistance. Rather, resistance is a cumulative process, 
with increasing numbers of mutations generally correlating with higher MICs. Thus 
mutations that confer fluoroquinolone resistance occur in internal regions called the 
quinolone resistance-determining region (QRDR) of the genes gyrA and gyrB 
(encoding the gyrase subunits) and parC and parE (encoding the topoisomerase IV 
subunits). While gyrA and parC mutations are frequent, changes in gyrB and parE also 
occur but are less common (189).  
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GBS were uniformly susceptible to quinolones until 2003, when three isolates 
highly resistant to multiple quinolones were described in Japan, due to double-point 
mutations in the QRDR of gyrA and parC (88). Also in a report from Japan, high 
resistant rates to quinolones were later observed, particularly among invasive disease in 
non-pregnant adults (31.4%) and significantly associated to serotype Ib (134). Another 
survey from the United States identified 5% of the isolates as being resistant to 
levofloxacin, and suggested that healthcare-associated spread had occurred, as an 
association with prior quinolone therapy was observed (185).  
 
 
3.5 Chloramphenicol 
Chloramphenicol inhibits protein synthesis by specifically blocking the 50S 
subunit of the bacterial ribosomes. Resistance to this antibiotic is generally due to the 
synthesis of the enzyme chloramphenicol acetyltransferase, encoded by the gene cat, 
which inactivates the antibiotic by chemical conversion, losing the ability to bind to the 
ribosomes. In GBS, both chromosomally integrated through transposons and plasmid 
carried cat genes have been detected (173). 
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4. Vaccines 
Development of a vaccine as a prophylactic measure is the most promising 
approach to the prevention of GBS infections, given the potential adverse effects of IAP 
discussed previously, as well as the need for effective prevention of LOD and invasive 
disease in non-pregnant adults (48, 187).  
The rationale for the development of a GBS vaccine was experimental and 
clinical evidence that specific antibodies directed against surface structures of the 
bacteria are protective (187). However, it is important to note that most pregnant 
women (85-90%) lack protective antibodies at the time of delivery (90). A maternal 
GBS vaccine given before or during pregnancy could confer immunity to peripartum 
maternal infection as well as passive immunity to the newborn due to efficient transport 
of protective IgG antibodies through the placenta (156, 187). Additionally, it is thought 
that immunization of pregnant women and their infants can have a herd effect, 
providing additional health benefits among non-vaccinated members of a population, 
particularly the adults at high risk for GBS disease (159). 
The investigation regarding immunization against GBS goes back to the 1960s, 
when Rebecca Lancefield showed that capsular polysaccharide (CPS) specific 
antibodies have a protective role for GBS infection in mice (102). Further studies 
revealed that immunization with purified CPS alone was safe and well tolerated, 
however insufficiently immunogenic, suggesting that conjugation with a carrier protein 
might elicit better immune responses to the capsule polysaccharides (5). 
The first GBS polysaccharide-protein conjugate vaccine tested in humans 
coupled a type III polysaccharide with tetanus toxoid (TT), and proved to be safe and 
immunogenic in pregnant women (87). However, the lack of cross reactivity between 
different serotypes revealed that individual serotypes only offered protection to 
homologous capsular types, driving the design of a multivalent conjugated vaccine that 
would provide a broader coverage (187). A vaccine formulation based on independent 
conjugation of GBS capsular polysaccharides Ia, Ib, II, III and V to TT, plus a bivalent 
(II and III) preparation, undergone phase I and II clinical trials. All the formulations 
revealed safety and high immunogenicity in healthy adults, and the co-administration of 
two conjugates did not suffer from immune interference (141). Later, immunization of 
healthy elderly persons with a GBS serotype V-TT conjugate vaccine elicited protective 
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type-specific antibodies, suggesting the potential for vaccination to prevent the 
increasing number of invasive GBS infections observed in this age group (140). 
A major problem associated to a CPS-based vaccine is the choice of serotypes to 
include in such a vaccine. In the United States, a vaccine against serotypes Ia, Ib, II, III, 
and V is thought to offer protection to 80-95% of the population including neonates, 
pregnant women and non-pregnant adults (75, 95, 160, 176). Although this vaccine 
would likely provide coverage against pathogenic serotypes that are currently causing 
disease in the United States and most European countries, it does not offer protection 
against serotypes that are more prevalent in other parts of the world. Serotypes VI and 
VIII are predominant among Japanese women (98), serotype IV is the most frequent in 
the United Arab Emirates (3) and also in some European countries a significant 
prevalence of other serotypes has been reported, such as Ib among invasive isolates in 
Ireland (45) and colonizing isolates in Germany (15). Whereas the prevalence of 
particular serotypes has been shown to vary geographically, there are also significant 
discrepancies over time in the same region. In the United States, serotype V was not 
recognized as an important serotype causing GBS invasive disease until the late 1990s 
(14), and there is recent work reporting the emergence of serotype IV (40). 
Furthermore, non-typeable (NT) isolates can account for up to 29% of colonizing (81) 
and 15% of invasive isolates (176). Whether these isolates express an unknown capsule 
or no capsule at all, they will not be covered by the current formulations of 
polysaccharide-based vaccines.  
Other concerns regarding polysaccharide-based vaccines are serotype 
replacement and capsular switching. Serotype replacement due to vaccines has been 
observed in recent studies of S. pneumoniae, with the expansion of particular serotypes 
that were not included in the pneumococcal vaccine following a decrease in the 
infections caused by vaccine serotypes (1). Additionally, capsular switching was 
thought from the beginning to be a mechanism that could erode the benefits of 
pneumococcal vaccination programs since vaccination could provide the selective 
pressure for virulent genotypes to switch capsules and escape vaccine induced immunity 
(22). It is possible that similar responses will be seen with a future introduction of GBS 
vaccination (159). Changes in the prominence of various GBS serotypes over time have 
provided an additional challenge to vaccine development and may dictate reformulation 
of a multivalent vaccine. The need to overcome serotype-dependence drove the search 
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for other surface antigens, and some surface proteins revealed potential to elicit 
protective immunity, namely the α- and β-antigens of protein C (69, 113), C5a-
peptidase (29), as well as the Rib (103) and Sip (20) proteins. However, due to the fact 
that most of these proteins are not conserved at the gene level in all GBS isolates, 
additional efforts have been directed towards identifying bacterial surface proteins that, 
combined in a single vaccine, could provide serotype-independent protection against 
GBS (115). 
The identification of pilus-like structures on the GBS surface (104), their 
potential importance in GBS pathogenesis and the fact that these are ubiquitously 
expressed rendered these structures important candidates for the development of a 
universal GBS vaccine that could be potentially capable of preventing GBS disease in 
all age groups. In a recent study, the offspring of mice immunized with a combination 
of components of the three known pilus-islands was protected against challenge by GBS 
strains of all serotypes. Furthermore, the role of pili in promoting bacterial adherence to 
host tissue suggests that pilus-based vaccines might also elicit antibodies capable of 
preventing colonization (126). 
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5. Characterization of GBS isolates 
Bacterial epidemiologists use typing methods to study the dissemination and 
population dynamics of human bacterial pathogens in clinical and environmental 
settings, including their transmission patterns and the identification of risk-factors for 
the control of infectious diseases in human populations (179).  
 
 
5.1 Phenotyping methods 
Bacteriologists have long used phenotypic typing methods to group 
microorganisms according to their similarity in observable traits (phenotypes), which in 
turn result from the expression of their genotypes (179). Conventional phenotypic 
methods include serotyping (based on differences in surface epitopes), phage-typing 
(based on resistance to infection by a standard set of bacteriophages), biotyping 
(according to the different metabolic capabilities of the cell), bacteriocin typing (the 
presence or susceptibility to a specific group of bacteriocins), and antibiotic resistance 
typing (susceptibility to a panel of antimicrobials). Although providing convenient 
means to identify outbreak isolates in the short term, such methods are in general 
inadequate for evolutionary studies and increasingly recognized not to afford sufficient 
resolution (56). 
 
Serotyping 
For GBS, serotyping is the most commonly used method of phenotypic 
assessment. It is based on the expression of distinct polysaccharide capsules at the 
bacterial surface that react with serotype-specific antibodies. There are nine different 
serotypes known: Ia, Ib and II-VIII (156). A new provisional serotype IX was proposed 
in 2007 (161); however, the inexistence of a commercially available sera renders this 
serotype unaccountable in the phenotypic characterization of GBS. Moreover, a 
significant number of strains lack detectable capsule polysaccharide, being considered 
non-typeable (NT). Whether these strains do not express a capsular polysaccharide 
(non-encapsulated) or express polysaccharide variants that fail to react with available 
sera, they are not discriminated by the methodologies used (7).    
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Antimicrobial susceptibility testing 
The discrimination of strains based on antimicrobial susceptibility testing is 
dependent on the diversity, stability and relative prevalence of the detectable resistance 
in study isolates (179). In clinical practice, most microbiology laboratories perform 
antimicrobial susceptibility tests in automated systems, since its results are useful in 
guiding clinicians in selecting appropriate therapy.  
For research purposes, susceptibility testing of selected antibiotics is usually 
performed by the Kirby-Bauer disk diffusion method. Small disks pre-impregnated with 
a standard concentration of antibiotic are placed onto a plate upon which bacteria are 
growing. After incubation, the diameter of inhibition around the disk can be compared 
to reference tables to determine whether the bacterial isolate is susceptible, 
intermediately susceptible, or resistant to the antibiotic. A variation on this approach is 
to use a strip impregnated along its length with gradual concentrations of antibiotic (E-
test), which after incubation creates an ellipse shaped zone of no growth. The minimum 
inhibitory concentration (MIC) can be read from the concentration marking where the 
ellipse meets the strip (179). Additionally, detection of resistance phenotypes by a disk 
approximation method (D-test) can be performed. Methods and interpretative criteria 
follow recommendations from international and independent organizations, such as the 
Clinical and Laboratory Standards Institute (CLSI) (33). 
 
 
5.2 Genotyping methods  
Genotypic typing methods assess variation in the genomes of bacterial isolates 
with respect to composition (presence or absence of plasmids or mobile genetic 
elements), overall structure (restriction endonuclease profiles, number and position of 
repetitive elements), or precise nucleotide sequence (of genes or intergenic regions) 
(178). 
 
Restriction Fragment Length Polymorphism (RFLP) 
This method is based on DNA digestion with one or more endonucleases. The 
resulting restriction pattern of variable length fragments is obtained by separation in 
conventional electrophoresis and reflects the frequency and distribution of endonuclease 
recognition sites (129). The DNA fragments can be further transferred to a membrane 
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and hybridized to a probe, allowing additional subtyping of the isolates (Southern blot). 
The fingerprint obtained is dependent on the recognition of fragments carrying DNA 
sequences identical to the probe. The choice of the probe is critical for the 
discriminatory power and typeability of the method (129). 
In GBS, RFLP was used to study the population structure of serotype III 
isolates, discriminating three distinct phylogenetic lineages, and further identified a 
particular one associated with invasive disease in neonates, suggesting that this lineage 
could have increased virulence (166). RFLP and Southern blot have also proved helpful 
in classifying non-typeable isolates and effective as a tool for subtyping GBS based on 
insertion sequences (167). 
 
Pulsed-field gel electrophoresis (PFGE) 
PFGE involves the exposure of chromosomal DNA to endonucleases that 
recognize only a few sites in the bacterial genome, generating macrorestriction 
fragments. Agarose plugs containing the digested chromosomal DNA are inserted into 
the wells of an agarose gel, and the restriction fragments are resolved into a pattern of 
discrete bands by an apparatus that periodically switches the orientation of the electric 
field across the gel. The DNA restriction patterns of the isolates are then compared with 
one another to determine their relatedness (129, 170). 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 1.4 PFGE profiles generated following SmaI digestion of 
GBS chromosomal DNA. Fragment sizes (Kb) of the Lambda (λ) 
PFGE marker (New England Biolabs, Beverly, MA) are presented.  
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PFGE’s potential value in molecular epidemiologic studies of GBS infections 
was first described when compared to conventional electrophoresis. PFGE was shown 
to yield reproducible and easily readable profiles, and had enough sensitivity and 
discriminatory power for appropriate evaluation of the genetic relatedness of strains 
within a serotype and from different serotypes (55, 66).  
However, manual analysis and comparison of large numbers of PFGE profiles 
was difficult. The need to translate these data into epidemiologically useful information 
led to the proposal of interpretative criteria, as follows: isolates are categorized as 
closely related if one genetic event (usually a point mutation or an insertion or deletion 
of DNA) generates two to three band differences in their PFGE profiles; possibly 
related if two independent genetic events generate four to six band differences; or 
unrelated if the PFGE patterns differ by changes consistent with three or more 
independent genetic events (generally seven or more band differences) (170). 
Development of sophisticated software programs such as Bionumerics (Applied Maths, 
Sint-Martens-Latem, Belgium) has allowed the comparison of numerous collections of 
isolates by normalization of the band patterns over multiple gels and consequent 
construction of dendrograms from which phylogenetic relationships can be assessed.  
PFGE has been extensively used in epidemiological studies of large populations 
of GBS isolates, and on evaluation of population dynamics of GBS within restricted 
cohorts. It has been particularly relevant in addressing questions of transmission and 
acquisition of GBS, by demonstrating that newborns and young infants usually carry the 
same GBS clone as their mothers (72); that recurrence of GBS disease in infants can be 
associated with either the original infecting strain or a second acquired strain (71); and 
that sex couples frequently share the same strain, which is likely to be transmitted by 
sexual contact (120).  
 
Multilocus sequence typing (MLST) 
MLST is a sequence-based typing method that involves sequencing of internal 
fragments of seven housekeeping genes. The sequences are then compared with known 
alleles deposited at the MLST database (http://pubmlst.org/sagalactiae), and an allele 
number is assigned to each sequence, generating an allelic profile. Each isolate is 
therefore characterized by an allelic profile, a seven-integer number that can also be 
designated by a sequence type (ST) (86). MLST offers a valuable tool for the 
  General Introduction 
 
 
27 
characterization of bacterial strains. The major advantage of MLST over PFGE is the 
precise, unambiguous and portable nature of the data obtained, so that the isolates typed 
in one laboratory can be rapidly compared with all previously typed strains (56).  
In recent years, MLST became increasingly used for the characterization of 
bacterial populations because of its ability to infer levels of relatedness between strains 
and the reconstruction of evolutionary events (57). These questions have been addressed 
based on an algorithm, eBURST, that divides an MLST data set into groups of related 
isolates by implementing a simple model of clonal expansion and diversification (57). 
This model predicts that the emergence of clonal complexes (CCs) is due to an 
increase in the population of the frequency of the founding genotype, as a consequence 
of either a fitness advantage or of random genetic drift. This genotype increases in 
numbers and by gradual diversification (point mutation or recombination) gives rise to a 
clonal complex. In terms of MLST, the descendants of the founder allelic profile will 
initially remain unchanged, but over time variants in one of the seven alleles will arise. 
These genotypes, which have allelic profiles that differ from that of the founder at only 
one of the seven MLST loci, are called single-locus variants (SLVs). Eventually, SLVs 
will diversify further, to produce variants that differ at two of the seven loci, called 
double-locus variants (DLVs), and so on. Within each clonal complex, eBURST 
displays links between STs that correspond to an hypothetical pattern of descent (57).  
However, due to the fact that the eBURST algorithm is locally optimized, which 
can result in links within the clonal complexes that violate the rules proposed, a globally 
optimized implementation of the algorithm was proposed, goeBURST (62). This 
solution provides the representation of the level of tiebreak rule reached before deciding 
if two STs should be linked, which can be used to visually evaluate the reliability of the 
represented hypothetical pattern of descent. A software implementation of the 
goeBURST algorithm is available at http://goeBURST.phyloviz.net (62). 
 
PCR-based gene profiling 
Polymerase chain reaction (PCR) is a nearly universal typing method, with 
several applications in bacterial typing systems, and exhibits an easily adjustable level 
of discrimination. Its major advantages include high reproducibility, technical 
simplicity, wide availability of equipment and reagents, and rapid turnover time (179). 
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Several PCR-based typing systems have been used to genotype GBS isolates and 
include, among other, molecular serotyping (92, 128), sub-typing within particular 
serotypes (121), surface protein gene profiling (34), detection of mobile genetic 
elements (93), and of antimicrobial resistance genes (165). 
 
Whole-genome sequences comparisons 
The development of efficient and less expensive sequencing methods has 
produced a significant number of complete genome sequences of pathogenic 
microorganisms in recent years. The comparison of whole-genome sequences offers the 
possibility to assess genetic differences within a bacterial species, providing insights on 
how genetic variability drives the evolution of virulence mechanisms. 
The first complete GBS genome sequences were made available in 2002 (65, 
172). The GBS genome is nearly 2.2 Mbp long and has over 2100 predicted coding 
regions. Both studies revealed substantial similarity with the genomes of the related 
human pathogens Streptococcus pyogenes and S. pneumoniae, representing a conserved 
backbone between streptococcal species. On the other hand, GBS differed from other 
streptococci in genome regions containing known and putative virulence genes, mostly 
encoding surface proteins and genes related to mobile elements, suggesting that these 
regions could be considered as pathogenicity islands (65). These genes were probably 
related to adaptation of GBS to distinct niches in its human and animal hosts and were 
expected to play a role in colonization or disease. Accordingly, the high number of 
genes associated with mobile genetic elements, including bacteriophages, transposons 
and insertion sequences supported the acquisition of virulence traits from other species 
(172). 
Comparative analysis of multiple genomes introduced the concept of a “pan-
genome”, consisting of a core genome shared by all isolates, accounting for 
approximately 80% of any single genome, and involved in housekeeping and regulatory 
functions, plus a dispensable genome consisting mostly of strain-specific genes. Again, 
the abundance of genes associated with mobile and extrachromosomal elements found 
in the variable portion of the genome, supported the hypothesis that the acquisition of 
the majority of strain specific traits depends on lateral gene transfer (171). 
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FIGURE 1.5 Circular representation of GBS genomes by comparative genomic 
hybridization. GBS strains of serotypes Ia, Ib, II-V, VIII and NT are represented. 
Red bars inside the circle represent genes absent from the strain; blue bars represent 
genes with ambiguous hybridization result. Numbers outside the circle represent the 
scale in bp. Adapted from (172). 
 
 
Furthermore, genetic heterogeneity among GBS strains, even of the same 
serotype, revealed that evolution within genes encoding surface and secreted proteins 
and those involved in the biosynthesis of the capsule is mainly due to recombination 
events leading to gene acquisition, duplication, and reassortment with the consequent 
replacement of several genes or to the allelic exchange within a particular gene. These 
processes allow GBS to express various combinations of virulence factors, which are 
likely to serve as means of adapting to host immunity (18, 172). Integrative conjugative 
elements are also thought to play a role in the evolution of the GBS genome through 
their plasticity and potential for gene acquisition and mobilization, as well as exchange 
with other species (17). 
Finally, it was demonstrated that GBS strains can exchange DNA segments of 
up to 334 Kb of the chromosome, probably through mobilization by conjugative 
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elements. The analysis of the contribution of such recombinational exchanges to the 
dynamics of the GBS chromosome, has led to the proposal of an evolutionary model in 
which clonal complexes of clinical importance are derived from a single clone and 
evolved through the exchange of large chromosomal regions with more distantly related 
strains (19). This study, in agreement with previous observations that the GBS 
chromosome is a mosaic of large chromosomal fragments from different ancestors 
(171), suggests that particular combinations of genes could be horizontally transferred 
together. If advantageous fitness is achieved by specific combinations of genes that 
increase the ability to cause disease or persist through asymptomatic colonization, these 
beneficial alleles would not be randomly distributed among population members, but 
found more often than expected (i.e., at linkage disequilibrium). If this is the case, 
associations of specific alleles within the GBS lineages, including housekeeping 
(MLST) and virulence genes, as well as a new distribution of endonuclease recognition 
sites generating PFGE patterns, can be investigated within GBS populations. 
 
 
5.3 Molecular epidemiology of GBS 
Molecular epidemiology has been used to discriminate genetic lineages in order 
to probe for associations between specific GBS genotypes and disease. DNA-based 
typing methods such as PFGE and MLST are now extensively used in molecular typing 
of GBS isolates, alongside with classical serotyping and antimicrobial susceptibility 
testing.  
 
Serotype distribution 
Serotyping remains an important methodology in epidemiological studies 
evaluating fluctuations of different GBS clones in the human population (14, 78, 98). 
Serotypes have been shown to vary geographically and over time, which may have a 
serious impact on a future vaccine formulation. Additionally, the prevalence of the GBS 
serotypes is age-dependent and different among colonizing and invasive isolates.  
A recent review of the GBS seroprevalence in pregnant women in the United 
States as compared to other geographic locations revealed substantial differences (81). 
While back in the 1990s most studies from the United States described serotype V as 
the most frequent among colonizing isolates, serotypes Ia and III have become more 
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prevalent in recent years. In Canada all these three serotypes were similarly prevalent 
and in Europe serotype III is dominant in most countries (81), excluding Greece (175), 
and Germany where serotype Ib is emerging (15). In a recent review, three African 
countries reported serotypes III and V as being equally relevant (81). In Asian countries, 
after serotype III, serotype Ib and serotype V are equally frequent (81), but in the 
particular case of Japan serotypes VI and VIII are predominant among pregnant women 
(98), and these are serotypes not frequently detected elsewhere. Also in the Middle-east 
serotypes Ia, II, III and V have similar prevalence (81), but in the United Arab Emirates, 
serotype IV is the most frequent, again an infrequent serotype (3).  
An obvious assumption is that major differences in the serotype prevalence of 
GBS isolates colonizing pregnant women will be reflected on vertical transmission, 
therefore on the isolates that cause invasive disease in their newborns. Yet this is not the 
case, since serotype III is by far the most frequent serotype among neonatal invasive 
isolates in all continents (8, 114, 134, 144, 190). These observations led to the 
suggestion of an enhanced invasive potential of this serotype, resulting in its higher 
representation in neonatal invasive disease that has been shown to be mainly 
attributable to a particular genetic lineage of serotype III, which will be discussed later 
in this section. Furthermore, considering the significant decrease observed in EOD cases 
upon wide application of antimicrobial prophylaxis, as opposed to no remarkable 
changes in LOD cases, it is possible that different serotypes from sources other than 
maternal colonization will emerge in coming years. 
In the past two decades GBS has been increasingly associated with invasive 
disease in non-pregnant adults, particularly the elderly (9, 130, 144, 160). However, the 
epidemiology of GBS in infections among adults is less well known than that of 
neonates and pregnant women, and information on colonizing isolates is nearly residual 
in these populations, probably reflecting the recent emergence of GBS as an important 
pathogen in adults.  
Among the isolates causing invasive infections in non-pregnant adults, serotype 
V is the most frequent in North America (144, 160, 176) and Europe (99), even though 
in Norway a recent report describes both serotypes V and III as equally frequent (8), 
which was also recently observed in Korea (158). A main exception is again Japan, 
where serotype Ib is the most prevalent among invasive disease in non-pregnant adults 
(134). Serotypes VI and VIII are less commonly found as causes of invasive disease 
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than of maternal colonization in Japan (134) but have been detected elsewhere, together 
with serotype VII (158, 160, 190). 
 
PFGE and MLST-based genetic lineages 
Molecular methods have provided new clues about the population structure of 
GBS, particularly the recognition of genetic lineages within serotypes that were shown 
to differ in virulence potential and tropism. Among serotype III isolates, two main 
genetic lineages have been identified based on MLST. While ST19 is more frequently 
found among colonizing isolates (86, 151), ST17 has been mostly recognized as a 
hypervirulent clone, and strongly associated with neonatal invasive infections (12, 86, 
107, 109, 124), even though not all studies are in agreement with the correlation 
between this ST and increased pathogenic potential (37). The potential application of 
MLST to infer the phylogenetic evolution of GBS has led to the proposal of a bovine 
origin for ST17 (11, 77), yet this issue remains controversial (18, 162). In Hong Kong 
another serotype III genetic lineage (ST283) prevails among isolates recovered from 
invasive disease in non-pregnant adults (80). Considering that ST17 and ST283 do not 
have in common any of the seven MLST alleles, these lineages are likely unrelated from 
a recent evolutionary standpoint. ST17 and ST283 are causing infections almost 
exclusively on neonates and adults, respectively, and ST17 is worldwide spread while 
ST283 is apparently confined to a geographic location. These observations support for a 
distinct evolution of these lineages while sharing the same capsular type III, with ST283 
likely being more recent, and probably account for their particular success and tropism.  
Other MLST-based genetic lineages have been described as dominant among 
GBS isolates causing invasive disease, particularly serotype Ia/ST23 and serotype 
V/ST1 (8, 109, 124, 164). Despite the fact that ST1 is the dominant genetic lineage 
among serotype V GBS isolates in Europe and the United States, other countries have 
reported a major prevalence of other lineages. ST26 is more frequent in Senegal and 
Central African Republic (16) and has also been found in Brazil (139). Again, the fact 
that ST1 and ST26 share only three out of the seven MLST alleles suggests a separate 
evolution of these lineages within serotype V, to which local factors can also contribute, 
determining emergence of regional successful lineages.  
Although the distinction of lineages within a particular serotype has proved 
useful, a complete correlation between capsular type and the genetic lineages as defined 
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by PFGE and MLST was never found (18, 109, 122). The serotype-independent 
clustering of strains implies that the diversification of the GBS populations is ongoing. 
These observations support the hypothesis that closely and divergently related clones 
share the genes coding for a particular capsular type, suggesting that capsular switching 
probably occurs in GBS (37, 86, 109, 122). 
PFGE is a whole-genome based technique, yet of low resolution, and MLST 
relies on housekeeping genes, not taking into account the variable genome. 
Consequently, methodologies based on identification of putative virulence genes from 
the variable portion of the genome, such as those encoding the alpha-like surface 
proteins and pili, could be of further assistance for differentiation of the GBS 
populations. The presence of particular surface protein genes has been often correlated 
with the capsular type (Table 1.2) and it has been proposed that such associations may 
represent evolutionary lineages, considering that immune selection has probably 
favoured certain combinations of surface structures because of their greater fitness 
(108).  
 
TABLE 1.2 Association between Alp surface protein genes and serotypes. 
Serotype Alp surface protein gene References 
Ia bca, eps (108, 112, 142, 164) 
Ib bca (108, 112, 142, 164) 
II bca, rib (108, 112, 142) 
III rib (108, 112, 142, 164) 
IV bca (40) 
V alp3 (108, 112, 142, 164) 
VII alp3 (164) 
VIII alp2, alp3 (108, 112, 164) 
 
 
The complement of surface protein gene profiling to serotyping and MLST 
resulted in an overall good correlation of typing methods, which in combination allow 
the discrimination of otherwise undistinguishable clones. Up to now, the genetic 
lineages more frequently found among GBS isolates are III/ST19/rib, III/ST17/rib, 
Ia/ST23/eps, Ib/ST9/bca, II/ST28/rib and V/ST1/alp3 (64, 151, 164), this last one 
significantly associated to erythromycin resistance (64, 151).  
The epidemiological characterization of GBS populations has revealed a large 
number of genetically distinct lineages, most capable of both asymptomatic colonization 
and of causing invasive disease in different age groups. The stability and dominance of 
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a few worldwide disseminated lineages that are responsible for the majority of 
infections regardless of continuous antibiotic and immune selective pressures, suggest 
that they are extremely well adapted to their particular niche. 
Nevertheless, the prevalence of serotypes and genotypes among different human 
populations is not the same, suggesting that particular lineages may be better adapted to 
particular host characteristics, including age. Furthermore, the occurrence of infrequent 
clones as causes of invasive infections in specific regions raises the possibility that 
lineages with enhanced invasiveness may be emerging and expanding at a regional 
level. Continuous surveillance is crucial for a better understanding of the dynamic 
nature of GBS populations. 
 
 
 
 
 
 
 
  
 
  General Introduction 
 
 
35 
References 
1. Aguiar, S. I., I. Serrano, F. R. Pinto, J. Melo-Cristino, and M. Ramirez. 2008. Changes in 
Streptococcus pneumoniae serotypes causing invasive disease with non-universal vaccination 
coverage of the seven-valent conjugate vaccine. Clin Microbiol Infect 14:835-43. 
2. Almeida, A., J. Agro, and L. Ferreira. 2004. Estreptococo Beta Hemolítico do Grupo B - 
Protocolo de Rastreio e Prevenção de Doença Perinatal. Consensos Nacionais em 
Neonatologia:191-198. 
3. Amin, A., Y. M. Abdulrazzaq, and S. Uduman. 2002. Group B streptococcal serotype 
distribution of isolates from colonized pregnant women at the time of delivery in United Arab 
Emirates. J Infect 45:42-6. 
4. Andreu, A., I. Sanfeliu, L. Vinas, M. Barranco, J. Bosch, E. Dopico, C. Guardia, T. Juncosa, 
J. Lite, L. Matas, F. Sanchez, and M. Sierr. 2003. Decreasing incidence of perinatal group B 
streptococcal disease (Barcelona 1994-2002). Relation with hospital prevention policies. Enferm 
Infecc Microbiol Clin 21:174-9. 
5. Baker, C. J. 1990. Immunization to prevent group B streptococcal disease: victories and 
vexations. J Infect Dis 161:917-21. 
6. Barcaite, E., A. Bartusevicius, R. Tameliene, M. Kliucinskas, L. Maleckiene, and R. 
Nadisauskiene. 2008. Prevalence of maternal group B streptococcal colonisation in European 
countries. Acta Obstet Gynecol Scand 87:260-71. 
7. Benson, J. A., A. E. Flores, C. J. Baker, S. L. Hillier, and P. Ferrieri. 2002. Improved methods 
for typing nontypeable isolates of group B streptococci. Int J Med Microbiol 292:37-42. 
8. Bergseng, H., J. E. Afset, A. Radtke, K. Loeseth, R. V. Lyng, M. Rygg, and K. Bergh. 2009. 
Molecular and phenotypic characterization of invasive group B streptococcus strains from infants 
in Norway 2006-2007. Clin Microbiol Infect 15:1182-5. 
9. Bergseng, H., M. Rygg, L. Bevanger, and K. Bergh. 2008. Invasive group B streptococcus 
(GBS) disease in Norway 1996-2006. Eur J Clin Microbiol Infect Dis 27:1193-9. 
10. Bingen, E., E. Denamur, N. Lambert-Zechovsky, Y. Aujard, N. Brahimi, P. Geslin, and J. 
Elion. 1992. Analysis of DNA restriction fragment length polymorphism extends the evidence for 
breast milk transmission in Streptococcus agalactiae late-onset neonatal infection. J Infect Dis 
165:569-73. 
11. Bisharat, N., D. W. Crook, J. Leigh, R. M. Harding, P. N. Ward, T. J. Coffey, M. C. Maiden, 
T. Peto, and N. Jones. 2004. Hyperinvasive neonatal group B Streptococcus has arisen from a 
bovine ancestor. J Clin Microbiol 42:2161-7. 
12. Bisharat, N., N. Jones, D. Marchaim, C. Block, R. M. Harding, P. Yagupsky, T. Peto, and D. 
W. Crook. 2005. Population structure of group B streptococcus from a low-incidence region for 
invasive neonatal disease. Microbiology 151:1875-81. 
13. Bliss, S. J., S. D. Manning, P. Tallman, C. J. Baker, M. D. Pearlman, C. F. Marrs, and B. 
Foxman. 2002. Group B Streptococcus colonization in male and nonpregnant female university 
students: a cross-sectional prevalence study. Clin Infect Dis 34:184-90. 
Chapter 1    
 
36
14. Blumberg, H. M., D. S. Stephens, M. Modansky, M. Erwin, J. Elliot, R. R. Facklam, A. 
Schuchat, W. Baughman, and M. M. Farley. 1996. Invasive group B streptococcal disease: the 
emergence of serotype V. J Infect Dis 173:365-73. 
15. Brimil, N., E. Barthell, U. Heindrichs, M. Kuhn, R. Lutticken, and B. Spellerberg. 2006. 
Epidemiology of Streptococcus agalactiae colonization in Germany. Int J Med Microbiol 296:39-
44. 
16. Brochet, M., E. Couve, R. Bercion, J. M. Sire, and P. Glaser. 2009. Population structure of 
human isolates of Streptococcus agalactiae from Dakar and Bangui. J Clin Microbiol 47:800-3. 
17. Brochet, M., E. Couve, P. Glaser, G. Guedon, and S. Payot. 2008. Integrative conjugative 
elements and related elements are major contributors to the genome diversity of Streptococcus 
agalactiae. J Bacteriol 190:6913-7. 
18. Brochet, M., E. Couve, M. Zouine, T. Vallaeys, C. Rusniok, M. C. Lamy, C. Buchrieser, P. 
Trieu-Cuot, F. Kunst, C. Poyart, and P. Glaser. 2006. Genomic diversity and evolution within 
the species Streptococcus agalactiae. Microbes Infect 8:1227-43. 
19. Brochet, M., C. Rusniok, E. Couve, S. Dramsi, C. Poyart, P. Trieu-Cuot, F. Kunst, and P. 
Glaser. 2008. Shaping a bacterial genome by large chromosomal replacements, the evolutionary 
history of Streptococcus agalactiae. Proc Natl Acad Sci U S A 105:15961-6. 
20. Brodeur, B. R., M. Boyer, I. Charlebois, J. Hamel, F. Couture, C. R. Rioux, and D. Martin. 
2000. Identification of group B streptococcal Sip protein, which elicits cross-protective immunity. 
Infect Immun 68:5610-8. 
21. Broughton, D. D., W. G. Mitchell, M. Grossman, W. K. Hadley, and M. S. Cohen. 1976. 
Recurrence of group B streptococcal infection. J Pediatr 89:182-5. 
22. Brueggemann, A. B., R. Pai, D. W. Crook, and B. Beall. 2007. Vaccine escape recombinants 
emerge after pneumococcal vaccination in the United States. PLoS Pathog 3:e168. 
23. Brzychczy-Wloch, M., T. Gosiewski, M. Bodaszewska, W. Pabian, M. Bulanda, P. Kochan, 
M. Strus, and P. B. Heczko. 2010. Genetic characterization and diversity of Streptococcus 
agalactiae isolates with macrolide resistance. J Med Microbiol 59:780-6. 
24. Castor, M. L., C. G. Whitney, K. Como-Sabetti, R. R. Facklam, P. Ferrieri, J. M. Bartkus, B. 
A. Juni, P. R. Cieslak, M. M. Farley, N. B. Dumas, S. J. Schrag, and R. Lynfield. 2008. 
Antibiotic resistance patterns in invasive group B streptococcal isolates. Infect Dis Obstet Gynecol 
2008:727505. 
25. Centers for Disease Control and Prevention. 2005. Early-onset and late-onset neonatal group B 
streptococcal disease--United States, 1996-2004. MMWR Morb Mortal Wkly Rep 54:1205-8. 
26. Centers for Disease Control and Prevention. 2007. Perinatal group B streptococcal disease after 
universal screening recommendations--United States, 2003-2005. MMWR Morb Mortal Wkly Rep 
56:701-5. 
27. Centers for Disease Control and Prevention. 1996. Prevention of perinatal group B 
streptococcal disease: a public health perspective. MMWR Recomm Rep 45:1-24. 
28. Centers for Disease Control and Prevention. 2002. Prevention of perinatal group B 
streptococcal disease: revised guidelines from CDC. Jama 287:1106-7. 
  General Introduction 
 
 
37 
29. Cheng, Q., S. Debol, H. Lam, R. Eby, L. Edwards, Y. Matsuka, S. B. Olmsted, and P. P. 
Cleary. 2002. Immunization with C5a peptidase or peptidase-type III polysaccharide conjugate 
vaccines enhances clearance of group B Streptococci from lungs of infected mice. Infect Immun 
70:6409-15. 
30. Chopra, I., and M. Roberts. 2001. Tetracycline antibiotics: mode of action, applications, 
molecular biology, and epidemiology of bacterial resistance. Microbiol Mol Biol Rev 65:232-60. 
31. Cieslewicz, M. J., D. Chaffin, G. Glusman, D. Kasper, A. Madan, S. Rodrigues, J. Fahey, M. 
R. Wessels, and C. E. Rubens. 2005. Structural and genetic diversity of group B Streptococcus 
capsular polysaccharides. Infect Immun 73:3096-103. 
32. Cieslewicz, M. J., D. L. Kasper, Y. Wang, and M. R. Wessels. 2001. Functional analysis in type 
Ia group B Streptococcus of a cluster of genes involved in extracellular polysaccharide production 
by diverse species of streptococci. J Biol Chem 276:139-46. 
33. Clinical and Laboratory Standards Institute. 2009. Performance Standards for Antimicrobial 
Susceptibility Testing - Nineteenth Informational Supplement, vol. 29, nº. 3 (M100-S19). National 
Committee for Clinical Laboratory Standards, Wayne, PA. 
34. Creti, R., F. Fabretti, G. Orefici, and C. von Hunolstein. 2004. Multiplex PCR assay for direct 
identification of group B streptococcal alpha-protein-like protein genes. J Clin Microbiol 42:1326-
9. 
35. Culebras, E., I. Rodriguez-Avial, C. Betriu, M. Redondo, and J. J. Picazo. 2002. Macrolide 
and tetracycline resistance and molecular relationships of clinical strains of Streptococcus 
agalactiae. Antimicrob Agents Chemother 46:1574-6. 
36. Dahesh, S., M. E. Hensler, N. M. Van Sorge, R. E. Gertz, Jr., S. Schrag, V. Nizet, and B. W. 
Beall. 2008. Point mutation in the group B streptococcal pbp2x gene conferring decreased 
susceptibility to beta-lactam antibiotics. Antimicrob Agents Chemother 52:2915-8. 
37. Davies, H. D., N. Jones, T. S. Whittam, S. Elsayed, N. Bisharat, and C. J. Baker. 2004. 
Multilocus sequence typing of serotype III group B Streptococcus and correlation with pathogenic 
potential. J Infect Dis 189:1097-102. 
38. de Azavedo, J. C., M. McGavin, C. Duncan, D. E. Low, and A. McGeer. 2001. Prevalence and 
mechanisms of macrolide resistance in invasive and noninvasive group B streptococcus isolates 
from Ontario, Canada. Antimicrob Agents Chemother 45:3504-8. 
39. de la Rosa Fraile, M., L. Cabero, A. Andreu, and G. G. Rao. 2001. Prevention of group B 
streptococcal neonatal disease: a plea for a European consensus. Clin Microbiol Infect 7:25-7. 
40. Diedrick, M. J., A. E. Flores, S. L. Hillier, R. Creti, and P. Ferrieri. 2010. Clonal analysis of 
colonizing group B Streptococcus, serotype IV, an emerging pathogen in the United States. J Clin 
Microbiol 48:3100-4. 
41. Dipersio, L. P., and J. R. Dipersio. 2007. Identification of an erm(T) gene in strains of inducibly 
clindamycin-resistant group B Streptococcus. Diagn Microbiol Infect Dis 57:189-93. 
42. Dogan, B., Y. H. Schukken, C. Santisteban, and K. J. Boor. 2005. Distribution of serotypes and 
antimicrobial resistance genes among Streptococcus agalactiae isolates from bovine and human 
hosts. J Clin Microbiol 43:5899-906. 
Chapter 1    
 
38
43. Domingo, P., N. Barquet, M. Alvarez, P. Coll, J. Nava, and J. Garau. 1997. Group B 
streptococcal meningitis in adults: report of twelve cases and review. Clin Infect Dis 25:1180-7. 
44. Doran, K. S., and V. Nizet. 2004. Molecular pathogenesis of neonatal group B streptococcal 
infection: no longer in its infancy. Mol Microbiol 54:23-31. 
45. Dore, N., D. Bennett, M. Kaliszer, M. Cafferkey, and C. J. Smyth. 2003. Molecular 
epidemiology of group B streptococci in Ireland: associations between serotype, invasive status 
and presence of genes encoding putative virulence factors. Epidemiol Infect 131:823-33. 
46. Dramsi, S., E. Caliot, I. Bonne, S. Guadagnini, M. C. Prevost, M. Kojadinovic, L. Lalioui, C. 
Poyart, and P. Trieu-Cuot. 2006. Assembly and role of pili in group B streptococci. Mol 
Microbiol 60:1401-13. 
47. Duarte, R. S., B. C. Bellei, O. P. Miranda, M. A. Brito, and L. M. Teixeira. 2005. Distribution 
of antimicrobial resistance and virulence-related genes among Brazilian group B streptococci 
recovered from bovine and human sources. Antimicrob Agents Chemother 49:97-103. 
48. Edwards, M. S. 2008. Group B streptococcal conjugate vaccine: a timely concept for which the 
time has come. Hum Vaccin 4:444-8. 
49. Edwards, M. S., and C. J. Baker. 2005. Group B streptococcal infections in elderly adults. Clin 
Infect Dis 41:839-47. 
50. Edwards, M. S., and C. J. Baker. 2000. Streptococcus agalactiae (Group B Streptococcus), p. 
2156-2167. In G. L. Mandell, J. E. Bennett, and R. Dolin (ed.), Pinciples and Practice of Infectious 
Diseases, 5th ed, vol. 2nd. Churchill Livingstone, Ltd., New York. 
51. Edwards, M. S., M. A. Rench, D. L. Palazzi, and C. J. Baker. 2005. Group B streptococcal 
colonization and serotype-specific immunity in healthy elderly persons. Clin Infect Dis 40:352-7. 
52. Eickel, V., B. Kahl, B. Reinisch, A. Dubbers, P. Kuster, C. Brandt, and B. Spellerberg. 2009. 
Emergence of respiratory Streptococcus agalactiae isolates in cystic fibrosis patients. PLoS ONE 
4:e4650. 
53. Farley, M. M. 2001. Group B streptococcal disease in nonpregnant adults. Clin Infect Dis 33:556-
61. 
54. Farley, M. M., R. C. Harvey, T. Stull, J. D. Smith, A. Schuchat, J. D. Wenger, and D. S. 
Stephens. 1993. A population-based assessment of invasive disease due to group B Streptococcus 
in nonpregnant adults. N Engl J Med 328:1807-11. 
55. Fasola, E., C. Livdahl, and P. Ferrieri. 1993. Molecular analysis of multiple isolates of the major 
serotypes of group B streptococci. J Clin Microbiol 31:2616-20. 
56. Feil, E. J., and M. C. Enright. 2004. Analyses of clonality and the evolution of bacterial 
pathogens. Curr Opin Microbiol 7:308-13. 
57. Feil, E. J., B. C. Li, D. M. Aanensen, W. P. Hanage, and B. G. Spratt. 2004. eBURST: inferring 
patterns of evolutionary descent among clusters of related bacterial genotypes from multilocus 
sequence typing data. J Bacteriol 186:1518-30. 
58. Figueira-Coelho, J., M. Ramirez, M. J. Salgado, and J. Melo-Cristino. 2004. Streptococcus 
agalactiae in a large Portuguese teaching hospital: antimicrobial susceptibility, serotype 
distribution, and clonal analysis of macrolide-resistant isolates. Microb Drug Resist 10:31-6. 
  General Introduction 
 
 
39 
59. Fluegge, K., A. Siedler, B. Heinrich, J. Schulte-Moenting, M. J. Moennig, D. B. Bartels, O. 
Dammann, R. von Kries, and R. Berner. 2006. Incidence and clinical presentation of invasive 
neonatal group B streptococcal infections in Germany. Pediatrics 117:e1139-45. 
60. Fluegge, K., S. Supper, A. Siedler, and R. Berner. 2004. Antibiotic susceptibility in neonatal 
invasive isolates of Streptococcus agalactiae in a 2-year nationwide surveillance study in 
Germany. Antimicrob Agents Chemother 48:4444-6. 
61. Foxman, B., C. L. de Azevedo, M. Buxton, J. Debusscher, P. Pillai, N. S. De Carvalho, and C. 
Barbosa-Cesnik. 2008. Acquisition and transmission of Group B Streptococcus during pregnancy. 
J Infect Dis 198:1375-1378. 
62. Francisco, A. P., M. Bugalho, M. Ramirez, and J. A. Carriço. 2009. Global optimal eBURST 
analysis of multilocus typing data using a graphic matroid approach. BMC Bioinformatics 10:152. 
63. Fry, R. M. 1938. Fatal infections by haemolytic Streptococcus group B. The Lancet 231:199-201. 
64. Gherardi, G., M. Imperi, L. Baldassarri, M. Pataracchia, G. Alfarone, S. Recchia, G. Orefici, 
G. Dicuonzo, and R. Creti. 2007. Molecular epidemiology and distribution of serotypes, surface 
proteins, and antibiotic resistance among group B streptococci in Italy. J Clin Microbiol 45:2909-
16. 
65. Glaser, P., C. Rusniok, C. Buchrieser, F. Chevalier, L. Frangeul, T. Msadek, M. Zouine, E. 
Couve, L. Lalioui, C. Poyart, P. Trieu-Cuot, and F. Kunst. 2002. Genome sequence of 
Streptococcus agalactiae, a pathogen causing invasive neonatal disease. Mol Microbiol 45:1499-
513. 
66. Gordillo, M. E., K. V. Singh, C. J. Baker, and B. E. Murray. 1993. Typing of group B 
streptococci: comparison of pulsed-field gel electrophoresis and conventional electrophoresis. J 
Clin Microbiol 31:1430-4. 
67. Gravekamp, C., D. S. Horensky, J. L. Michel, and L. C. Madoff. 1996. Variation in repeat 
number within the alpha C protein of group B streptococci alters antigenicity and protective 
epitopes. Infect Immun 64:3576-83. 
68. Gravekamp, C., D. L. Kasper, J. L. Michel, D. E. Kling, V. Carey, and L. C. Madoff. 1997. 
Immunogenicity and protective efficacy of the alpha C protein of group B streptococci are 
inversely related to the number of repeats. Infect Immun 65:5216-21. 
69. Gravekamp, C., D. L. Kasper, L. C. Paoletti, and L. C. Madoff. 1999. Alpha C protein as a 
carrier for type III capsular polysaccharide and as a protective protein in group B streptococcal 
vaccines. Infect Immun 67:2491-6. 
70. Gravekamp, C., B. Rosner, and L. C. Madoff. 1998. Deletion of repeats in the alpha C protein 
enhances the pathogenicity of group B streptococci in immune mice. Infect Immun 66:4347-54. 
71. Green, P. A., K. V. Singh, B. E. Murray, and C. J. Baker. 1994. Recurrent group B 
streptococcal infections in infants: clinical and microbiologic aspects. J Pediatr 125:931-8. 
72. Hansen, S. M., N. Uldbjerg, M. Kilian, and U. B. Sorensen. 2004. Dynamics of Streptococcus 
agalactiae colonization in women during and after pregnancy and in their infants. J Clin Microbiol 
42:83-9. 
Chapter 1    
 
40
73. Harper, I. A. 1971. The importance of group B streptococci as human pathogens in the British 
Isles. J Clin Pathol 24:438-41. 
74. Harrison, L. H., A. Ali, D. M. Dwyer, J. P. Libonati, M. W. Reeves, J. A. Elliott, L. Billmann, 
T. Lashkerwala, and J. A. Johnson. 1995. Relapsing invasive group B streptococcal infection in 
adults. Ann Intern Med 123:421-7. 
75. Harrison, L. H., J. A. Elliott, D. M. Dwyer, J. P. Libonati, P. Ferrieri, L. Billmann, and A. 
Schuchat. 1998. Serotype distribution of invasive group B streptococcal isolates in Maryland: 
implications for vaccine formulation. Maryland Emerging Infections Program. J Infect Dis 
177:998-1002. 
76. Henning, K. J., E. L. Hall, D. M. Dwyer, L. Billmann, A. Schuchat, J. A. Johnson, and L. H. 
Harrison. 2001. Invasive group B streptococcal disease in Maryland nursing home residents. J 
Infect Dis 183:1138-42. 
77. Hery-Arnaud, G., G. Bruant, P. Lanotte, S. Brun, B. Picard, A. Rosenau, N. van der Mee-
Marquet, P. Rainard, R. Quentin, and L. Mereghetti. 2007. Mobile genetic elements provide 
evidence for a bovine origin of clonal complex 17 of Streptococcus agalactiae. Appl Environ 
Microbiol 73:4668-72. 
78. Hickman, M. E., M. A. Rench, P. Ferrieri, and C. J. Baker. 1999. Changing epidemiology of 
group B streptococcal colonization. Pediatrics 104:203-9. 
79. Ho, Y. R., C. M. Li, H. P. Su, J. H. Wu, Y. C. Tseng, Y. J. Lin, and J. J. Wu. 2007. Variation 
in the number of tandem repeats and profile of surface protein genes among invasive group B 
streptococci correlates with patient age. J Clin Microbiol 45:1634-6. 
80. Ip, M., E. S. Cheuk, M. H. Tsui, F. Kong, T. N. Leung, and G. L. Gilbert. 2006. Identification 
of a Streptococcus agalactiae serotype III subtype 4 clone in association with adult invasive 
disease in Hong Kong. J Clin Microbiol 44:4252-4. 
81. Ippolito, D. L., W. A. James, D. Tinnemore, R. R. Huang, M. J. Dehart, J. Williams, M. A. 
Wingerd, and S. T. Demons. 2010. Group B streptococcus serotype prevalence in reproductive-
age women at a tertiary care military medical center relative to global serotype distribution. BMC 
Infect Dis 10:336. 
82. Jackson, L. A., R. Hilsdon, M. M. Farley, L. H. Harrison, A. L. Reingold, B. D. Plikaytis, J. 
D. Wenger, and A. Schuchat. 1995. Risk factors for group B streptococcal disease in adults. Ann 
Intern Med 123:415-20. 
83. Janapatla, R. P., Y. R. Ho, J. J. Yan, H. M. Wu, and J. J. Wu. 2008. The prevalence of 
erythromycin resistance in group B streptococcal isolates at a University Hospital in Taiwan. 
Microb Drug Resist 14:293-7. 
84. Johnson, D. R., and P. Ferrieri. 1984. Group B streptococcal Ibc protein antigen: distribution of 
two determinants in wild-type strains of common serotypes. J Clin Microbiol 19:506-10. 
85. Jones, A. L., and C. E. Rubens. 2007. Molecular pathogenesis of group B streptococcal 
infections, p. 379-409. In R. Hakenbeck and S. Chhatwal (ed.), Molecular Biology of Streptococci. 
Horizon Scientific Press, Norfolk, UK. 
  General Introduction 
 
 
41 
86. Jones, N., J. F. Bohnsack, S. Takahashi, K. A. Oliver, M. S. Chan, F. Kunst, P. Glaser, C. 
Rusniok, D. W. Crook, R. M. Harding, N. Bisharat, and B. G. Spratt. 2003. Multilocus 
sequence typing system for group B Streptococcus. J Clin Microbiol 41:2530-6. 
87. Kasper, D. L., L. C. Paoletti, M. R. Wessels, H. K. Guttormsen, V. J. Carey, H. J. Jennings, 
and C. J. Baker. 1996. Immune response to type III group B streptococcal polysaccharide-tetanus 
toxoid conjugate vaccine. J Clin Invest 98:2308-14. 
88. Kawamura, Y., H. Fujiwara, N. Mishima, Y. Tanaka, A. Tanimoto, S. Ikawa, Y. Itoh, and T. 
Ezaki. 2003. First Streptococcus agalactiae isolates highly resistant to quinolones, with point 
mutations in gyrA and parC. Antimicrob Agents Chemother 47:3605-9. 
89. Kimura, K., S. Suzuki, J. Wachino, H. Kurokawa, K. Yamane, N. Shibata, N. Nagano, H. 
Kato, K. Shibayama, and Y. Arakawa. 2008. First molecular characterization of group B 
streptococci with reduced penicillin susceptibility. Antimicrob Agents Chemother 52:2890-7. 
90. Koenig, J. M., and W. J. Keenan. 2009. Group B streptococcus and early-onset sepsis in the era 
of maternal prophylaxis. Pediatr Clin North Am 56:689-708. 
91. Kong, F., S. Gowan, D. Martin, G. James, and G. L. Gilbert. 2002. Molecular profiles of group 
B streptococcal surface protein antigen genes: relationship to molecular serotypes. J Clin Microbiol 
40:620-6. 
92. Kong, F., S. Gowan, D. Martin, G. James, and G. L. Gilbert. 2002. Serotype identification of 
group B streptococci by PCR and sequencing. J Clin Microbiol 40:216-26. 
93. Kong, F., D. Martin, G. James, and G. L. Gilbert. 2003. Towards a genotyping system for 
Streptococcus agalactiae (group B Streptococcus): use of mobile genetic elements in Australasian 
invasive isolates. J Med Microbiol 52:337-44. 
94. Konto-Ghiorghi, Y., E. Mairey, A. Mallet, G. Dumenil, E. Caliot, P. Trieu-Cuot, and S. 
Dramsi. 2009. Dual role for pilus in adherence to epithelial cells and biofilm formation in 
Streptococcus agalactiae. PLoS Pathog 5:e1000422. 
95. Kothari, N. J., C. A. Morin, A. Glennen, D. Jackson, J. Harper, S. J. Schrag, and R. Lynfield. 
2009. Invasive group B streptococcal disease in the elderly, Minnesota, USA, 2003-2007. Emerg 
Infect Dis 15:1279-81. 
96. Krohn, M. A., S. L. Hillier, and C. J. Baker. 1999. Maternal peripartum complications 
associated with vaginal group B streptococci colonization. J Infect Dis 179:1410-5. 
97. Lachenauer, C. S., R. Creti, J. L. Michel, and L. C. Madoff. 2000. Mosaicism in the alpha-like 
protein genes of group B streptococci. Proc Natl Acad Sci U S A 97:9630-5. 
98. Lachenauer, C. S., D. L. Kasper, J. Shimada, Y. Ichiman, H. Ohtsuka, M. Kaku, L. C. 
Paoletti, P. Ferrieri, and L. C. Madoff. 1999. Serotypes VI and VIII predominate among group 
B streptococci isolated from pregnant Japanese women. J Infect Dis 179:1030-3. 
99. Lambertsen, L., K. Ekelund, I. C. Skovsted, A. Liboriussen, and H. C. Slotved. 2010. 
Characterisation of invasive group B streptococci from adults in Denmark 1999 to 2004. Eur J Clin 
Microbiol Infect Dis 29:1071-7. 
100. Lancefield, R., and R. Hare. 1935. The serological differentiation of pathogenic and non-
pathogenic strains of hemolytic streptococci from parturient women. J Exp Med 61:335-349. 
Chapter 1    
 
42
101. Lancefield, R. C. 1933. A serological differentiation of human and other groups of hemolytic 
streptococci. J Exp Med 57:571-95. 
102. Lancefield, R. C., and E. H. Freimer. 1966. Type-specific polysaccharide antigens of group B 
streptococci. J Hyg (Lond) 64:191-203. 
103. Larsson, C., J. Holmgren, G. Lindahl, and C. Bergquist. 2004. Intranasal immunization of mice 
with group B streptococcal protein rib and cholera toxin B subunit confers protection against lethal 
infection. Infect Immun 72:1184-7. 
104. Lauer, P., C. D. Rinaudo, M. Soriani, I. Margarit, D. Maione, R. Rosini, A. R. Taddei, M. 
Mora, R. Rappuoli, G. Grandi, and J. L. Telford. 2005. Genome analysis reveals pili in Group 
B Streptococcus. Science 309:105. 
105. Leclercq, R. 2002. Mechanisms of resistance to macrolides and lincosamides: nature of the 
resistance elements and their clinical implications. Clin Infect Dis 34:482-92. 
106. Lim, D. V., K. S. Kanarek, and M. E. Peterson. 1982. Magnitude of colonization and sepsis by 
group B streptococci in newborn infants. Curr Microbiol 7:99-101. 
107. Lin, F. Y., A. Whiting, E. Adderson, S. Takahashi, D. M. Dunn, R. Weiss, P. H. Azimi, J. B. 
Philips, 3rd, L. E. Weisman, J. Regan, P. Clark, G. G. Rhoads, C. E. Frasch, J. Troendle, P. 
Moyer, and J. F. Bohnsack. 2006. Phylogenetic lineages of invasive and colonizing strains of 
serotype III group B Streptococci from neonates: a multicenter prospective study. J Clin Microbiol 
44:1257-61. 
108. Lindahl, G., M. Stalhammar-Carlemalm, and T. Areschoug. 2005. Surface proteins of 
Streptococcus agalactiae and related proteins in other bacterial pathogens. Clin Microbiol Rev 
18:102-27. 
109. Luan, S. L., M. Granlund, M. Sellin, T. Lagergard, B. G. Spratt, and M. Norgren. 2005. 
Multilocus sequence typing of Swedish invasive group B Streptococcus isolates indicates a 
neonatally associated genetic lineage and capsule switching. J Clin Microbiol 43:3727-33. 
110. Lyytikainen, O., J. P. Nuorti, E. Halmesmaki, P. Carlson, J. Uotila, R. Vuento, T. Ranta, H. 
Sarkkinen, M. Ammala, A. Kostiala, and A. L. Jarvenpaa. 2003. Invasive group B 
streptococcal infections in Finland: a population-based study. Emerg Infect Dis 9:469-73. 
111. Madoff, L. C., J. L. Michel, E. W. Gong, D. E. Kling, and D. L. Kasper. 1996. Group B 
streptococci escape host immunity by deletion of tandem repeat elements of the alpha C protein. 
Proc Natl Acad Sci U S A 93:4131-6. 
112. Madoff, L. C., L. C. Paoletti, and D. L. Kasper. 2006. Surface structures of group B streptococci 
important in human immunity, p. 169-185. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. 
Portnoy, and J. I. Rood (ed.), Gram-Positive Pathogens, 2nd ed. ASM Press, Washington, D.C. 
113. Madoff, L. C., L. C. Paoletti, J. Y. Tai, and D. L. Kasper. 1994. Maternal immunization of mice 
with group B streptococcal type III polysaccharide-beta C protein conjugate elicits protective 
antibody to multiple serotypes. J Clin Invest 94:286-92. 
114. Madzivhandila, M., P. V. Adrian, C. L. Cutland, L. Kuwanda, S. J. Schrag, and S. A. Madhi. 
2011. Serotype distribution and invasive potential of group B streptococcus isolates causing 
disease in infants and colonizing maternal-newborn dyads. PLoS One 6:e17861. 
  General Introduction 
 
 
43 
115. Maione, D., I. Margarit, C. D. Rinaudo, V. Masignani, M. Mora, M. Scarselli, H. Tettelin, C. 
Brettoni, E. T. Iacobini, R. Rosini, N. D'Agostino, L. Miorin, S. Buccato, M. Mariani, G. 
Galli, R. Nogarotto, V. Nardi Dei, F. Vegni, C. Fraser, G. Mancuso, G. Teti, L. C. Madoff, L. 
C. Paoletti, R. Rappuoli, D. L. Kasper, J. L. Telford, and G. Grandi. 2005. Identification of a 
universal Group B Streptococcus vaccine by multiple genome screen. Science 309:148-50. 
116. Maisey, H. C., K. S. Doran, and V. Nizet. 2008. Recent advances in understanding the molecular 
basis of group B Streptococcus virulence. Expert Rev Mol Med 10:e27. 
117. Maisey, H. C., M. Hensler, V. Nizet, and K. S. Doran. 2007. Group B streptococcal pilus 
proteins contribute to adherence to and invasion of brain microvascular endothelial cells. J 
Bacteriol 189:1464-7. 
118. Malbruny, B., A. M. Werno, T. P. Anderson, D. R. Murdoch, and R. Leclercq. 2004. A new 
phenotype of resistance to lincosamide and streptogramin A-type antibiotics in Streptococcus 
agalactiae in New Zealand. J Antimicrob Chemother 54:1040-4. 
119. Mandlik, A., A. Swierczynski, A. Das, and H. Ton-That. 2008. Pili in Gram-positive bacteria: 
assembly, involvement in colonization and biofilm development. Trends Microbiol 16:33-40. 
120. Manning, S., P. Tallman, and B. Foxman. 2000. Prevalence and co-colonization with group B 
Streptococcus (GBS) among heterosexual college couples. Ann Epidemiol 10:472. 
121. Manning, S. D., D. W. Lacher, H. D. Davies, B. Foxman, and T. S. Whittam. 2005. DNA 
polymorphism and molecular subtyping of the capsular gene cluster of group B Streptococcus. J 
Clin Microbiol 43:6113-6. 
122. Manning, S. D., M. A. Lewis, A. C. Springman, E. Lehotzky, T. S. Whittam, and H. D. 
Davies. 2008. Genotypic diversity and serotype distribution of group B streptococcus isolated 
from women before and after delivery. Clin Infect Dis 46:1829-37. 
123. Manning, S. D., K. Neighbors, P. A. Tallman, B. Gillespie, C. F. Marrs, S. M. Borchardt, C. 
J. Baker, M. D. Pearlman, and B. Foxman. 2004. Prevalence of group B Streptococcus 
colonization and potential for transmission by casual contact in healthy young men and women. 
Clin Infect Dis 39:380-8. 
124. Manning, S. D., A. C. Springman, E. Lehotzky, M. A. Lewis, T. S. Whittam, and H. D. 
Davies. 2009. Multilocus sequence types associated with neonatal group B streptococcal sepsis 
and meningitis in Canada. J Clin Microbiol 47:1143-8. 
125. Manning, S. D., A. C. Springman, A. D. Million, N. R. Milton, S. E. McNamara, P. A. Somsel, 
P. Bartlett, and H. D. Davies. 2010. Association of Group B Streptococcus colonization and 
bovine exposure: a prospective cross-sectional cohort study. PLoS One 5:e8795. 
126. Margarit, I., C. D. Rinaudo, C. L. Galeotti, D. Maione, C. Ghezzo, E. Buttazzoni, R. Rosini, 
Y. Runci, M. Mora, S. Buccato, M. Pagani, E. Tresoldi, A. Berardi, R. Creti, C. J. Baker, J. 
L. Telford, and G. Grandi. 2009. Preventing bacterial infections with pilus-based vaccines: the 
group B streptococcus paradigm. J Infect Dis 199:108-15. 
127. Marimon, J. M., A. Valiente, M. Ercibengoa, J. M. Garcia-Arenzana, and E. Perez-Trallero. 
2005. Erythromycin resistance and genetic elements carrying macrolide efflux genes in 
Streptococcus agalactiae. Antimicrob Agents Chemother 49:5069-74. 
Chapter 1    
 
44
128. Martins, E. R., J. Melo-Cristino, and M. Ramirez. 2007. Reevaluating the serotype II capsular 
locus of Streptococcus agalactiae. J Clin Microbiol 45:3384-6. 
129. Maslow, J. N., M. E. Mulligan, and R. D. Arbeit. 1993. Molecular epidemiology: application of 
contemporary techniques to the typing of microorganisms. Clin Infect Dis 17:153-62; quiz 163-4. 
130. Matsubara, K., and G. Yamamoto. 2009. Invasive group B streptococcal infections in a tertiary 
care hospital between 1998 and 2007 in Japan. Int J Infect Dis 13:679-84. 
131. Michel, J. L., L. C. Madoff, D. E. Kling, D. L. Kasper, and F. M. Ausubel. 1991. Cloned alpha 
and beta C-protein antigens of group B streptococci elicit protective immunity. Infect Immun 
59:2023-8. 
132. Michel, J. L., L. C. Madoff, K. Olson, D. E. Kling, D. L. Kasper, and F. M. Ausubel. 1992. 
Large, identical, tandem repeating units in the C protein alpha antigen gene, bca, of group B 
streptococci. Proc Natl Acad Sci U S A 89:10060-4. 
133. Moore, M. R., S. J. Schrag, and A. Schuchat. 2003. Effects of intrapartum antimicrobial 
prophylaxis for prevention of group-B-streptococcal disease on the incidence and ecology of early-
onset neonatal sepsis. Lancet Infect Dis 3:201-13. 
134. Murayama, S. Y., C. Seki, H. Sakata, K. Sunaoshi, E. Nakayama, S. Iwata, K. Sunakawa, 
and K. Ubukata. 2009. Capsular type and antibiotic resistance in Streptococcus agalactiae 
isolates from patients, ranging from newborns to the elderly, with invasive infections. Antimicrob 
Agents Chemother 53:2650-3. 
135. Neto, M. T. 2008. Group B streptococcal disease in Portuguese infants younger than 90 days. Arch 
Dis Child Fetal Neonatal Ed 93:F90-3. 
136. Nizet, V., P. Ferrieri, and C. E. Rubens. 2000. Molecular pathogenesis of group B streptococcal 
disease in newborns, p. 180-221. In D. L. Stevens and E. L. Kaplan (ed.), Streptococcal Infections 
- Clinical Aspects, Microbiology, and Molecular Pathogenesis. Oxford University Press, New 
York. 
137. Nizet, V., and C. E. Rubens. 2006. Pathogenic mechanisms and virulence factors of group B 
streptococci, p. 152-168. In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. 
Rood (ed.), Gram-Positive Pathogens, 2nd ed. ASM Press, Washington, D.C. 
138. Oladottir, G. L., H. Erlendsdottir, G. Palsson, E. S. Bjornsdottir, K. G. Kristinsson, and A. 
Haraldsson. 2011. Increasing incidence of late-onset neonatal invasive group B streptococcal 
infections in Iceland. Pediatr Infect Dis J 30:661-3. 
139. Oliveira, I. C., M. C. de Mattos, T. A. Pinto, B. T. Ferreira-Carvalho, L. C. Benchetrit, A. A. 
Whiting, J. F. Bohnsack, and A. M. Figueiredo. 2006. Genetic relatedness between group B 
streptococci originating from bovine mastitis and a human group B Streptococcus type V cluster 
displaying an identical pulsed-field gel electrophoresis pattern. Clin Microbiol Infect 12:887-93. 
140. Palazzi, D. L., M. A. Rench, M. S. Edwards, and C. J. Baker. 2004. Use of type V group B 
streptococcal conjugate vaccine in adults 65-85 years old. J Infect Dis 190:558-64. 
141. Paoletti, L. C., and D. L. Kasper. 2003. Glycoconjugate vaccines to prevent group B 
streptococcal infections. Expert Opin Biol Ther 3:975-84. 
  General Introduction 
 
 
45 
142. Persson, E., S. Berg, L. Bevanger, K. Bergh, R. Valso-Lyng, and B. Trollfors. 2008. 
Characterisation of invasive group B streptococci based on investigation of surface proteins and 
genes encoding surface proteins. Clin Microbiol Infect 14:66-73. 
143. Pezzicoli, A., I. Santi, P. Lauer, R. Rosini, D. Rinaudo, G. Grandi, J. L. Telford, and M. 
Soriani. 2008. Pilus backbone contributes to group B Streptococcus paracellular translocation 
through epithelial cells. J Infect Dis 198:890-8. 
144. Phares, C. R., R. Lynfield, M. M. Farley, J. Mohle-Boetani, L. H. Harrison, S. Petit, A. S. 
Craig, W. Schaffner, S. M. Zansky, K. Gershman, K. R. Stefonek, B. A. Albanese, E. R. Zell, 
A. Schuchat, and S. J. Schrag. 2008. Epidemiology of invasive group B streptococcal disease in 
the United States, 1999-2005. Jama 299:2056-65. 
145. Poyart, C., L. Jardy, G. Quesne, P. Berche, and P. Trieu-Cuot. 2003. Genetic basis of 
antibiotic resistance in Streptococcus agalactiae strains isolated in a French hospital. Antimicrob 
Agents Chemother 47:794-7. 
146. Rajagopal, L. 2009. Understanding the regulation of Group B Streptococcal virulence factors. 
Future Microbiol 4:201-21. 
147. Regan, J. A., M. A. Klebanoff, and R. P. Nugent. 1991. The epidemiology of group B 
streptococcal colonization in pregnancy. Vaginal Infections and Prematurity Study Group. Obstet 
Gynecol 77:604-10. 
148. Rinaudo, C. D., R. Rosini, C. L. Galeotti, F. Berti, F. Necchi, V. Reguzzi, C. Ghezzo, J. L. 
Telford, G. Grandi, and D. Maione. 2010. Specific involvement of pilus type 2a in biofilm 
formation in group B Streptococcus. PLoS One 5:e9216. 
149. Rosini, R., C. D. Rinaudo, M. Soriani, P. Lauer, M. Mora, D. Maione, A. Taddei, I. Santi, C. 
Ghezzo, C. Brettoni, S. Buccato, I. Margarit, G. Grandi, and J. L. Telford. 2006. Identification 
of novel genomic islands coding for antigenic pilus-like structures in Streptococcus agalactiae. 
Mol Microbiol 61:126-41. 
150. Rubens, C. E., M. R. Wessels, L. M. Heggen, and D. L. Kasper. 1987. Transposon mutagenesis 
of type III group B Streptococcus: correlation of capsule expression with virulence. Proc Natl Acad 
Sci U S A 84:7208-12. 
151. Sadowy, E., B. Matynia, and W. Hryniewicz. 2010. Population structure, virulence factors and 
resistance determinants of invasive, non-invasive and colonizing Streptococcus agalactiae in 
Poland. J Antimicrob Chemother 65:1907-14. 
152. Sambola, A., J. M. Miro, M. P. Tornos, B. Almirante, A. Moreno-Torrico, M. Gurgui, E. 
Martinez, A. Del Rio, M. Azqueta, F. Marco, and J. M. Gatell. 2002. Streptococcus agalactiae 
infective endocarditis: analysis of 30 cases and review of the literature, 1962-1998. Clin Infect Dis 
34:1576-84. 
153. Schrag, S., R. Gorwitz, K. Fultz-Butts, and A. Schuchat. 2002. Prevention of perinatal group B 
streptococcal disease. Revised guidelines from CDC. MMWR Recomm Rep 51:1-22. 
154. Schrag, S. J., C. G. Whitney, and A. Schuchat. 2000. Neonatal group B streptococcal disease: 
how infection control teams can contribute to prevention efforts. Infect Control Hosp Epidemiol 
21:473-83. 
Chapter 1    
 
46
155. Schrag, S. J., S. Zywicki, M. M. Farley, A. L. Reingold, L. H. Harrison, L. B. Lefkowitz, J. L. 
Hadler, R. Danila, P. R. Cieslak, and A. Schuchat. 2000. Group B streptococcal disease in the 
era of intrapartum antibiotic prophylaxis. N Engl J Med 342:15-20. 
156. Schuchat, A. 1998. Epidemiology of group B streptococcal disease in the United States: shifting 
paradigms. Clin Microbiol Rev 11:497-513. 
157. Schuchat, A., and S. Balter. 2006. Epidemiology of group B streptococcal infections, p. 186-195. 
In V. A. Fischetti, R. P. Novick, J. J. Ferretti, D. A. Portnoy, and J. I. Rood (ed.), Gram-Positive 
Pathogens, 2nd ed. ASM Press, Washington, D.C. 
158. Seo, Y. S., U. Srinivasan, K. Y. Oh, J. H. Shin, J. D. Chae, M. Y. Kim, J. H. Yang, H. R. 
Yoon, B. Miller, J. DeBusscher, B. Foxman, and M. Ki. 2010. Changing molecular 
epidemiology of group B streptococcus in Korea. J Korean Med Sci 25:817-23. 
159. Sinha, A., T. A. Lieu, L. C. Paoletti, M. C. Weinstein, and R. Platt. 2005. The projected health 
benefits of maternal group B streptococcal vaccination in the era of chemoprophylaxis. Vaccine 
23:3187-95. 
160. Skoff, T. H., M. M. Farley, S. Petit, A. S. Craig, W. Schaffner, K. Gershman, L. H. Harrison, 
R. Lynfield, J. Mohle-Boetani, S. Zansky, B. A. Albanese, K. Stefonek, E. R. Zell, D. Jackson, 
T. Thompson, and S. J. Schrag. 2009. Increasing burden of invasive group B streptococcal 
disease in nonpregnant adults, 1990-2007. Clin Infect Dis 49:85-92. 
161. Slotved, H. C., F. Kong, L. Lambertsen, S. Sauer, and G. L. Gilbert. 2007. Serotype IX, a 
proposed new Streptococcus agalactiae serotype. J Clin Microbiol 45:2929-36. 
162. Sorensen, U. B., K. Poulsen, C. Ghezzo, I. Margarit, and M. Kilian. 2010. Emergence and 
global dissemination of host-specific Streptococcus agalactiae clones. MBio 1:1-9. 
163. Sukhnanand, S., B. Dogan, M. O. Ayodele, R. N. Zadoks, M. P. Craver, N. B. Dumas, Y. H. 
Schukken, K. J. Boor, and M. Wiedmann. 2005. Molecular subtyping and characterization of 
bovine and human Streptococcus agalactiae isolates. J Clin Microbiol 43:1177-86. 
164. Sun, Y., F. Kong, Z. Zhao, and G. L. Gilbert. 2005. Comparison of a 3-set genotyping system 
with multilocus sequence typing for Streptococcus agalactiae (Group B Streptococcus). J Clin 
Microbiol 43:4704-7. 
165. Sutcliffe, J., T. Grebe, A. Tait-Kamradt, and L. Wondrack. 1996. Detection of erythromycin-
resistant determinants by PCR. Antimicrob Agents Chemother 40:2562-6. 
166. Takahashi, S., E. E. Adderson, Y. Nagano, N. Nagano, M. R. Briesacher, and J. F. Bohnsack. 
1998. Identification of a highly encapsulated, genetically related group of invasive type III group B 
streptococci. J Infect Dis 177:1116-9. 
167. Tamura, G. S., M. Herndon, J. Przekwas, C. E. Rubens, P. Ferrieri, and S. L. Hillier. 2000. 
Analysis of restriction fragment length polymorphisms of the insertion sequence IS1381 in group 
B Streptococci. J Infect Dis 181:364-8. 
168. Tamura, G. S., J. M. Kuypers, S. Smith, H. Raff, and C. E. Rubens. 1994. Adherence of group 
B streptococci to cultured epithelial cells: roles of environmental factors and bacterial surface 
components. Infect Immun 62:2450-8. 
  General Introduction 
 
 
47 
169. Telford, J. L., M. A. Barocchi, I. Margarit, R. Rappuoli, and G. Grandi. 2006. Pili in gram-
positive pathogens. Nat Rev Microbiol 4:509-19. 
170. Tenover, F. C., R. D. Arbeit, R. V. Goering, P. A. Mickelsen, B. E. Murray, D. H. Persing, 
and B. Swaminathan. 1995. Interpreting chromosomal DNA restriction patterns produced by 
pulsed-field gel electrophoresis: criteria for bacterial strain typing. J Clin Microbiol 33:2233-9. 
171. Tettelin, H., V. Masignani, M. J. Cieslewicz, C. Donati, D. Medini, N. L. Ward, S. V. 
Angiuoli, J. Crabtree, A. L. Jones, A. S. Durkin, R. T. Deboy, T. M. Davidsen, M. Mora, M. 
Scarselli, I. Margarit y Ros, J. D. Peterson, C. R. Hauser, J. P. Sundaram, W. C. Nelson, R. 
Madupu, L. M. Brinkac, R. J. Dodson, M. J. Rosovitz, S. A. Sullivan, S. C. Daugherty, D. H. 
Haft, J. Selengut, M. L. Gwinn, L. Zhou, N. Zafar, H. Khouri, D. Radune, G. Dimitrov, K. 
Watkins, K. J. O'Connor, S. Smith, T. R. Utterback, O. White, C. E. Rubens, G. Grandi, L. 
C. Madoff, D. L. Kasper, J. L. Telford, M. R. Wessels, R. Rappuoli, and C. M. Fraser. 2005. 
Genome analysis of multiple pathogenic isolates of Streptococcus agalactiae: implications for the 
microbial "pan-genome". Proc Natl Acad Sci U S A 102:13950-5. 
172. Tettelin, H., V. Masignani, M. J. Cieslewicz, J. A. Eisen, S. Peterson, M. R. Wessels, I. T. 
Paulsen, K. E. Nelson, I. Margarit, T. D. Read, L. C. Madoff, A. M. Wolf, M. J. Beanan, L. 
M. Brinkac, S. C. Daugherty, R. T. DeBoy, A. S. Durkin, J. F. Kolonay, R. Madupu, M. R. 
Lewis, D. Radune, N. B. Fedorova, D. Scanlan, H. Khouri, S. Mulligan, H. A. Carty, R. T. 
Cline, S. E. Van Aken, J. Gill, M. Scarselli, M. Mora, E. T. Iacobini, C. Brettoni, G. Galli, M. 
Mariani, F. Vegni, D. Maione, D. Rinaudo, R. Rappuoli, J. L. Telford, D. L. Kasper, G. 
Grandi, and C. M. Fraser. 2002. Complete genome sequence and comparative genomic analysis 
of an emerging human pathogen, serotype V Streptococcus agalactiae. Proc Natl Acad Sci U S A 
99:12391-6. 
173. Trieu-Cuot, P., G. de Cespedes, F. Bentorcha, F. Delbos, E. Gaspar, and T. Horaud. 1993. 
Study of heterogeneity of chloramphenicol acetyltransferase (CAT) genes in streptococci and 
enterococci by polymerase chain reaction: characterization of a new CAT determinant. Antimicrob 
Agents Chemother 37:2593-8. 
174. Trijbels-Smeulders, M. A., L. A. Kollee, A. H. Adriaanse, J. L. Kimpen, and L. J. Gerards. 
2004. Neonatal group B streptococcal infection: incidence and strategies for prevention in Europe. 
Pediatr Infect Dis J 23:172-3. 
175. Tsolia, M., M. Psoma, S. Gavrili, V. Petrochilou, S. Michalas, N. Legakis, and T. Karpathios. 
2003. Group B streptococcus colonization of Greek pregnant women and neonates: prevalence, 
risk factors and serotypes. Clin Microbiol Infect 9:832-8. 
176. Tyrrell, G. J., L. D. Senzilet, J. S. Spika, D. A. Kertesz, M. Alagaratnam, M. Lovgren, and J. 
A. Talbot. 2000. Invasive disease due to group B streptococcal infection in adults: results from a 
Canadian, population-based, active laboratory surveillance study--1996. Sentinel Health Unit 
Surveillance System Site Coordinators. J Infect Dis 182:168-73. 
177. Uh, Y., H. Y. Kim, I. H. Jang, G. Y. Hwang, and K. J. Yoon. 2005. Correlation of serotypes and 
genotypes of macrolide-resistant Streptococcus agalactiae. Yonsei Med J 46:480-3. 
Chapter 1    
 
48
178. van Belkum, A., M. Struelens, A. de Visser, H. Verbrugh, and M. Tibayrenc. 2001. Role of 
genomic typing in taxonomy, evolutionary genetics, and microbial epidemiology. Clin Microbiol 
Rev 14:547-60. 
179. van Belkum, A., P. T. Tassios, L. Dijkshoorn, S. Haeggman, B. Cookson, N. K. Fry, V. 
Fussing, J. Green, E. Feil, P. Gerner-Smidt, S. Brisse, and M. Struelens. 2007. Guidelines for 
the validation and application of typing methods for use in bacterial epidemiology. Clin Microbiol 
Infect 13 Suppl 3:1-46. 
180. Van Dyke, M. K., C. R. Phares, R. Lynfield, A. R. Thomas, K. E. Arnold, A. S. Craig, J. 
Mohle-Boetani, K. Gershman, W. Schaffner, S. Petit, S. M. Zansky, C. A. Morin, N. L. Spina, 
K. Wymore, L. H. Harrison, K. A. Shutt, J. Bareta, S. N. Bulens, E. R. Zell, A. Schuchat, and 
S. J. Schrag. 2009. Evaluation of universal antenatal screening for group B streptococcus. N Engl 
J Med 360:2626-36. 
181. Verani, J. R., L. McGee, and S. J. Schrag. 2010. Prevention of perinatal group B streptococcal 
disease--revised guidelines from CDC, 2010. MMWR Recomm Rep 59:1-36. 
182. von Both, U., M. Ruess, U. Mueller, K. Fluegge, A. Sander, and R. Berner. 2003. A serotype V 
clone is predominant among erythromycin-resistant Streptococcus agalactiae isolates in a 
southwestern region of Germany. J Clin Microbiol 41:2166-9. 
183. Wang, Y. H., L. H. Su, J. N. Hou, T. H. Yang, T. Y. Lin, C. Chu, and C. H. Chiu. 2010. Group 
B streptococcal disease in nonpregnant patients: emergence of highly resistant strains of serotype 
Ib in Taiwan in 2006 to 2008. J Clin Microbiol 48:2571-4. 
184. Wastfelt, M., M. Stalhammar-Carlemalm, A. M. Delisse, T. Cabezon, and G. Lindahl. 1996. 
Identification of a family of streptococcal surface proteins with extremely repetitive structure. J 
Biol Chem 271:18892-7. 
185. Wehbeh, W., R. Rojas-Diaz, X. Li, N. Mariano, L. Grenner, S. Segal-Maurer, B. Tommasulo, 
K. Drlica, C. Urban, and J. J. Rahal. 2005. Fluoroquinolone-resistant Streptococcus agalactiae: 
epidemiology and mechanism of resistance. Antimicrob Agents Chemother 49:2495-7. 
186. Weisner, A. M., A. P. Johnson, T. L. Lamagni, E. Arnold, M. Warner, P. T. Heath, and A. 
Efstratiou. 2004. Characterization of group B streptococci recovered from infants with invasive 
disease in England and Wales. Clin Infect Dis 38:1203-8. 
187. Wessels, M. R., and D. L. Kasper. 2000. Group B streptococcal vaccines, p. 402-418. In D. L. 
Stevens and E. L. Kaplan (ed.), Streptococcal Infections - Clinical Aspects, Microbiology, and 
Molecular Pathogenesis. Oxford University Press, New York. 
188. Wessels, M. R., C. E. Rubens, V. J. Benedi, and D. L. Kasper. 1989. Definition of a bacterial 
virulence factor: sialylation of the group B streptococcal capsule. Proc Natl Acad Sci U S A 
86:8983-7. 
189. Woodford, N. 2005. Biological counterstrike: antibiotic resistance mechanisms of Gram-positive 
cocci. Clin Microbiol Infect 11 Suppl 3:2-21. 
190. Zhao, Z., F. Kong, X. Zeng, H. F. Gidding, J. Morgan, and G. L. Gilbert. 2008. Distribution of 
genotypes and antibiotic resistance genes among invasive Streptococcus agalactiae (group B 
  General Introduction 
 
 
49 
streptococcus) isolates from Australasian patients belonging to different age groups. Clin 
Microbiol Infect 14:260-7. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
 
  
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
Analysis of group B streptococcal isolates from 
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two lineages with enhanced invasiveness 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
This chapter is published in: 
Martins, E. R.*, M. A. Pessanha*, M. Ramirez, and J. Melo-Cristino. 2007. Analysis of group B 
streptococcal isolates from infants and pregnant women in Portugal revealing two lineages with 
enhanced invasiveness. J Clin Microbiol 45:3224-9. 
* Both authors contributed equally to this work 
  
                                                                                             GBS in infants and pregnant women in Portugal 
 
 
53 
Summary 
The populations of group B streptococcus (GBS) associated with vaginal 
carriage in pregnant women and invasive neonatal infections in Portugal were 
compared. GBS isolates were characterized by serotyping, pulsed-field gel 
electrophoresis (PFGE) profiling, and multilocus sequence typing (MLST). Serotypes 
III and V accounted for 44% of all colonization isolates (n=269) whereas serotypes III 
and Ia amounted to 69% of all invasive isolates (n=64).  Whereas serotype Ia was 
associated with early-onset disease (EOD), serotype III was associated with late-onset 
disease (LOD). Characterization by PFGE and MLST identified very diverse 
populations in carriage and invasive disease. Serotype Ia was represented mainly by a 
single PFGE cluster defined by sequence type 23 (ST23) and the infrequent ST24. In 
contrast, serotype III was found in a large number of PFGE clusters and STs, but a 
single PFGE cluster defined by ST17 was found to be associated with invasive disease. 
Although serotype III was only associated with LOD, ST17 showed an enhanced 
capacity to cause both EOD and LOD. Our data reinforce the evidence for enhanced 
invasiveness of ST17 and identify a lineage expressing serotype Ia capsule and 
represented by ST23 and ST24 as having enhanced potential to cause EOD. 
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Introduction 
Streptococcus agalactiae, or group B streptococcus (GBS), emerged during the 
1960s as an important cause of neonatal disease, and by the 1970s, it was already 
established as a leading cause of infections in the newborn (19, 21, 30). In neonates and 
infants, GBS disease is defined as either early-onset disease (EOD) (age, 0 to 6 days) or 
late-onset disease (LOD) (age, 7 to 90 days) (10). EOD is associated with the presence 
of GBS in the vagina of the mother, and transmission is thought to occur vertically 
through aspiration of infected amniotic fluid or passage through the birth canal. Several 
studies have documented the serotypes of isolates colonizing the vaginas of pregnant 
women and those causing invasive infections in newborns (18, 27, 30, 36). The source 
of bacterial strains causing LOD is less well understood, and may involve community or 
nosocomial acquisition, although there is also evidence that in some infants with LOD, 
the GBS causing the infection shares the same serotype as the GBS isolated from their 
mothers, suggesting a maternal source (30). 
Although, prevention of GBS neonatal infections by antimicrobial prophylaxis 
was suggested as early as the mid 1960s and a selective screen for carriage in pregnant 
women was also proposed a few years later (19), it was not until 1996 that guidelines 
for the prevention of GBS neonatal infections were published in the United States (10). 
The initial guidelines suggested a mixed risk-based and screening-based approach, but 
later guidelines suggested the universal screening of pregnant women for GBS vaginal 
colonization at 35 to 37 weeks of gestation and the administration of intrapartum 
antibiotics to carriers (9). The implementation of these guidelines resulted in a massive 
decrease in EOD but has not affected the rate of LOD (8). Moreover, it was also noted 
that antimicrobial prophylaxis could have unwanted long-term effects due to increased 
antimicrobial use (31), and alternative prevention strategies have focused on the 
development of vaccines. Vaccine formulations based on the conjugation of GBS 
capsular polysaccharides to tetanus toxoid have already undergone phase I and II 
clinical trials, and studies evaluating their potential impact in the management of GBS 
disease suggest that vaccination may provide additional benefits over antimicrobial 
prophylaxis, especially due to the expected reduction in LOD (34). As an alternative or 
complement to these conjugate vaccines, efforts have been directed toward identifying 
bacterial surface proteins that could be used in vaccination (26). 
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To supplement these approaches, the genetic lineages responsible for neonatal 
infections and vaginal colonization were characterized, with the objective of identifying 
particularly virulent clones.  Recent studies have relied on multilocus sequence typing 
(MLST) and have identified a serotype III lineage defined by sequence type 17 (ST17), 
of bovine origin, as having enhanced virulence (3, 23). However, these comparative 
studies have been carried out in only two geographic areas (3, 4), and it would be of 
interest to perform these studies in other regions, were GBS disease may present 
different characteristics, to test the global validity of these findings. 
We undertook the characterization of GBS isolates recovered from vaginal 
carriage of pregnant women screened at 35 to 37 weeks of gestation and isolates 
responsible for invasive infections in infants in Portugal with the aim of identifying 
particular genetic lineages with enhanced virulence. The overrepresentation of serotype 
III, ST17, among neonatal invasive isolates was confirmed, and this lineage was 
responsible for almost half of the cases of LOD. In contrast, a lineage expressing 
serotype Ia and presenting ST23 and ST24 was also found to have enhanced virulence 
but was mainly associated with EOD. 
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Materials and Methods 
Bacterial strains 
GBS carriage isolates (n=269) were recovered from vaginorectal swabs of 
healthy asymptomatic women in their last trimester of pregnancy, using the 
recommended procedures for enhanced recovery of GBS (9). The bacteria were isolated 
during the normal antenatal follow-up of women in the Lisbon area from 2002 to 2004. 
Invasive GBS isolates (n=64) were recovered from blood or cerebrospinal fluid (CSF) 
of infants up to 3 months of age. From 2000 to 2002, only two laboratories from tertiary 
hospitals in the Lisbon area participated in the survey, and in 2003 and 2004, an 
additional nine laboratories geographically scattered in Portugal joined the survey. 
Accordingly, the majority of the isolates were recovered in 2003 and 2004 (n=45/64). 
The results of the preliminary characterization of 17 invasive isolates recovered from 
2000 to 2002 in one of the hospitals were reported previously (16). The laboratories 
were asked to submit all nonduplicate GBS isolated from normally sterile sites. 
Whenever isolates were available from blood and CSF of the same patient, only the 
CSF isolate was included in the study.  Isolates were identified to the species level by 
Gram stain, colony morphology, catalase test, and a commercial latex-agglutination 
technique (Slidex Strepto B, bioMérieux). 
 
Serotyping, Pulse-field gel electrophoresis (PFGE) and multilocus sequence 
typing (MLST) 
Capsular serotyping was done by slide agglutination using sera for types Ia, Ib, 
and II to VIII (Hemolytic Streptococcus Typing antisera for Group B, SEIKEN, Japan) 
according to the instructions of the manufacturer. Preparation of genomic DNA for 
pulsed-field gel electrophoresis (PFGE) analysis was done as described elsewhere (16). 
After digestion with SmaI (Fermentas, Vilnius, Lithuania), the fragments were resolved 
by PFGE as described previously (16). Comparison of PFGE patterns was performed by 
using Bionumerics software (Applied-Maths, Sint-Martens-Latem, Belgium) to create 
unweighted-pair group method with arithmetic means (UPGMA) dendrograms. The 
Dice similarity coefficient was used with optimization and position tolerance settings of 
1.0 and 1.5, respectively. Clones were defined as groups of isolates (n≥3) presenting 
profiles ≥80% related on the dendrogram, as previously described for Streptococcus 
pneumoniae (33). The choice of this cut-off value for the definition of clones is 
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supported by prior work in other streptococcal species showing that this value 
minimized incorrect classifications due to the inherent variability of the PFGE analysis 
(6) and that the groups defined showed extensive concordance with those defined by 
visual classification systems (35), as well as with those defined using other typing 
methods (6, 7). 
The characterization by MLST of selected isolates was performed as described 
previously (22). At least one isolate of each PFGE clone was characterized by MLST. 
In larger PFGE clones, isolates representing both colonization and infection and also the 
different serotypes grouped in the same PFGE cluster, were characterized by MLST. 
Whenever an invasive isolate of a particular serotype was not grouped into a PFGE 
clone, the isolate was characterized by MLST. eBURST software (14) and the entire 
GBS MLST database (http://pubmlst.org/sagalactiae/) were used to define relationships 
between STs. A recently described framework was used to analyze the relationships 
between the results of the typing methods (7). Fisher’s exact test (two-tailed) was used 
to test associations and a P value of <0.050 was considered significant. 
 
Estimation of the invasiveness of serotypes and PFGE defined clones 
In order to compare the probability of invasive disease due to individual 
serotypes and clones, empirical odds ratios (OR) and 95% confidence intervals (CI95%) 
were calculated by reference to all other serotypes and clones as previously described 
(5). The OR was calculated as follows: OR=(ad)/(bc), where a is the number of invasive 
A serotypes or clones, b is the number of carriage A serotypes or clones, c is the number 
of non-A serotypes or clones and d is the number of carriage non-A serotypes or clones. 
It follows from the presented formula that it is not possible to calculate an OR value 
when none of the isolates of a given serotype or clone is recovered from invasive 
infections or carriage. The choice of using all other serotypes and clones to measure the 
reference OR was substantiated by prior studies ( reference 5 and references therein) 
that also provide a discussion of the strengths of this method. 
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Results 
Capsular serotyping 
The results of serotyping the 64 invasive GBS isolates from infants and the 269 
isolates from asymptomatic colonization of pregnant women recovered in the last 
trimester of pregnancy are summarized in Table 2.1. Serotypes III and V were the most 
prevalent among asymptomatic colonization isolates, together accounting for 44% of all 
colonization isolates, whereas serotypes Ia and III were the most prevalent among 
invasive disease isolates, together accounting for 69% of the isolates. There were more 
isolates recovered from the CSF in cases of LOD (n=6) than in EOD (n=3), but the 
difference was not significant (Fisher’s exact test, P=0.051).  Serotype III was found to 
be more frequently isolated from CSF than expected from its representation in invasive 
isolates (figure 2.1), with seven isolates recovered from the CSF (Fisher’s exact test, 
P=0.025). 
 
PFGE and MLST 
A total of 225 isolates were analyzed by PFGE, including all isolates expressing 
capsular types III (n=85) and Ia (n=60); all infection isolates from the remaining 
serotypes and three randomly chosen colonization isolates for each invasive infection 
isolate expressing these serotypes. The clones defined by PFGE are represented in 
figure 2.1. To further characterize the genetic lineages associated with each PFGE 
clone, selected isolates (n=75) were characterized by MLST. Six novel alleles (adhP58, 
pheS25 and -26, atr37, glnA36, glcK30) and seven novel STs (ST286, ST288 to ST291, 
ST293, and ST295) were identified among the studied isolates.  Each PFGE cluster was 
composed mostly of isolates of the same serotype – Wallace index 0.865, meaning that 
only 1 out of every 10 pairs of isolates grouped together by PFGE will not share the 
same serotype – but each serotype could be clearly separated into several PFGE clusters 
(Wallace index 0.411). However, one of the largest PFGE clusters (cluster C, Figure 
2.1) was composed of significant numbers of both serotype III (n=20) and serotype II 
(n=8) isolates. Although these represented STs that were single locus variants of each 
other, no ST was found associated with both serotypes. The isolates grouped in each 
PFGE cluster belonged to the same genetic lineage, as determined by MLST and 
eBURST analysis, being single locus variants (SLVs) or double locus variants (DLVs) 
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of at least another isolate in the same PFGE cluster, confirming the usefulness of PFGE 
for identifying GBS clones.  
 
Estimation of the invasiveness of serotypes and PFGE defined clones 
The OR were calculated for all serotypes identified among invasive isolates, and 
the results are presented in Table 2.1. The distribution of the capsular serotypes between 
EOD and LOD was not homogeneous. To test if the enhanced invasiveness of some 
serotypes correlates with an association with each of the disease manifestations, the OR 
were also calculated by comparing the isolates recovered from vaginal colonization and 
EOD and LOD separately, and the results are also summarized in Table 2.1.   
 
TABLE 2.1 Enhanced disease potential of Streptococcus agalactiae serotypes 
Serotype Total (no.) 
Colonization 
(no.) 
Infection 
(no.) 
OR 
(CI95%)a 
EOD 
(no.) 
OR 
(CI95%) 
LOD 
(no.) 
OR  
(CI95%) 
Ia 60 42 18 2.11 (1.12-4.00) 13 
2.42 
(1.16-5.04) 5 NS 
Ib 16 14 2 NS 1 NS 1 NS 
II 54 46 8 NS 8 NS 0 NA 
III 85 59 26 2.44 (1.37-4.34) 12 NS 14 
6.23 
(2.49-15.56) 
IV 8 6 2 NS 1 NS 1 NS 
V 66 59 7 NS 7 NS 0 NA 
VII 5 5 0 NA 0 NA 0 NA 
NTb 39 38 1 0.10 (0.01-0.72) 0 NA 1 NS 
Total 333 269 64  42  22  
a
 An OR of >1 indicates increased invasive disease potential. NS, not significant; NA, not applicable. 
b
 NT, non-typeable.  
 
 
The two serotypes with higher OR for disease (Ia and III) were found to have 
solely higher and significant OR for EOD and LOD, respectively. The majority of 
isolates of serotype Ia were clustered together in the same PFGE group (cluster A) but 
presented three distinct STs (ST23, ST24 and ST144); however, they are at most DLVs 
of each other and belong to the same eBURST group (figure 2.1). In contrast, isolates 
presenting serotype III were found in various PFGE clusters, the two larger ones clearly 
distinguishing the ST17 lineage (cluster B) and the ST19 lineage (cluster C).  
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FIGURE 2.1 PFGE, MLST, and sources of the isolates analyzed in this study. Shown is a dendrogram 
from PFGE SmaI macrorestriction profile analysis of 225 isolates from neonatal invasive infections and 
vaginal carriage in Portugal. Unweighted-pair group method using average linkages and the Dice 
coefficient (indicated as percentages in the scale above the dendrogram) were used to cluster the isolates. 
Each PFGE clone (defined as a group of ≥3 isolates with a Dice coefficient of ≥80%) is represented by a 
triangle with a size proportional to the number of isolates included in the cluster. The serotypes 
corresponding to the isolates are indicated, as well as the number of isolates recovered from blood, CSF 
or associated with vaginal colonization. In brackets are indicated the STs that were identified in each 
group, and the number in parenthesis following the ST indicates the number of isolates in which that 
particular ST was identified. The four major clones are identified by capital letters: A, serotype Ia, ST23 
and ST24; B, serotype III, ST17; C, serotype II, ST28 and serotype III, ST19 and related STs; D, serotype 
V, ST1 and ST2. 
 
 
The majority of the serotype III isolates responsible for invasive disease were 
found in the ST17 lineage (n=19/26). Isolates causing infection belonged more 
frequently to this lineage than to any other lineage found within serotype III (Fisher’s 
exact test, P=0.0003). To further explore the invasive potential of this lineage, we 
calculated the OR for the PFGE cluster exhibiting ST17 against all other isolates, 
assuming that none of the isolates expressing serotypes other than III would present this 
ST. We believe this to be a reasonable assumption, since no such isolates have been 
described in the literature to date. An enhanced invasive-disease potential was found for 
ST17 for both EOD (OR=4.63, CI95% 1.95 to 10.98) and LOD (OR=10.59, CI95% 4.10 to 
27.34). A similar approach for the PFGE cluster with isolates presenting ST23 and 
ST24 showed an enhanced EOD potential (OR=2.23, CI95% 1.08 to 4.62) but not for 
LOD (OR=2.05, CI95% 0.80 to 5.23). 
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Discussion 
Similarly to previous studies, we found a diverse population among GBS 
colonization isolates, as well as among those causing invasive disease in Portugal, not 
only in terms of capsular polysaccharides, but also in genetic lineages defined by both 
PFGE and MLST (table 2.1 and figure 2.1). Apart from serotypes VI and VIII, all other 
serotypes were found among our collection, and all except serotype VII were associated 
with both carriage and infection. Among the isolates causing infection, two isolates 
were identified expressing serotype IV, a serotype frequently associated with carriage in 
Asia (1) but infrequently found as a cause of neonatal infections in Western countries 
(29). Also noteworthy was the high prevalence of ST24 found exclusively among 
isolates of PFGE cluster A (n=7/18 isolates characterized by MLST). ST24 was 
described in the publication proposing the GBS MLST scheme in a single isolate of 
serotype Ia (22) but has rarely been found among large collections of GBS isolates 
characterized by MLST since then; for instance, only 1.9% of 369 isolates, including 
both colonization and infection isolates, recovered in the Oxford region presented ST24 
(23). None of the PFGE clones with ≥5 isolates could be solely associated with 
colonization or infection (figure 2.1), indicating that all major lineages are capable of 
both asymptomatic colonization and causing invasive disease. The isolates belonging to 
each serotype were dispersed into a widely variable number of PFGE clusters, from 
only 2 in serotype Ia to 19 in serotype III isolates. 
When the population associated with carriage and the one causing infection were 
compared, serotypes Ia and III were found to have an increased invasive-disease 
potential. On the other hand, non-typeable isolates, frequently representing variants that 
express little or no capsular polysaccharide, which is an important GBS virulence factor 
(32), showed a lowered invasive-disease potential. However, there was a clear 
asymmetry in the prevalence of the various serotypes in EOD and LOD, and a more 
detailed analysis, stratifying by early and late-onset infections, indicated that serotype Ia 
had a significant OR for EOD while serotype III was only significant in LOD. Serotype 
III was also overrepresented in isolates recovered from the CSF, in agreement with 
previous studies suggesting an association of this serotype with meningitis (20). A 
higher proportion of LOD caused by serotype III is not unusual, and several reports, 
both from Europe (2, 13, 37) and from the United States and Canada (11, 20), have 
documented the prominent roles of serotypes Ia and III in EOD and LOD, respectively. 
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None of these reports, however, offer data regarding serotype prevalence in vaginal 
colonization, preventing an evaluation of the invasive potential of these serotypes in 
these contexts. 
Among serotype III isolates, two main lineages were distinguished by PFGE and 
MLST – a PFGE cluster represented exclusively by ST17 and a PFGE cluster 
represented by ST19 and associated STs, with the former being significantly associated 
with infection. These findings are in agreement with previous suggestions that the ST17 
lineage constitutes a particularly virulent lineage (4, 22, 23) and that ST19 is mostly 
associated with carriage (25). The two studies that suggested an enhanced virulence 
potential for the ST17 lineage did not distinguish between EOD and LOD (4, 22), but a 
later study in the Oxfordshire region, United Kingdom, found a significant association 
of the ST17 lineage with both EOD and LOD (23). 
When calculating OR, the implicit assumption is that one is comparing the 
distribution of serotypes in the reservoir to that of the one causing disease. A higher 
representation of a particular serotype or clone among the isolates causing disease can 
then be interpreted as a higher disease potential of that particular serotype or clone.  In 
the case of neonatal GBS infections, the reservoir is assumed to be the asymptomatic 
vaginal colonization of pregnant women. Multiple lines of evidence support this 
assumption for EOD, including the dramatic reduction in EOD brought about by 
intrapartum antibiotic prophylaxis (8); however, the case for LOD is not so well 
established. A maternal source was clearly implicated in some cases of LOD, but this 
was associated with ingestion of contaminated breast-milk and not with vaginal 
colonization (17), while in other cases a maternal source seems to be excluded due to 
negative vaginal and rectal colonization (24). Nosocomial acquisition of GBS was 
shown to occur (12, 28) and to be a possible cause of LOD (24), but its prevalence 
remains unknown, as well as the ultimate source of these isolates. Colonization of the 
human host is not restricted to the vagina and gastrointestinal tract but was also shown 
to occur in the upper respiratory tract, which could also be an important reservoir for 
GBS (15) and a significant source for transmission of  these bacteria to infants. These 
data argue for caution when interpreting OR calculated by including isolates causing 
LOD. 
Since serotype III showed only a significantly enhanced potential to cause LOD 
but was also a serotype including a large number of distinct clones, we calculated the 
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OR for the PFGE cluster exhibiting ST17 against all other isolates. An enhanced 
invasive-disease potential of ST17 for both EOD and LOD was found, confirming a 
previous report (23) but in contrast to the results obtained when all serotype III isolates 
were considered (table 2.1). A similar approach for the PFGE cluster with isolates 
presenting ST23 and ST24 showed an enhanced EOD potential, but not for LOD, in line 
with the results for serotype Ia, as expected from the genetically homogeneous nature of 
this serotype in our collection. 
The characteristics of GBS associated with carriage and responsible for invasive 
neonatal infections in Portugal were similar to those of comparable populations from 
different geographic areas. Our data identified the genetically homogeneous serotype Ia 
as having enhanced potential to cause EOD and confirmed the identification of the 
ST17 lineage, expressing serotype III, as having enhanced potential to cause both EOD 
and LOD, although the interpretation of the values for LOD warrants caution due to the 
uncertain nature of the reservoir for these infections. Most prior studies did not 
distinguish between EOD and LOD for the calculation of OR, and this may have 
prevented the identification of the enhanced potential of serotype Ia clones to cause 
EOD. The unusually high proportion of ST24 isolates among serotype Ia found in our 
collection may also have influenced the recognition of an enhanced capacity of this 
serotype to cause EOD, since prior studies did not find ST23 to be particularly virulent 
(23).  Similar to the way in which the case for enhanced invasive-disease potential of 
ST17 was strengthened by the independent study of geographically separated 
populations, the propensity of serotype Ia to cause EOD should be evaluated elsewhere. 
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Summary 
We analyzed 212 group B streptococci (GBS) from invasive infections in 
newborns in the Barcelona area between 1992-2009, with the aim of documenting 
changes in the prevalence of serotypes, antimicrobial resistance and genetic lineages 
and evaluating their association with either early-onset (EOD) or late-onset disease 
(LOD). Serotypes III (n=118) and Ia (n=47) together accounted for nearly 78% of the 
isolates. All isolates carried an alpha or alpha-like protein gene, with specific 
associations between genes and serotypes such as, Ib/bca, II/bca, III/rib and V/alp3, 
reflecting the presence of particular genetic lineages. Macrolide resistance (14.2%) was 
significantly associated to serotype V. Pulsed-field gel electrophoresis (PFGE) 
clustering was an excellent predictor of serotype and antibiotic resistance. The 
combination of PFGE and multilocus sequence typing revealed a large number of 
genetically distinct lineages. Still, specific lineages were dominant in our collection, 
particularly the serotype III/ST17/rib that had enhanced potential to cause LOD. 
Serotype Ia was concentrated on a single PFGE cluster composed of two genetic 
lineages: ST23/eps and ST24/bca. The ST24/bca sub-lineage of serotype Ia, that is 
infrequently found elsewhere, may be emerging as an important cause of neonatal 
invasive infections in the Mediterranean region. In spite of the introduction of 
prophylaxis, resulting in a pronounced decline of EOD, the study revealed a remarkably 
stable clonal structure of GBS causing neonatal infections in Barcelona in a period of 18 
years. 
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Introduction 
Streptococcus agalactiae, or group B streptococcus (GBS) is well established as 
a leading cause of neonatal sepsis and meningitis (25, 45). In neonates, early-onset 
disease (EOD) is defined as occurring within the first 7 days and late-onset disease 
(LOD) from day 8 to 90 (12). While vertical transmission is commonly accepted to be 
the cause of EOD (24, 37, 51), the source of bacterial strains causing LOD is less well 
understood (45). In 1996 guidelines for prevention of GBS neonatal infections by 
antimicrobial prophylaxis were published in the United States (12). Whereas a mixed 
risk-based and screening-based approach was initially suggested in the guidelines, the 
universal screening of pregnant women for GBS vaginal colonization at 35 to 37 weeks 
of gestation and the administration of intrapartum antimicrobial prophylaxis to carriers 
was proposed shortly afterwards (11). As a consequence, the incidence of EOD has 
fallen significantly over the past decade where these guidelines have been followed, yet 
this strategy is raising concern that the widespread use of intrapartum antimicrobials 
might delay, rather than prevent, the onset of GBS disease (10, 16). In the area of 
Barcelona, Spain, after the local implementation of the intrapartum antimicrobial 
prophylaxis guidelines, the incidence of EOD declined by 86%, from 1.92 cases per 
1,000 live births in 1994 to 0.26 in 2001 (p<0.001) (2), and has remained at low levels 
since (ranging from 0.47 cases per 1,000 live births in 2007 to 0.18 in 2009). In the 
same area, the incidence of LOD increased from 0.11 cases per 1,000 live births in 1996 
to 0.81 in 2009, but in spite of the difference between these values, these changes did 
not reflect a significant trend. 
Furthermore, the increase in the use of antimicrobials due to intrapartum 
antibiotic prophylaxis can lead to the emergence of resistant bacteria (46), a concern 
that has been strengthened by the recent description of GBS strains showing reduced 
susceptibility to beta-lactams (28). 
These considerations are driving the search for alternative prevention strategies. 
Studies evaluating the potential impact of vaccines in the management of GBS disease 
suggest that vaccination may provide additional benefits over antimicrobial prophylaxis, 
especially due to the expected reduction in LOD incidence (49). Vaccine formulations 
currently on trial are based on GBS capsular polysaccharides; however, they are not 
expected to provide optimal coverage in different regions, due to geographical 
differences in serotype distribution. In order to overcome serotype specificity, whole-
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genome-based approaches have been directed toward identifying protein antigens, 
which hold promise as components of globally effective vaccines (26, 33). 
In addition to the capsular polysaccharides, multiple virulence factors have been 
recognized and extensively characterized in recent decades. These virulence factors may 
be unevenly distributed within a particular serotype and may contribute significantly to 
the invasive potential of a particular lineage, independently of its capsular 
polysaccharide. Molecular epidemiology has been used to distinguish genetic lineages 
in order to probe for associations between specific GBS genotypes and disease. Most of 
these studies, using multilocus sequence typing (MLST), have identified a lineage with 
enhanced invasive capacity expressing serotype III and defined by sequence type 17 
(ST17) (6, 15, 31). Moreover, in a study of carriage and invasive isolates from Portugal, 
we found that serotype Ia presented an enhanced invasive disease potential and that it 
was particularly associated with EOD (36). In that study, serotype Ia was associated 
mostly with a single pulsed-field gel electrophoresis (PFGE) cluster and with two 
sequence types (ST23 and ST24), again pointing to the possible existence of particular 
genetic lineages with enhanced invasive disease potential. 
We undertook the analysis of GBS isolates responsible for invasive infections in 
newborns in the Barcelona area from 1992 to 2009 with the aim of documenting 
changes over this 18-year period and of testing associations with EOD and LOD. To 
this end, we have characterized the isolates with regard to their serotypes and 
antimicrobial resistance patterns and have identified the genetic lineages present by 
PFGE profiling, MLST, and surface protein gene profiling. 
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Materials and Methods 
Eight hospitals located in the Barcelona metropolitan area monitored all EOD 
cases from 1994 on and all LOD cases from 1996 on. In these hospitals, GBS 
prevention policies were implemented progressively from 1994 onward. Invasive 
disease was defined as the presence of GBS in a normally sterile fluid (blood or 
cerebrospinal fluid [CSF]). During the period from 1994 to 2009, a total of 351.950 live 
infants were born in the 8 hospitals, and EOD was diagnosed in 243 cases (189 infants 
born in the 8 hospitals and 54 referred from other hospitals). During the period from 
1996 to 2009, of a total of 315.576 live births, LOD was diagnosed in 131 infants. 
 
Bacterial isolates 
We characterized the 207 isolates available from the 374 GBS cases identified 
between 1994 and 2009 in the 8 Barcelona-area hospitals. Additionally, we also 
included 5 isolates recovered from patients with invasive GBS disease in the same 
centers between 1992 and 1993. Only the first isolate of each case was considered. A 
total of 212 GBS isolates were characterized: 123 from EOD and 89 from LOD patients.  
 
Serotyping, antimicrobial susceptibility testing and macrolide-resistance 
phenotype  
Capsular serotyping was carried out by a latex agglutination assay with a GBS 
serotyping kit (Essum, Umeå, Sweden) according to the manufacturer’s instructions. 
All GBS isolates were tested for susceptibility to erythromycin, clindamycin, 
tetracycline, chloramphenicol, levofloxacin, and penicillin by using the disk diffusion 
method according to the Clinical and Laboratory Standards Institute (CLSI) guidelines 
(13). The macrolide resistance phenotype was determined according to a double-disk 
test as described previously (38). 
 
PCR determination of macrolide-resistance genotype 
Total bacterial DNA was isolated by treatment of the cells with mutanolysin and 
boiling. Multiplex PCR was performed to detect the presence of the erm(B), erm(A) 
[erm(TR) subclass] and mef genes, as described elsewhere (17). 
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Pulsed-field gel profiling and MLST 
Total bacterial DNAs of the strains were isolated, digested with SmaI, and 
separated by PFGE as described previously (36). Whenever a complete digestion with 
SmaI was not achieved, the isoschizomer Cfr9I was used (48). PFGE patterns were 
compared by using Bionumerics software (Applied Maths, Sint-Martens-Latem, 
Belgium) to create dendrograms by the unweighted pair-group method with arithmetic 
averages (UPGMA). The Dice similarity coefficient was used with optimization and 
position tolerance settings of 1.0 and 1.5, respectively. PFGE-based clusters were 
defined as isolates with ≥80% relatedness on the dendrogram (36). MLST was 
performed by sequencing seven housekeeping genes as described previously (27), and 
sequence types (STs) were identified by using the S. agalactiae MLST database 
(http://pubmlst.org/sagalactiae) and were analyzed using the entire database and 
goeBURST (20). Alleles and sequence types not previously described were deposited at 
the S. agalactiae MLST database. DNA sequences were analyzed by using Bionumerics 
software. 
 
Surface protein gene profile 
Total bacterial DNA was isolated by treatment of the cells with mutanolysin and 
boiling. A multiplex PCR assay was performed for direct identification of GBS alpha-
like protein genes, as described elsewhere (14). This assay allowed the direct 
determination of the following GBS surface protein genes by analysis of the amplicon 
size: the alpha-C protein gene (bca); the epsilon protein gene (eps); and the rib, alp2/3, 
and alp4 genes. A previously described assay was performed to differentiate the alp2 
and alp3 protein antigen genes (34). 
 
Typing concordance and statistics 
The Wallace (W) and adjusted Rand (AR) coefficients were calculated to 
determine the concordance between the different typing methods (9, 40, 47). The AR 
coefficient provides a measurement of the overall concordance between the results of 
two methods, whereas the W coefficient provides a directional measurement of 
clustering concordance between different typing methods, i.e., if the results of one 
typing method can predict the results of another method. Simpson’s index of diversity 
(SID) was calculated to evaluate the diversity found among the isolates studied (9). All 
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these calculations were performed at the Comparing Partitions website 
(www.comparingpartitions.info). The Fisher exact test was used to evaluate 
associations. Odds ratios (OR) with 95% Wald confidence intervals (CI95%) (1), were 
calculated against all other serotypes or PFGE clusters and were used to identify 
particular serotypes or PFGE clusters associated with certain characteristics, controlling 
for a false discovery rate (FDR) under or equal to 0.05 (3). Spearman's non-parametric 
test was used to evaluate correlations (1). 
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Results 
Capsular serotyping 
The results of serotyping the 212 invasive GBS isolates from neonates are 
summarized in Table 3.1. Serotypes III (n=118) and Ia (n=47) were the most frequent 
among the population, together accounting for 77.8% of the isolates. The serotypes 
were also differently distributed in EOD and LOD (p=0.0067, Fisher’s exact test). 
Serotypes III and Ia were found in 44% and 26% of EOD cases, respectively, and in 
72% and 17% of LOD cases, respectively. In fact, the number of serotype III isolates 
found in LOD (n=64) was more than double the sum of all other serotypes (n=25), and 
this was the only serotype that showed a significant association with disease 
presentation (OR=2.980, CI95% 1.581 to 5.734, for an association with LOD). Although 
more isolates were recovered from the CSF in LOD cases (n=25) than in EOD cases 
(n=21), in agreement with a previous report (36), we did not find any association 
between the serotype and the biological product from which the isolate was recovered. 
 
 
TABLE 3.1 Serotype distribution among invasive GBS isolates causing EOD and LOD  
EOD  LOD  Serotype Blood CSF Total (%)  Blood CSF Total  (%)  Total 
Ia 27 5 32 (26)  11 4 15 (17)  47 
Ib 8 0 8 (7)  4 1 5 (6)  13 
II 9 1 10 (8)  1 0 1 (1)  11 
III 41 13 54 (44)  46 18 64 (72)  118 
IV 2 0 2 (2)  0 1 1 (1)  3 
V 11 1 12 (10)  2 0 2 (2)  14 
NTa 4 1 5 (4)  0 1 1 (1)  6 
Total 102 21 123 (100)  64 25 89 (100)  212 
aNT, nontypeable 
 
 
PFGE cluster analysis and MLST 
All isolates were analyzed by PFGE, and 43 different profiles were identified 
and were grouped into 18 different PFGE clusters (≥3 isolates), of which the major 5 
accounted for nearly 60% of the isolates (Figure 3.1). The remaining isolates (n=34) 
were included in minor PFGE groups (≤2 isolates) or had unique profiles.  
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FIGURE 3.1 Representative SmaI macrorestriction profiles of each PFGE cluster. Capital letters above 
the lanes correspond to cluster designations. Lane N, incomplete digestion with SmaI; lane N*, the same 
strain as in lane N but now digested with Cfr9I (see the text); lane λ, Lambda Ladder PFG Marker (New 
England Biolabs, Beverly, MA). 
 
 
The dendrogram depicting the relationship between these PFGE clusters is 
shown in Figure 3.2. The SID for the classification of the isolates into PFGE clusters 
was 0.894 (CI95% 0.867 to 0.921), indicating that the collection analyzed is genetically 
very diverse. Each PFGE cluster was almost exclusively composed of isolates of the 
same serotype (W=0.955, CI95% 0.910 to 1.000), indicating a very good predictive 
power of the PFGE-based genotypes for the serotype. The converse was not so; 
inspection of Figure 3.2 and Table 3.2 reveals that each serotype was subdivided into 
several PFGE clusters, as expected from the existence of several genetic lineages 
sharing the same serotype. 
To further identify the genetic lineages associated with each PFGE clone, all 
isolates were characterized by MLST. Thirteen novel alleles and 13 novel STs (ST469 
to ST471 and ST542 to ST551) were identified among the isolates studied. The detailed 
characterization of the clusters depicted in Figures 3.1 and 3.2 is summarized in Table 
3.2. 
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rib (3), eps (1) 
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alp3 
FIGURE 3.2 Dendrogram of the PFGE profiles 
of 212 GBS isolates and distribution of the 
surface protein genes. The dendrogram was 
constructed using UPGMA. Dice coefficients 
(percentages) are indicated in the scale above the 
dendrogram. Each cluster (defined as a group of 
three or more isolates with a Dice coefficient of 
≥80%) is represented by a triangle proportional to 
the number of isolates included in the cluster. 
Clusters are designated by capital letters with a 
subscript number indicating the number of 
isolates included in the cluster. The surface 
protein genes found in each particular cluster are 
given on the right. If more than one gene was 
found in strains of the same PFGE cluster, the 
number of isolates carrying each gene is indicated 
in parentheses. 
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TABLE 3.2 Properties of the genetic lineages found among the 212 invasive isolates 
No. of isolates not 
susceptible toc PFGE 
clustera Serotype  
EOD/LOD 
(no.) 
STs in PFGE cluster with the same 
serotype (n)b 
ERYd CHL TET 
Susceptible 
isolates 
(no.)e 
A53 III 23/30 [ST17 (48), ST147 (1), ST148 (1), 
ST542 (1), ST543 (1), ST550 (1)] 
1 0 51 2 
B3 III 2/1 [ST17 (2), ST180 (1)] 0 0 3 0 
C5 III 3/2 [ST17 (4), ST148 (1)] 0 0 5 0 
D15 III 3/12 ST17 (15) 0 0 15 0 
E6 III 2/4 [ST17 (4), ST469 (2)] 0 1 6 0 
F4 III 1/3 ST17 (4) 0 0 4 0 
G3 Ia 
III 
2/0 
1/0 
ST23 (2) 
ST19 (1) 
0 
1 
0 
1 
2 
1 
0 
0 
H38 Ia 
 
III 
22/14 
 
0/2 
[ST23 (25), ST24 (9), ST223 (1), 
ST545 (1)] 
ST17 (1), ST27 (1) 
0 
 
0 
1 
 
0 
34 
 
1 
3 
 
1 
I3 Ia 3/0 ST23 (3) 0 0 3 0 
J9 III 
 
II 
6/2 
 
1/0 
[ST19 (5), ST456 (1), ST471 (1), 
ST547 (1)]* 
ST28 (1)* 
3f 
 
0 
0 
 
0 
6 
 
1 
1 
 
0 
K5 III 
NTg 
0/3 
1/1 
ST17(3) 
ST28(2) 
0 
0 
0 
0 
3 
2 
0 
0 
L6 II 
Ia 
Ib 
3/0 
2/0 
0/1 
[ST2 (1), ST9 (1), ST12 (1)]* 
ST7 (2)* 
ST1 (1)* 
1 
2h 
0 
0 
0 
0 
0 
1 
1 
2 
0 
0 
M4 Ib 3/1 [ST8 (1), ST9 (2) ST10 (1)] 0 0 2 2 
N4 III 
V 
2/1 
1/0 
[ST19 (2), ST27 (1)]* 
ST19 (1)* 
0 
0 
0 
0 
2 
2 
0 
0 
O3 Ib 2/1 ST12 (3) 0 0 3 0 
P3 II 3/0 ST22 (3) 3f 0 3 0 
Q11 V 9/2 ST1 (11) 8 0 11 0 
R3 Ia 
NTg 
2/0 
1/0 
ST23 (2) 
ST19 (1) 
0 
0 
0 
0 
2 
0 
0 
1 
Other34 III 
 
Ib 
 
II 
 
IV 
NTg 
Ia 
V 
11/4 
 
3/2 
 
3/1 
 
2/1 
3/0 
1/1 
2/0 
ST17 (4), ST19 (6), ST24 (1), 
ST106 (2), ST470 (1), ST546 (1) 
ST2 (1), ST9 (1), ST10 (1),         
ST12 (1), ST548 (1) 
ST1 (1), ST12 (1), ST22 (1),   
ST544 (1) 
ST2 (1), ST196 (1), ST549 (1) 
ST19 (1), ST27 (1), ST130 (1) 
ST7 (1), ST196 (1) 
ST26 (1), ST551 (1) 
6 
 
2 
 
1f 
 
0 
1f 
0 
1f 
3 
 
0 
 
0 
 
0 
0 
0 
0 
14 
 
3 
 
3 
 
2 
1 
1 
1 
1 
 
2 
 
1 
 
1 
1 
1 
0 
Total  123/89  30 6 189 19 
aPFGE clusters are identified as indicated in Figure 3.1. Clusters are designated by capital letters and a 
subscript number indicating the number of isolates included in the cluster. 
bBrackets indicate STs that were grouped into the same PFGE cluster and belonged to the same clonal 
complex by goeBURST and expressed the same serotype. Asterisks indicate STs or groups of STs that were 
found in the same PFGE cluster and belonged to the same clonal complex by goeBURST but expressed 
different serotypes. 
cERY, erythromycin; CLI, clindamycin; CHL, chloramphenicol; TET, tetracycline 
dAll isolates were simultaneously resistant to erythromycin and clindamycin, presenting with the cMLSB 
phenotype associated to the erm(B) gene, except when indicated. 
eIsolates susceptible to all antimicrobials tested (ERY, CLI, CHL, and TET) 
fOne isolate carried the erm(A) gene 
gNT, nontypeable 
hTwo isolates carried the erm(A) gene 
  GBS neonatal infections in Barcelona 
 
 
81 
The SID for the classification of the isolates according to their MLST-based 
sequence types was 0.805 (CI95% 0.758 to 0.852), also indicating a genetically diverse 
collection but less diverse than the classification in PFGE profiles. Overall, the isolates 
sharing the same ST also shared the same serotype (W=0.978, CI95% 0.961 to 0.997), 
indicating that MLST is a good predictor of serotype, a finding similar to that for the 
PFGE profiles.  
In agreement with these observations, serotype III isolates representing ST17 
were found mostly in PFGE clusters A53 and D15. Likewise, most serotype Ia isolates 
(of which the majority belonged to ST23 but a significant proportion belonged to ST24) 
and serotype V isolates (ST1) grouped into particular clusters, H38 and Q11, respectively. 
Interestingly, most of the new STs were identified in serotype III isolates. 
Whereas ST469, ST542, ST543 and ST550 are single-locus variants (SLVs) of ST17, 
ST470 is a double-locus variant (DLV) of ST17 (exhibiting two novel alleles). On the 
other hand, ST471 and ST547 are SLVs of ST19, a sequence type previously associated 
with colonization (27, 31, 36). ST19 was found to be poorly represented in our 
collection; the largest PFGE cluster where this ST was found was J9. This was expected, 
because the collection analyzed included only isolates that had caused invasive neonatal 
infections. 
Six of the newly described STs (ST470, ST544, ST546, ST548, ST549, and 
ST551) were found in isolates included in minor PFGE clusters or showing unique 
profiles (Table 3.2). The combination of rare PFGE profiles and STs suggests that the 
GBS populations causing invasive neonatal disease may reflect the larger genetic 
diversity found in the overall GBS population to a limited extent. 
In testing for an association between the largest PFGE clusters (n≥10) and the 
timing of disease presentation, both the major clusters of serotype III (A53 and D15) 
presented significant OR for an association with LOD (OR=2.202, CI95% 1.121 to 4.376 
and OR= 6.182, CI95% 1.598 to 35.220, respectively) but only the latter association was 
significant when controlled for the FDR (p=0.018). In agreement to what was found for 
the serotypes, none of these largest PFGE clusters was associated with recovery from 
blood or CSF. 
Among sequence types, ST17 was the only genetic lineage defined by MLST 
that was overrepresented in LOD (OR=4.972, CI95% 2.659 to 9.488). Of the two major 
serotype III/ST17 clusters defined by PFGE (A53 and D15), only the latter was 
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significantly associated with LOD, suggesting that PFGE could distinguish between two 
ST17 lineages that are otherwise indistinguishable by their serotypes, ST and surface 
protein, but that could have other significant differences. This hypothesis remains to be 
studied further. 
 
Antimicrobial susceptibility testing 
All isolates were susceptible to penicillin and to levofloxacin. The overall rate of 
erythromycin resistance was 14.2% (n=30). All erythromycin-resistant isolates 
displayed the constitutive MLSB phenotype (cMLSB), defined by cross-resistance to all 
macrolides, lincosamides, and streptogramin B. None of the erythromycin-resistant 
isolates carried the mef gene,; the erm(B) gene was present in 76.7% (n=23) and the 
erm(A) [erm(TR) subclass] gene in 23.3% (n=7) of the isolates. Resistance to 
tetracycline was found in 89.2% (n=189) of the isolates and resistance to 
chloramphenicol in 2.8% (n=6). 
While resistance to tetracycline or chloramphenicol was not clustered in 
particular serotypes, the same was not true for resistance to erythromycin (p<0.001, 
Fisher’s exact test) (Table 3.2). Analysis of individual serotypes revealed that serotypes 
Ia (n=2/47 [4.3%]) and III (n=11/118 [9.3%]) presented less erythromycin resistance 
than expected (OR=0.219, CI95% 0.024 to 0.926 and OR=0.408, CI95% 0.165 to 0.962, 
respectively), while serotypes II (n=5/11 [45.5%]) and V (n=9/14 [64.3%]) presented 
more erythromycin-resistant isolates than expected (OR=5.788, CI95% 1.297 to 24.7061 
and OR=14.806, CI95% 4.024 to 61.874, respectively), but only the finding for serotype 
V was significant when controlled for the FDR (p<0.001). 
Analysis of the largest PFGE clusters (n≥10) revealed three clusters with 
significant associations with erythromycin resistance, clusters H38 (OR=0, CI95% 0 to 
0.528) and A53 (OR=0.087, CI95% 0.002 to 0.552) with reduced resistance and cluster 
Q11 (OR=21.092, CI95% 4.645 to 131.992) with higher resistance; all these associations 
remained significant when controlled for the FDR (p=0.009 for both H38 and A53 and 
p<0.001 for Q11). These results were not surprising. PFGE cluster Q11 includes the 
majority of serotype V isolates, all presenting with ST1, a sequence type that was also 
significantly associated with erythromycin resistance (OR=12.589, CI95% 3.303 to 
53.599). On the other hand, PFGE cluster H38 includes the majority of ST23/serotype Ia 
isolates, and cluster A53 represents the ST17/serotype III and related lineages. Both 
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clusters were associated with erythromycin susceptibility, a result that had already been 
suggested by the serotype analysis but that had failed to reach statistical significance. 
However, the MLST analysis revealed that both ST23 and ST17 were significantly 
associated to erythromycin susceptibility (OR= 0, CI95% 0 to 0.658 and OR=0.040, 
CI95% 0.001 to 0.256, respectively), supporting the indication given by the PFGE cluster 
analysis. 
Even though ST19 was poorly represented in our collection, in agreement with 
its association with colonization (31), it was also overrepresented among erythromycin-
resistant isolates (OR=6.885, CI95% 2.082 to 22.557). This association was reported 
previously in Portugal (19). 
 
Surface protein gene profiling 
All isolates gave positive results for the presence of only one surface protein 
gene, with the exception of one isolate for which we failed to amplify any of the genes 
tested. The surface protein gene rib was the most prevalent, followed by the eps, bca 
and alp3 genes, showing variable distributions across serotypes (Table 3.3).  
 
 
Table 3.3 Distribution of genes encoding surface proteins across serotypes 
Surface protein genea 
Serotype 
bca eps rib alp3 
Total 
Ia 12 35    
Ib 11 1  1 47 
II 7 1 2 1 13 
III 2  116  11 
IV 1 2 1  118 
V  2  11 3 
NTb 1  5  13c 
Total 34 41 123 13 6 
aBoldface numbers indicate a significant correlation between surface protein 
 gene and serotype (see the text) 
bNT, nontypeable 
cOne isolate failed to amplify any of the surface proteins tested 
 
 
No alp2 or alp4 genes were found among the isolates. There was a very high 
correspondence between serotypes and surface protein genes (AR=0.789, CI95% 0.713 to 
0.867). This was reflected in significant OR for the association of most serotypes (n≥10) 
with particular surface protein genes: serotype Ia with eps, serotypes Ib and II with bca, 
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serotype III with rib, and serotype V with alp3; all these association remained 
significant when controlled for the FDR (p<0.001) (Table 3.3). 
Surface protein genes were differently distributed across PFGE clusters (Figure 
3.2), correlating with the proportions of serotypes within the clusters. A main exception 
was serotype Ia isolates, which grouped in PFGE cluster H38, although they presented 
with surface protein gene eps or bca. In this cluster, an absolute association was found 
between the ST and the surface protein gene, with all ST23 isolates carrying the eps 
gene and all ST24 isolates carrying the bca gene exclusively, in support of our 
hypothesis that they constitute sub-lineages. In addition, we have also identified two 
isolates, one representing ST223 and the other representing the newly identified ST545, 
that are SLVs of ST23 but not of ST24, both harboring the eps gene, suggesting 
diversification of ST23 with retention of the characteristic surface protein gene. 
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Discussion 
This study comprises a considerable number of invasive GBS isolates collected 
over an 18-year period in the Barcelona region. In spite of the overall large number of 
isolates, the number of yearly infections was low, preventing detailed evaluation of the 
temporal changes in serotypes or PFGE clusters. Still, serotype III was present in all 
years and serotype Ia was absent in only two years of the study period. The remaining 
serotypes were represented by fewer isolates than the number of years studied, but there 
was an overall correlation between the number of isolates and the number of years in 
which they were found (r= 0.964, p=0.0028, Spearman’s test), indicating that no 
significant changes in the serotypes causing neonatal infections occurred in Barcelona 
in the 18 years studied. A similar analysis by PFGE cluster is complicated by their 
larger number; still, each of the five largest clusters (n≥10) was found in at least 7 years, 
and the two largest (A53 and H38) were found in all but 2 of the study years. Taken 
together, these data reveal a remarkably stable clonal structure of the GBS causing 
neonatal infections in Barcelona over a period of 18 years. This occurred in spite of the 
major epidemiological changes in neonatal GBS infections due to the introduction of 
prophylaxis in 1994, which resulted in a pronounced decline in EOD incidence (2). 
We found substantial diversity among the GBS isolates causing neonatal 
invasive disease, not only in terms of capsular polysaccharides, but also in the genetic 
lineages defined by both PFGE and MLST (Figure 3.2 and Table 3.2). However, most 
isolates belonged to two serotypes and to a few STs and major PFGE clusters. The 
serotype distribution found in the population was similar to that described in some 
European countries, where capsular types Ia and III prevail among isolates causing 
invasive neonatal infections (5, 36, 41). In contrast to some U.S. studies, where the 
prevalence of serotype V reached as high as 30% (42), and to the recent increase 
reported in the prevalence of this serotype in Scandinavia (4, 39), serotype V was found 
much less frequently in Barcelona, in agreement with the results of most studies across 
Europe. 
Classification by PFGE and MLST defined groups of isolates frequently sharing 
the same serotype and surface protein gene, indicating that both techniques are 
identifying groups of closely related isolates. Strong correlations between the genes 
encoding surface proteins and serotypes were also found (Table 3.3): most serotypes 
were associated primarily with a single surface protein gene. The exception was 
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serotype Ia that was associated with two proteins, although only one reached 
significance, with approximately one-quarter of the isolates carrying the bca gene and 
the remaining three-quarters carrying the eps gene. While our data are consistent with 
those reported elsewhere in Europe, contrasting data can be found in some studies from 
the United States reporting the absence of the bca surface protein gene in all serotype Ia 
isolates causing invasive neonatal infections (32). We believe that this is a defining 
characteristic of a sub-lineage of serotype Ia, as discussed below. Also in contrast to the 
data reported here, another study from the United States found the bca surface protein 
gene in more than 50% of serotype V isolates (50). Considering that most studies 
describe a strong association of serotype V with the alp3 gene (21, 29, 43), it is possible 
that the higher prevalence of serotype V in the United States than in Europe results from 
the expansion of a sub-lineage not found in Europe. This is despite the fact that most 
serotype V isolates on either continent share the same sequence type (ST1). 
As more collections are analyzed by their complement of surface protein genes, 
a broader understanding of these genes’ relationships with serotypes may be obtained. 
However, our data suggest that it may be naïve to expect an absolute correlation with 
serotype and that additional typing methods, such as PFGE or MLST, are potentially 
useful for identifying distinct genetic lineages within each serotype that may also differ 
in their surface proteins. 
Of note in this context was the high prevalence of ST24 found among serotype 
Ia isolates, which concentrated mostly in PFGE cluster H38, together with the more 
widely disseminated ST23. ST24 is a DLV of ST23 that has rarely been found among 
large collections of GBS isolates characterized by MLST, with the exception of 
Portugal, where a significant prevalence of this ST was first reported in 2007 (36). Also 
in 2007, a study from Italy showed most serotype Ia isolates grouping together in the 
same PFGE cluster, presenting either the bca or the eps surface protein genes as 
described here, and the one representative isolate of this cluster characterized by MLST 
harbored the bca gene and was ST24 (21). Later, ST24 was found in 3 out of 52 
serotype Ia invasive isolates from neonates in the United States; these 3 isolates were 
reported as a rare invasive clone (8). This suggests that within serotype Ia there are two 
different sub-lineages not distinguishable by PFGE, but discriminated by MLST and 
surface protein gene profiling. In agreement with this hypothesis is the absolute 
association between the ST and the surface protein gene in our collection, with all ST23 
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isolates carrying the eps gene and all ST24 isolates carrying the bca gene exclusively. 
Previous results from our laboratory had provided strong support for the circulation of 
both sub-lineages in Portugal (35). Taken together, these observations suggest that the 
presence of a particular alpha or alpha-like surface protein gene is a clonal property 
rather than a feature of the serotype. Interestingly, we have also found an additional 
ST24/bca isolate belonging to serotype III that may be the result of capsular switching 
(34). 
This study, together with previous data from Portugal and Italy (21, 36) suggests 
that a particular sub-lineage of serotype Ia may be disseminated in the Mediterranean 
region. Although we could not find a correlation between each of the surface protein 
defined sub-lineages and the isolate source (blood or CSF) or the timing of disease 
presentation (EOD or LOD), the ST24 sub-lineage may have other properties that could 
explain its success. 
In spite of the recent report of penicillin non-susceptibility among GBS (28) and 
the intensive use of beta-lactams in prophylaxis in Barcelona since 1994, all isolates 
were fully susceptible to penicillin. The macrolides can also be used in 
chemoprophylaxis, and in contrast to penicillin, a significant proportion of 
erythromycin resistance was found (14.2%), in line with previous results from a 
multicentre study in Spain (13.7%) (22). The phenotypes and genotypes of macrolide-
resistant isolates from Barcelona were also similar to those previously identified in 
Spain (23). In agreement with other studies in different geographic regions, we found an 
association between macrolide resistance, serotype V (7, 53), and ST1 (44). Still, only 
30% of erythromycin resistance was found in serotype V, while the remaining was 
dispersed in all other serotypes except serotype IV, a situation observed in a few 
previous studies (18, 30, 52). Resistance was also found to be dispersed in many genetic 
lineages as defined by PFGE and MLST, in agreement with the carriage of the 
methylase genes on mobile genetic elements. However, clonal expansion is also 
important in macrolide resistance; PFGE cluster Q11, expressing serotype V and ST1, 
was found to be significantly associated with resistance. On the other hand, cluster A53, 
representing the highly virulent ST17 and associated lineages, was less resistant than 
expected, reflecting the general observation that isolates representing ST17 are rarely 
macrolide resistant. The reasons why this highly virulent and successful lineage is 
seldom resistant are unknown. 
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The characterization of the population of GBS causing invasive infections in 
neonates in the Barcelona region revealed the existence of a large number of genetically 
distinct lineages that were present over a significant time span. The stability and 
dominance of a few lineages that are responsible for the majority of infections in spite 
of continuous antibiotic and immune selective pressures suggest that they are extremely 
well adapted to their particular niche. Although most of these lineages are widely 
disseminated worldwide, we have also identified seemingly regionally successful 
clones, raising the possibility of ongoing selection and expansion of specific virulent 
GBS clones. Continuous surveillance will shed further light on these processes and will 
determine if these clones will further expand beyond their current geographical 
boundaries. 
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Summary 
Two temporally and geographically clustered cases of meningitis caused by 
Streptococcus agalactiae expressing the infrequent Ib serotype are reported. 
Characterization by pulsed-field gel electrophoresis and multilocus sequence typing 
revealed that the isolates were identical and represented the widely distributed 
ST10/ST8 lineage associated with serotype Ib. 
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Case reports 
Case 1 
A 69-year-old woman, with no known risk factors for group B streptococcal 
(GBS) infection, was admitted on 7 January 2007 to a tertiary-care hospital in Lisbon 
with headache, nausea and vomiting, disturbances of consciousness, and blurred vision 
with an onset 24 hours prior to admission. On presentation, she was apyretic and 
confused and had no signs of meningeal irritation. Hematological investigations 
revealed a white blood cell (WBC) count of 4,630×106/liter (with 85% granulocytes) 
and a C-reactive protein level of 370 mg/liter. A lumbar puncture was performed, and 
blood samples were taken for culture. The cerebrospinal fluid (CSF) exhibited a WBC 
(granulocyte) count of 113/mm3, a glucose concentration of 1mg/dl, a protein 
concentration of 533mg/dl, and Gram staining showed gram-positive cocci. A head 
computed tomography (CAT) scan was unremarkable. 
On the basis of the initial results, empirical therapy consisting of ceftriaxone (4g 
daily, given intravenously) and ampicillin (12g daily, given intravenously) was started. 
Clinical evolution was rapid with loss of consciousness and multiple organ 
failure, and the patient died 12h after admission.  
Both CSF and blood cultures were positive 24h later for Streptococcus 
agalactiae susceptible to penicillin and ceftriaxone. 
 
 
Case 2 
Within a few hours of the first case, a second case was encountered at the same 
hospital. A 58-year-old woman was admitted with headache, prostration, fever, 
polyarthralgia and diarrhea with an onset 48h prior to admission. On presentation, she 
was comatose and febrile, and had positive signs of meningeal irritation. The WBC 
count was 17,900×106/liter (with 88% granulocytes), and the C-reactive protein level 
was 292mg /liter. A lumbar puncture was performed, and blood samples were taken for 
culture. The CSF revealed >500WBC (granulocytes)/mm3, a glucose concentration of 
<1mg/dl, a protein concentration of 736mg/dl, and the presence of gram-positive cocci. 
A head computed axial tomography scan was unremarkable.  
On the basis of the initial results, empirical therapy consisting of ceftriaxone (4g 
daily, given intravenously) and ampicillin (12g daily, given intravenously) was started. 
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Both CSF and blood cultures were positive 24h later for S. agalactiae 
susceptible to penicillin and ceftriaxone. On the basis of the microbiological results, the 
antimicrobial therapy was changed to penicillin G (24×106 U daily, given 
intravenously). 
Urine culture, a vaginorectal swab culture for detection of GBS, and another set 
of blood cultures performed 24h after admission were all negative. A review of the 
patient’s clinical history revealed a mastectomy due to breast cancer 10 years prior to 
the current episode as the only possible risk factor for GBS infection. On discharge, the 
patient revealed no motor deficits but was diagnosed with neurosensory deafness and 
diplopia. 
 
 
The patients lived on the same street, but interviews of the members of their 
households were not able to establish a prior social acquaintance. Isolates from both 
cases were serotyped by using specific sera (Denka Seiken, Japan) (5) and a genotyping 
method (9) as type Ib. Further characterization by pulsed-field gel electrophoresis 
(PFGE) (11) revealed identical profiles (Figure 4.1). To evaluate if the PFGE profiles 
were unusual among isolates expressing serotype Ib, 18 isolates from an ongoing 
nationwide survey of GBS infections focusing primarily on invasive infections (5, 11) 
were also characterized by both PFGE and multilocus sequence typing (8) and the 
results are reported in figure 4.1. 
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FIGURE 4.1 Characteristics of the GBS isolates responsible for the two cases of meningitis reported here 
(in bold) and of other serotype Ib isolates recovered in Portugal. The dendrogram was derived by the 
unweighted-pair group method using average linkages by using the Dice coefficient of the SmaI PFGE 
profiles of the isolates generated by using the Bionumerics software (Applied Maths, Sint-Martens-
Latem, Belgium). The horizontal scale at the top represents the percentage of relatedness between 
isolates. ND, not determined. Patient ages are indicated in years (yr) or days (d).  
 
 
Although the incidence of invasive GBS infections in non-pregnant adults has 
increased over the last decades, meningitis remains an uncommon manifestation (3). 
The incidence of GBS meningitis in adults in the United States is estimated to be 0.15 
cases per 100,000 adults (2), but it results in a high case-fatality rate (27 to 34%) (3). 
The incidence in Portugal is not known, but a prior study on a large hospital of the 
Lisbon area did not identify any cases (5) and our ongoing nationwide survey started in 
2003 identified only three cases, apart from the two reported here, among 916 GBS 
isolates responsible for infections in adults (136 of those were recovered from normally 
sterile sites). 
The majority of GBS meningitis cases is closely linked to the presence of 
underlying conditions (2, 4) or to the perinatal period (6), but in some cases no patient 
risk factors could be identified (1). In some of these cases, evidence of an external 
source of infection was presented (7). In the two cases reported here, only the patient in 
the second case had a known risk factor for GBS invasive infection – a mastectomy 
following a breast cancer diagnosis. Farley et al. have suggest that a mastectomy may 
continue to enhance the risk for invasive GBS infection many years after it was 
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performed, but the presentation of the patients is cellulitis of the arm or chest wall on 
the side that underwent the mastectomy (4). This did not occur in our case, and in fact, 
even though sometimes a distant focus of infection can be established (2), this was not 
possible in either of the cases presented here. Moreover, in the second case, vaginorectal 
colonization could not be established, suggesting an exogenous source. 
The temporal and geographical clustering of these two cases prompted further 
characterization of the isolates. The same serotype (Ib) was identified in both isolates. 
Serotype Ib is not among the most frequent serotypes associated with invasive disease 
in adults in the United States (3), and our previous study identified a single case of adult 
bacteremia due to this serotype (n=1/21) (5). Among neonatal infections and 
colonization of pregnant women in Portugal, serotype Ib was equally unremarkable in 
prevalence (11). Furthermore, none of the three adult GBS meningitis cases detected by 
our ongoing survey was associated with this serotype nor were any of the GBS 
infections in adults identified since January 2007 in the hospital where the two cases 
were detected (these isolates were serotyped as part of enhanced surveillance triggered 
by these meningitis cases). 
Characterization by PFGE revealed identical profiles (Figure 4.1) indicating that 
the isolates responsible for these two cases belong to the same bacterial clone. The 
characterization by PFGE of the isolates in our collection as serotype Ib identified a 
major cluster, and although no other isolate revealed the same PFGE profile as the 
isolates responsible for the two cases described here, these were included in the same 
cluster as the majority of the Ib isolates. This cluster included isolates associated with 
colonization and responsible for different clinical presentations in diverse age groups 
(Figure 4.1). Multilocus sequence typing analysis confirmed the distinction of the 
isolates in two clusters, in agreement with the PFGE analysis, since two sequence types 
(STs), ST8 and ST10, are single locus variants and therefore closely related, whereas 
ST24 differs at five out of seven loci of both of them. Again, the isolates responsible for 
the two cases presented here had the same ST – ST10. This was not an unusual ST 
among Ib isolates and was found in four additional isolates associated with both 
colonization and infection, including invasive disease (Figure 4.1). ST8 and ST10 are 
also the most frequent STs found among serotype Ib isolates from various sources and 
geographic origins (8, 10). A previous study could not establish an association between 
a particular genetic lineage and invasive disease in adults, but a significant fraction of 
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infections caused by clonal complex CC9, where ST8 and ST10 are included, was noted 
(10). 
Although a definite common source for the two cases was not established, their 
temporal clustering and the proximity of the homes of the two patients strongly 
suggested that such a common origin could exist. The microbiological findings further 
support this notion. Not only did the isolates present an unusual serotype, but they also 
displayed identical PFGE profiles, albeit belonging to the major genetic lineage 
associated with serotype Ib. The virulence of the strain causing these infections is 
apparent in the fatal outcome of one of the cases and the neurological sequelae of the 
surviving patient, in spite of appropriate antimicrobial therapy. GBS is an increasingly 
significant agent of bacterial meningitis in adults, and the high morbidity and mortality 
associated with these infections (3), even in adults with no risk factors, together with the 
possibility of community outbreaks, justify continued monitoring to obtain further 
insights into this important pathogen. 
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Summary 
The population of group B streptococcus (GBS) associated with invasive infections in 
non-pregnant adults in Portugal during 2001-2008 was analyzed (n=225). The isolates 
were characterized by pulsed-field gel electrophoresis (PFGE), multilocus sequence 
typing (MLST), antimicrobial resistance and surface protein gene profiling. GBS 
invasive cases were found more frequently among men in all age groups. Whereas 
serotype V is dominant among invasive isolates recovered from non-pregnant adults 
elsewhere, serotype Ia was the most frequent in our collection that notwithstanding 
presented significant diversity. Serotype Ia was represented mainly by a single PFGE 
cluster defined by sequence types 23 (ST23) and surface protein gene eps; and ST24 
and bca, as previously seen in neonatal invasive infections in Portugal, indicating that 
the same genetic lineages can be responsible for both vaginal colonization and invasive 
disease in all age groups. In contrast, the hypervirulent serotype III/ST17 neonatal 
lineage was responsible for a minority of infections. Serotype V isolates were 
distributed into two genetic lineages, one defined by ST1, surface protein gene alp3 and 
macrolide resistant, and another presenting with ST2, eps and fully susceptible to all 
antimicrobials tested. The erm(TR) gene was the most frequently found among  
erythromycin resistant isolates while the bovine associated  tet(O) gene was found in a 
minority of tetracycline resistant isolates. Our data emphasizes the need for identifying 
the genetic lineages responsible for GBS invasive infections in non-pregnant adults. The 
dominance of serotype Ia in invasive disease in Portugal, regardless of age, highlights 
the importance of this serotype in GBS pathogenesis. 
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Introduction 
Streptococcus agalactiae (group B streptococcus, GBS) is well established as a 
colonizing agent in pregnant women and an important cause of neonatal sepsis and 
meningitis (55). Nevertheless, in the past decade GBS has been increasingly associated 
with invasive disease in non-pregnant adults (23, 57). Such infections are held 
responsible for substantial morbidity and mortality, particularly in individuals with 
chronic underlying conditions such as malignancies, diabetes mellitus, cirrhosis and 
HIV infection, but several other risk factors have been identified in recent years (29). 
The spectrum of GBS disease in adults is broad, including more frequently bacteremia 
without a focus, skin and soft tissue, osteoarticular and urinary tract infections (23). 
Less frequent clinical presentations include meningitis and endocarditis that are, 
however associated with significantly higher morbidity and mortality (21, 40, 53). 
Although GBS infections are more frequently community acquired, nosocomial disease 
is also of concern (29).  
With the introduction of antenatal screening guidelines and effective prophylaxis 
a significant decrease in neonatal invasive infections was observed in the last decade. 
On the contrary, the incidence of invasive infections unrelated to pregnancy in adults 
seems to be increasing worldwide (47, 54) justifying their increased study. Since the 
1990’s, serotype V emerged in the US as the most frequent GBS serotype causing 
invasive disease in non-pregnant adults (33, 57). Later, other serotypes such as Ia and 
III have also been recognized worldwide as significant causes of invasive disease (23, 
45, 62), with the exception of Japan, where serotype Ib is reported as the leading cause 
of invasive disease in adults (44).  
GBS isolates still remain mostly susceptible to penicillin, the first drug of choice 
for the prophylaxis and treatment of GBS disease. However, increased levels of 
erythromycin and clindamycin resistance are being described worldwide, raising 
concerns as to their use as alternative second-line agents (5, 12, 27). Intrapartum 
antibiotic prophylaxis is proposed to contribute to the emergence and dissemination of 
antibiotic-resistant clones (13), as would be also expected from the high antibiotic usage 
among the older age groups. Therefore, the need for new preventive strategies for GBS 
disease is now focusing on the development of vaccines. While the first studies targeted 
exclusively the polysaccharide capsule, its poor immunogenicity and variable 
prevalence in different countries led to the suggestion of exploring vaccination 
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approaches that could overcome serotype-specificity. Polysaccharide-protein conjugate 
vaccines, showing more favourable immune responses than polysaccharide only 
vaccines, have undergone clinical trials with promising, although still preliminary, 
results (2, 22). Currently, purely protein vaccines, based on components of the recently 
described GBS pilus-like structures, are being discussed in the literature (10, 38).  
DNA-based typing methods such as pulsed-field gel electrophoresis (PFGE) and 
multilocus sequence typing (MLST) are now extensively used in molecular typing of 
GBS isolates, alongside classical serotyping and antimicrobial susceptibility testing. 
These methods have been helpful in discriminating GBS populations into specific 
genetic lineages, some recognized for their enhanced virulence potential (6, 28, 36, 42). 
Nevertheless, the diversity of genotype-phenotype combinations found among GBS 
isolates suggests ongoing diversification of GBS genetic lineages, to which capsular 
transformation is likely contributing, perhaps not as frequently as initially thought (41). 
Therefore, continuous surveillance and epidemiological studies are needed to ensure an 
accurate knowledge of how GBS serotypes and proteins are distributed among clones, 
across countries and over time, as this will impact on the vaccine strategies under 
development.   
The aim of our study was to characterize the isolates recovered from invasive 
disease in non-pregnant adults in Portugal, to evaluate how serotype, antimicrobial 
resistance and surface protein genes are distributed among PFGE and MLST-based 
genetic lineages, and to compare them to those responsible for neonatal invasive 
infections.   
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Materials and Methods 
Bacterial isolates 
A collection of 225 GBS isolates recovered from 2001 to 2008 from invasive 
disease in non-pregnant adults (≥ 18 years old) in Portugal was analyzed. The isolates 
were provided by the Microbiology laboratories of 24 Portuguese hospitals, which were 
asked to submit all non-duplicate GBS isolates recovered from normally sterile sites. 
Isolates and data were collected as part of a laboratory-based surveillance program but 
no audits of reporting laboratories were performed to ensure compliance. 
 Submitted isolates included those recovered from blood (n=183), ascitic fluid 
(n=15), synovial fluid (n=14), cerebrospinal fluid (CSF) (n=7), and pleural effusion 
(n=6). Isolates were identified to the species level by Gram stain, colony morphology, 
catalase test, and a commercial latex agglutination technique (Slidex Strepto B, 
bioMérieux, Marcy L’Étoile, France).  
 
Serotyping 
Capsular serotyping of all isolates was carried out by a latex agglutination assay 
with a GBS serotyping kit (Essum, Umeå, Sweden) according to the manufacturer’s 
instructions. 
 
Antimicrobial susceptibility testing and macrolide-resistance phenotype 
Susceptibility testing for penicillin G, erythromycin, clindamycin, tetracycline, 
chloramphenicol and levofloxacin was performed by disk diffusion. Clinical and 
Laboratory Standards Institute (CLSI) methods and interpretation criteria were used for 
all antimicrobial agents (14). The macrolide resistance phenotype was determined 
according to a double-disk test with erythromycin and clindamycin as previously 
described (43). 
 
Macrolide-resistance genotypes and tetracycline-resistance determinants 
Total bacterial DNA was isolated by treatment of the cells with mutanolysin and 
boiling. The presence of the erm(B), erm(A) [erm(TR) subclass] and mef genes was 
detected by a multiplex PCR reaction, as described elsewhere (24). Two isolates that 
were erythromycin resistant and did not amplify the erm(B), erm(A) nor the mef genes 
were also tested for the presence of the erm(T) gene (59). To further discriminate mef 
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genes into mef(A) or mef(E) an additional PCR was performed (56). All tetracycline 
resistant isolates were screened for the presence of the tet(K), tet(L), tet(M) and tet(O) 
genes as previously described (58). 
 
Pulsed-field gel profiling and MLST 
PFGE was performed to all isolates as previously described (42). Briefly, 
chromosomal DNA of the strains was prepared and digested with SmaI or, whenever 
necessary due to incomplete digestion, its isoschizomer Cfr9I, and separated by PFGE. 
The Bionumerics software (Applied Maths, Sint-Martens-Latem, Belgium) was used to 
generate a dendrogram with the comparison of the PFGE patterns by the unweighted 
pair-group method with arithmetic averages (UPGMA). The Dice similarity coefficient 
was used with optimization and position tolerance settings of 1.0 and 1.5%, 
respectively. PFGE-based clusters were defined as groups of 3 or more isolates with  
≥80% relatedness on the dendrogram (42). MLST was performed by sequencing seven 
housekeeping genes as described previously (31), and sequence type (ST) assignment 
was done by using the S. agalactiae MLST database (http://pubmlst.org/sagalactiae) 
and analyzed using the entire database and goeBURST (26). Alleles and sequence types 
not previously described were deposited at the S. agalactiae MLST database. Analysis 
of DNA sequences was done by using Bionumerics software (Applied Maths, Sint-
Martens-Latem, Belgium). 
 
Surface protein gene profile 
Total bacterial DNA was isolated by treatment of the cells with mutanolysin and 
boiling. A multiplex PCR assay was performed for direct identification of GBS alpha-
protein-like genes, as described elsewhere (15). The GBS alpha-C protein gene (bca) 
and the epsilon (eps), rib, alp2/3, and alp4 surface protein genes were identified by 
direct analysis of the amplicon size. The alp2 and alp3 protein antigen genes were 
differentiated by a previously described assay (41). 
 
Typing concordance and statistics 
Wallace coefficient (W) provides a quantitative measure of the clustering 
concordance between different typing methods (11, 48). In our collection, the Wallace 
coefficient was calculated to determine the concordance between PFGE-based 
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clustering, serotyping and surface protein gene profiling. Simpson’s index of diversity 
(SID) was used to evaluate the diversity found among the isolates studied (11). Both 
these calculations as well as the 95% Confidence Intervals (CI95%) were performed with 
the web tools available at www.comparingpartitions.info. Information about the sex 
ratios in different age groups in the Portuguese population were obtained from Statistics 
Portugal (www.ine.pt). The Fisher exact test was used to evaluate associations. The 
odds ratio (OR) with 95% Wald confidence intervals (CIs) (1), were calculated against 
all other serotypes or PFGE clusters and used to identify particular serotypes or PFGE 
clusters associated with certain characteristics, controlling for the false discovery rate 
(FDR) under or equal to 0.05 (3). 
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Results 
Isolates 
The collection of 225 GBS invasive isolates was recovered from patients with 
ages ranging from 19 to 92 years old, with a mean age of 63 years. Two sub-populations 
were considered in this study: the younger sub-population, defined as patients ranging 
in age from 18-64 years old, and the elderly sub-population (≥ 65 years old). Overall, 
the GBS isolates were more frequently recovered from men (n=132, 58.7%) than from 
women (n=93, 41.3%) but this varied markedly according to the age group (Table 5.1). 
 
 
TABLE 5.1 Distribution of the 225 GBS isolates by sex and age groups 
Age group (%) 
Sex 
18-64 years  ≥65 years  
Total 
M 64 (28.4)  68 (30.2)  132 (58.7) 
F 31 (13.8)  62 (27.6)  93 (41.3) 
Total 95 (42.2)  130 (57.8)  225 (100.0) 
 
 
Also, the majority of GBS isolates were recovered from the elderly and 
accounted for nearly 58% of all isolates. Whereas in the younger sub-population the 
number of isolates recovered from men (n=64) more than doubled the number 
recovered from women (n=31), in the elderly sub-population the isolates were 
recovered equally from both men and women (n=68 and n=62, respectively). To test if 
there was an overrepresentation of men, we made to simplifying assumptions: 1) there 
was no sex or age bias on reporting; and 2) the entire Portuguese population could be 
considered at risk of developing GBS invasive infection. According to the Portuguese 
demographic data available at Statistics Portugal (www.ine.pt), in the period of 2001 to 
2008 the mean sex ratio in Portugal among adults (15-64 years old) was 0.97 
males/female and 0.72 males/female in the elderly (≥65 years old). In our collection of 
GBS isolates, the mean sex ratio of invasive infections among the adults and the elderly 
were 2.1 and 1.1 males/female, respectively. Considering the Statistics Portugal sex 
ratios, there is a 2-fold increase in invasive disease among younger men as compared to 
the number of expected cases in a 0.97 males/female ratio, and a 1.5-fold increase in 
invasive disease among elderly men as compared to the number of expected cases in a 
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0.72 males/female ratio, suggesting that men are always at increased risk of having GBS 
invasive infection independently of age. 
 
Serotype and MLST distribution among PFGE clusters 
The results of serotyping are summarized in Table 5.2. Overall, serotype Ia was 
considerably more prevalent and nearly 9% of the isolates (n=19) were non-typeable 
with considerable overall serotype diversity (SID=0.794, CI95% 0.765 to 0.822). To our 
knowledge this is the first time a serotype VI isolate is identified in Portugal. This 
serotype is known to be one of the most prevalent among colonizing serotypes pregnant 
women in Japan and Malaysia (34), but was rarely found elsewhere.   
Again, serotypes were differently distributed according to patient age groups 
(Table 5.2).  
 
TABLE 5.2 Serotype distribution among age groups 
Age group (%) 
Serotype 
18-64 years  ≥65 years  
Total 
Ia 42 (18.6)  36 (16.0)  78 (34.7) 
Ib 8 (3.6)  12 (5.3)  20 (8.9) 
II 11 (4.9)  15 (6.7)  26 (11.6) 
III 14 (6.2)  20 (8.9)  34 (15.1) 
IV 1 (0.4)  1 (0.4)  2 (0.9) 
V 14 (6.2)  30 (13.3)  44 (19.6) 
VI 0   1 (0.4)  1 (0.4) 
VII 0   1 (0.4)  1 (0.4) 
NT 5 (2.2)  14 (6.2)  19 (8.4) 
Total 95 (42.2)  130 (57.8)  225 (100.0) 
 
 
In the younger sub-population, serotype Ia was isolated three times more 
frequently than other serotypes such as III, V and II, while in the elderly sub-population, 
although serotype Ia was still the most prevalent, serotypes such as V and III were 
almost as frequent. We then tested if there was a different distribution of each serotype 
in the two sub-populations. Although serotype Ia reached significance in the younger 
sub-population (Fisher’s exact test, p=0.011), it did not remain significant after FDR 
correction, indicating that, in spite of the differences described, none of the serotypes is 
statistically significant in their different distribution between the two age groups 
considered. 
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Serotype II was found to be more frequently isolated from synovial fluid than 
expected from its representation in invasive isolates (Fisher’s exact test, p=0.01). No 
other significant associations were found between the biological source of the isolate 
and either patient characteristics (sex or age), or any of the bacterial features studied 
such as serotype or antimicrobial resistance.  
PFGE analysis revealed 33 different profiles defined at ≥80% similarity that 
grouped in 13 PFGE clusters (having three or more isolates), of which the major five 
accounted for nearly 70% of the overall collection (Figure 5.1). The remaining isolates 
(n=26) were included in minor PFGE clusters (containing two or fewer isolates) or had 
unique profiles (Figure 5.1). The SID for the classification of the isolates in PFGE 
clusters was 0.858 (CI95% 0.824 to 0.893), indicating that the collection analyzed is very 
diverse. The concordance between PFGE-based genotypes and serotype as given by 
WPFGE→serotype=0.730 (CI95% 0.638 to 0.821), showed that 73% of any pair of isolates in 
the same PFGE cluster also share the same serotype. 
 Further analysis of the genetic lineages associated with each PFGE cluster 
included the characterization by MLST of representative isolates of all serotypes (n=81, 
corresponding to at least 30% of the isolates of each serotype). Among the isolates 
studied we identified five novel alleles [adhP(87), pheS(35), glnA(49), and sdhA(43 and 
44)] as well as five novel STs (ST472 to ST474, ST497 and ST498). 
The detailed characterization of the clusters depicted in Figure 5.1 is 
summarized in Table 5.3. While most serotype Ia isolates grouped together in a 
particular cluster (C73), serotype III isolates distributed mostly into two different 
clusters (A15 and D15), and serotype V isolates were mainly found in three clusters (K19, 
L10 and M5). Serotype Ia isolates presented mainly with ST23 and ST24 in agreement 
with similar observations in neonatal invasive disease and colonization in pregnant 
women (39, 42). 
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FIGURE 5.1 Dendrogram of the PFGE profiles of 
225 GBS isolates. The dendrogram was constructed 
using the unweighted pair group method with 
arithmetic mean (UPGMA) method. Dice coefficients 
(percentages) are indicated in the scale above the 
dendrogram. Each cluster (defined as a group of three 
or more isolates with a Dice coefficient ≥80%) is 
represented by a triangle proportional to the number of 
isolates included in the cluster. Clusters are designated 
by capital letters and a subscript number indicating the 
number of isolates included in the cluster. 
  
TABLE 5.3 Distribution of serotypes, MLST-based sequence types and antimicrobial susceptibility profiles among PFGE clones 
Macrolide resistance phenotype genotype (no.) PFGE 
clustera Serotype (no.) STs in PFGE cluster (no.)
b
  
cMLSB iMLSB M 
Tetracycline resistance genotype 
(no.) 
A15 III (11) 
II (2) 
V (2) 
[ST10 (1), ST19 (1), ST286 (1)]*, ST498 (1) 
ST28 (1)* 
ST19 (2)* 
0 
0 
0 
ermTR (3) 
0 
0 
0 
0 
0 
tetM (9) 
tetM (2) 
tetM (2) 
B10 II (7) 
V (2) 
NT (1) 
ST28 (1)* 
ST19 (1)* 
ST28 (1) 
0 
0 
0 
0 
0 
0 
1c 
0 
0 
tetM (6) 
tetM (2) 
tetM (1) 
C73 Ia (66) 
NT (3) 
II (2)  
Ib (1) 
III (1) 
[ST23 (13), ST24 (6), ST144 (1)]* 
None 
ST28 (1) 
ST23 (1)* 
ST17 (1) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
mefE (2) 
0 
0 
0 
0 
tetM (64) 
tetM (3) 
tetM (2) 
tetM (1) 
tetM (1) 
D15 III (13) 
NT (2) 
ST17 (4) 
None 
ermB (1) 
0 
0 
0 
0 
0 
tetM (10), tetO (1) 
tetM (2) 
E29 Ia (7) 
Ib (15) 
V (5) 
II (1) 
NT (1) 
ST8 (5)*, ST23 (2) 
[ST8 (2), ST9 (1), ST10 (3), ST12 (1)]* 
ST10 (1)* 
ST12 (1)* 
None 
ermB (1), ermTR (1) 
ermTR (1) 
ermB (2) 
ermTR (1) 
0 
0 
ermTR (1) 
0 
0 
0 
0 
0 
0 
0 
0 
tetM (7) 
tetM (13) 
tetM (4) 
tetM (1) 
tetM (1) 
F7 II (4) 
Ib (2) 
NT (1) 
ST474 (1)* 
ST10 (1)* 
ST10 (1) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
tetM (2) 
0 
0 
G7 NT (3) 
II (2) 
V (2) 
ST12 (1)* 
ST12 (1)* 
ST12 (1)* 
0 
ermTR (1) 
0 
0 
0 
0 
0 
0 
0 
tetO (3) 
tetO (2) 
tetO (2) 
H3 NT (3) ST130 (1) 1c 0 0 0 
I3 Ia (1) 
Ib (1) 
II (1) 
ST88 (1)* 
None 
ST88 (1)* 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
J3 III (2) 
Ia (1) 
ST23 (1)* 
ST23 (1)* 
0 
0 
0 
0 
0 
0 
tetM (1), tetO (1) 
0 
K19 V (13) 
NT (5) 
VII (1) 
[ST1 (4), ST497 (1)]* 
ST1 (1) 
ST1 (1)* 
ermB (1), ermTR (1) 
0 
0 
ermTR (5) 
0 
0 
0 
0 
0 
tetM (12) 
tetM (5) 
tetM (1) 
L10 V (10) ST2 (3) 0 0 0 0 
M5 V (5) ST1 (2) ermTR (1) ermTR (2) 0 tetM (5) 
Other26 II (7) 
III (7) 
V (5) 
Ia (3) 
IV (2) 
Ib (1) 
VI (1) 
[ST28 (1), ST472 (1)]* 
None 
None 
None 
[ST196 (1), ST473 (1)]* 
None 
ST10 (1)* 
0 
ermB (2) 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
0 
mefE (1) 
0 
0 
0 
tetM (4), tetO (1) 
tetM (2) 
tetM (2), tetO (1) 
tetM (2) 
tetM (2) 
tetM (1) 
0 
Total 225  14 11 4 181 
a
 PFGE clusters are presented as indicated in Figure 5.1. Clusters are designated by capital letters and a subscript number indicating the number of isolates included in the cluster. 
b
 Brackets indicate STs that were grouped into the same PFGE cluster and belonged to the same clonal complex by goeBURST and expressed the same serotype. Asterisks indicate STs that were  
grouped into the same PFGE cluster and belonged to the same clonal complex by goeBURST but expressed different serotypes. 
c Isolates failing to amplify the erm(B), erm(TR), mef(A/E) and erm(T) genes. 
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Interestingly, a small number of serotype Ia isolates (n=7) grouped in a different 
cluster (E29), together with other isolates exhibiting mainly serotype Ib (n=15). These 
serotype Ia isolates presented mostly with ST8 (n=5), a sequence type that was 
previously found in Portugal among invasive and colonizing GBS isolates presenting 
exclusively the type Ib capsular serotype (40).  
Serotype V was the second most prevalent serotype in our collection. While the 
isolates in clusters K19 and M5 presented with ST1, suggesting the existence of two sub-
lineages within this sequence type distinguishable only by PFGE, the isolates found in 
cluster L10 were ST2. These observations suggest the existence of two main lineages 
presenting this serotype. Serotype III isolates were predominantly represented in 
clusters A15 and D15, the first comprising mostly ST19, previously associated to 
colonization (31, 36), and the later accounting for the “hyper-virulent” ST17 lineage 
(37, 50). However, this lineage is poorly represented in our collection when compared 
to its overrepresentation in neonatal invasive disease (42).  
 
Surface protein gene profiling 
All except two isolates were positive for the presence of only one surface protein 
gene that were diversely distributed in the bacterial population (SID=0.747, CI95% 0.727 
to 0.768). The surface protein gene bca was the most prevalent, followed by the eps, 
rib, alp3 and alp2 genes, showing variable distributions across serotypes (Table 5.4).  
 
TABLE 5.4 Distribution of genes encoding surface proteins across serotypes 
 
 
 
 
 
 
 
 
a Highlighted in bold whenever a significant correlation between surface protein gene 
 and serotype was found (see text)  
b
 Total number of isolates excludes two serotype V isolates which failed to amplify any  
surface protein gene 
 
 
Surface protein genea Serotype bca  eps rib alp2 alp3 Total
b 
Ia 25 47 2 2 2 78 
Ib 15 2 1 2  20 
II 7 1 17 1  26 
III 3  29 2  34 
IV  2    2 
V 7 15 2  18 42 
VI 1     1 
VII     1 1 
NTb 8 3 4  4 19 
Total 66 70 55 7 25 223 
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The alp4 gene was not found among the isolates. There was a significant 
association of most serotypes with a particular surface protein gene, namely Ia and eps; 
Ib and bca; II and rib; III and rib; and V and alp3 (all Fisher’s exact test p<0.0001). 
Nevertheless, the concordance between PFGE-based genotypes and surface protein 
genes was low WPFGE→surface protein=0.566 (CI95% 0.491 to 0.641), as was the concordance 
between serotype and surface protein genes, Wserotype→surface protein=0.466 (CI95% 0.409 to 
0.523). These results reflect the fact that some serotypes frequently present with more 
than one surface protein gene, as seen for serotype Ia isolates that are mainly associated 
to surface protein genes eps and bca, and for serotype V that presents with alp3 and eps, 
although only one of these genes reached significance in each serotype (Table 5.4). 
Furthermore, serotype Ia isolates are mainly grouped together in a particular PFGE 
cluster (C73), regardless of presenting with surface protein genes eps or bca, thus having 
a significant contribution for a lower Wallace coefficient. 
 
Antimicrobial susceptibility testing 
The frequency of resistance to the antimicrobials tested differed among 
serotypes and was unevenly found in the PFGE clusters (Table 5.3). All isolates were 
susceptible to penicillin and chloramphenicol, 1.3% (n=3) were resistant to levofloxacin 
and 80.4% (n=181) to tetracycline.  
The overall rate of erythromycin resistance was 12.9% (n=29), higher than that 
documented previously (10.7%) in a Portuguese study analysing the GBS isolates 
responsible for invasive and non-invasive disease as well as colonization (24). Among 
the erythromycin-resistant isolates, 14 displayed the constitutive Macrolide-
Lincosamide-Streptogramin B resistance phenotype (cMLSB), 11 the inducible 
phenotype (iMLSB) and 4 the M phenotype. All erythromycin resistant isolates were 
tested by PCR for the presence of genes responsible for the macrolide resistance. Two 
isolates (one presenting with the M and the other with the cMLSB phenotypes) failed to 
amplify any of the genes erm(B), erm(A) [erm(TR) subclass] or mef, and were further 
tested for the presence of the erm(T) gene, frequently found among Streptococcus bovis 
isolates but already detected in GBS isolates (19), and again there was no amplification. 
Among the remaining 27 PCR-positive isolates, the erm(B) gene was present in 25.9% 
(n=7), the erm(TR) gene in 63.0% (n=17), and the mef gene in 11.1% (n=3) of the 
isolates. All iMLSB isolates carried the erm(TR) gene, whereas the cMLSB presented 
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with either erm(B) or erm(TR). Such an association between iMLSB and erm(TR) was 
previously reported in Canada (17). The three isolates presenting the M phenotype 
carried the mef(E) variant. Even though the MLSB phenotype was found to be 
distributed across serotypes and not particularly clustered; the M phenotype (in the mef-
positive isolates) was found exclusively in serotype Ia isolates. Erythromycin resistance 
was more frequent among serotype V isolates, in agreement with previous observations 
in other countries (12, 18, 60, 61); however, this association was not significant after 
FDR correction. In an analysis of individual clusters, erythromycin resistance was found 
to be overrepresented in cluster K19 (OR=7.453, CI95% 1.783 to 66.65), which clustered 
together most isolates of serotype V presenting with ST1, and underrepresented in 
serotype Ia cluster C73 (OR=0.207, CI95% 0.066 to 0.689), both significant after FDR 
correction (p=0.021 and p=0.044, respectively). Also, the high concordance between 
PFGE-based genotypes and erythromycin resistance (EryR) as given by 
WPFGE→EryR=0.873 (CI95% 0.815 to 0.931), indicates that PFGE clustering is a good 
predictor of erythromycin resistance. For instance, despite the fact that cluster E29 
grouped together isolates presenting four different serotypes, all of these serotypes 
included at least one macrolide resistant isolate. 
Among the tetracycline resistant isolates, 94% (n=170/181) carried the tet(M) 
gene and 6% (n=11/181) the tet(O) gene. The tet(K) and tet(L) genes were not detected 
in any of the isolates tested. Tetracycline resistance was found in all major PFGE 
clusters with the exception of L10, a cluster of serotype V isolates presenting with ST2. 
Interestingly, the majority of the isolates carrying the tet(O) gene grouped together in 
the same PFGE cluster (G7), regardless of the different capsular types expressed by the 
isolates included in the cluster (Table 5.3).  
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Discussion 
This is the first study exclusively focused on the analysis of the invasive group 
B streptococcal infections in non-pregnant adults in Portugal. The main limitation of our 
study is the fact that this is not a population-based study, although our network does 
include the majority of hospital-based microbiology laboratories. Taken together with 
the lack of audits to the reporting laboratories to ensure compliance, this makes it likely 
that not all cases of GBS invasive disease occurring in Portugal are reported within our 
surveillance network. Accordingly, we have refrained from calculating the incidence of 
GBS invasive disease in Portugal, since we would probably underestimate the actual 
incidence. Despite these limitations, we believe the collection studied is large enough to 
reflect the bacterial population diversity and to identify the major clones causing 
invasive disease among adults in Portugal. Also, since it is laboratory based 
surveillance, it is unlikely that any sex or age bias exists when reporting GBS invasive 
cases, indicating that any sex or age imbalance in the collection reflects the actual 
characteristics of the GBS invasive infection cases. Another limitation of our study is 
the absence of clinical data, which prevents us from evaluating the associations between 
GBS infection and patient history, including underlying medical conditions that were 
previously shown to be risk factors for GBS invasive infection (29). 
GBS invasive infections were more frequent in the elderly, reflecting the 
possible impact of risk factors that increase with age, such as co-morbidities and 
immune senescence. GBS invasive infections were also substantially more frequent in 
men, regardless of age. Our findings are in agreement with a higher proportion of 
invasive infections among younger and elderly men reported elsewhere (35, 57), but the 
reasons behind the higher susceptibility of men remain to be clarified. It was suggested 
previously that sex could be a surrogate marker for other risk factors including 
underlying medical conditions (29), however our study was not designed to address this 
issue. 
The GBS isolates characterized here revealed substantial diversity of genetic 
lineages defined by both PFGE and MLST (Figure 5.1 and Table 5.3), similar to that 
reported among isolates causing neonatal invasive infections in both Portugal (42) and 
Barcelona (39). However, the collection characterized here did present higher diversity 
in terms of surface protein genes and serotype than a similar size collection of invasive 
isolates from neonates (39), with higher SID values and non-overlapping CI95%. In 
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adults we also found GBS isolates of serotypes VI and VII and isolates carrying the 
alp2 gene for the first time as agents of infection in our country. Taken together, these 
observations suggest a more diverse genetic structure of the GBS population causing 
invasive disease in adults when compared to neonates. A possible explanation for this 
difference could be the multiplicity of clinical presentations of invasive infections in 
adults, together with frequent and varied underlying medical conditions presented by 
these patients. A previous history of antimicrobial consumption is another factor that 
may increase the diversity of the GBS population by selecting for resistant isolates. 
A very conserved and consistent serotype distribution is observed among the 
GBS isolates causing neonatal invasive disease in Europe, including Portugal, and the 
US, where capsular types Ia and III are preponderant (4, 42, 49). However, in the GBS 
isolates causing invasive disease in non-pregnant adults in Portugal, we observed that 
the dominant serotypes contrast with those found in other countries. Our data shows that 
serotype Ia was significantly more prevalent (35%), followed by serotypes V (20%), III 
(15%), II (12%), and Ib (9%). In other countries such as Spain (8), Sweden (46), 
Norway (4), the US (57), Australia and New Zealand (62), serotype V is the leading 
cause of invasive infections in non-pregnant adults, including the elderly, and serotype 
Ia is much less frequent. It is possible that in Portugal there are specific lineages of 
serotype Ia that are well adapted to their particular niche and that may be expanding. 
We have previously described the increased invasive potential of serotype Ia lineages 
presenting with ST23 and ST24, mainly when causing early-onset disease (EOD) in 
neonates (42). Considering the similar clonal structure observed in this study, it is 
possible that the same lineages are particularly prone to cause invasive infections in 
adults. Taken together, the dominance of serotype Ia in invasive disease in adults, as 
well as the previously documented importance of this serotype in neonatal invasive 
infections as well as colonization in pregnant women (39, 42), it is clear that the same 
genetic lineages can be responsible for both colonization and invasive disease in all age 
groups. We also found a small number of ST8 serotype Ia isolates grouping in a 
different cluster (E29), together with other isolates exhibiting mainly serotype Ib but also 
other serotypes, and presenting with ST8 and its single-locus variants (SLVs) ST9, 
ST10 and ST12. Moreover, these STs share only two alleles (in the atr and glcK loci) 
with ST24 and none with ST23, indicating that this lineage of serotype Ia isolates is 
unrelated to the dominant ST23 and ST24 lineage and may have resulted from capsular 
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switching. The recipient of this putative capsular switching event would belong to the 
lineage defined by PFGE cluster E29, as most of these serotype Ia and Ib isolates are 
not only grouped into the same PFGE cluster but also share the same surface protein 
(bca) and closely related STs. This particular lineage was not previously found among 
GBS serotype Ia isolates in Portugal characterized in previous studies, but had already 
been recovered from invasive and colonizing isolates in adults presenting exclusively 
the type Ib capsular serotype (40). This observation is consistent with this new serotype-
genotype combination having arisen from capsular switching and possibly having an 
adaptive advantage for causing invasive infections in adults, explaining why the 
Ia/ST8/bca lineage was not previously associated with vaginal colonization or neonatal 
infections. 
Serotype V was the second most prevalent serotype, distributed in three PFGE 
clusters, and characterized by different sequence types and surface protein genes. While 
the isolates in cluster K19 and M5 presented with ST1, the surface protein gene alp3, and 
a significant proportion of macrolide resistance, the isolates found in cluster L10 were 
ST2, displayed the surface protein gene eps and were fully susceptible to all 
antimicrobials tested, including tetracycline. The existence of this lineage justifies that 
serotype V was the only serotype significantly associated to tetracycline susceptibility 
(Fisher’s exact test P=0.0002).  
The prevalence of serotype III was much lower than that found in neonatal 
invasive disease in Portugal (42). The two main clusters of serotype III isolates, A15 and 
D15, presented mainly with ST19 and ST17, respectively. Whereas ST19 was previously 
associated to colonization, ST17 is recognized as a major lineage responsible for 
neonatal invasive infections (31, 36). The underrepresentation of this lineage in our 
collection, in agreement similar observations elsewhere (37), re-enforces the importance 
of other serotypes, particularly serotype Ia, in invasive infection in adults.  
We found a strong correlation between the genes encoding surface proteins and 
serotypes (Table 5.4). However, the correspondence is not absolute and the surface 
protein gene proved helpful in discriminating different genetic lineages within 
serotypes. Similarly to what was reported previously (39), serotype Ia was associated to 
two surface protein genes, bca and eps, although only eps reached significance. 
Considering the high number of bca carrying isolates in our collection, and the perfect 
association of this surface protein gene with ST24 (39), this particular sub-lineage 
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seems equally adept at causing infections in adults as it is in neonates. Future studies, 
particularly in other European countries, should help evaluate if serotype Ia is 
expanding in the continent or if, on the contrary, this represents successful clones within 
the more limited geographical boundaries of the Mediterranean region. Nevertheless, 
previous reports of the ST24 sub-lineage as a rare clone in both Europe (52) and the US 
(7) may indicate ongoing changes in the clonal composition of GBS causing invasive 
infections worldwide.  
Two distinct surface protein genes, alp3 and eps, were found to be similarly 
distributed among serotype V isolates, even though only the first was significantly 
associated to this serotype, mainly because eps is also overrepresented in the 
ST23/serotype Ia isolates. Considering that most studies describe a strong association of 
serotype V with the alp3 gene (27, 32, 51), it is possible that our observation of a 
similar frequency of the genetic lineage V/ST2/eps reflects the expansion of a sub-
lineage not frequent elsewhere.  
When comparing our surface protein gene profiling results to those found among 
neonatal invasive isolates (39), a considerable difference was also found in serotype II 
isolates. Even though the number of serotype II isolates causing invasive disease in 
neonates was smaller than in adults, the isolates responsible for neonatal infections 
carried mainly the bca gene, while in this study the number of isolates carrying the rib 
gene more than doubled those carrying the bca gene. In addition, we found that the 
isolates carrying the bca gene presented mostly with ST12 (and its double-locus variant 
ST474) whereas the isolates carrying the rib gene presented mainly with ST28 (and its 
SLV ST472). Both ST472 and ST474 were newly identified in this study and suggest 
diversification of two different serotype II lineages carrying different surface protein 
genes. It is possible that the rib carrying lineage of serotype II isolates shows a higher 
propensity to cause joint infections (4 out of the 5 serotype II isolates recovered from 
synovial fluid presented with the surface protein rib), being responsible for the overall 
association of this serotype with synovial fluid.  
Erythromycin resistance was found to be similarly distributed among the 
constitutive and inducible MLSB phenotypes (cMLSB, n=14; and iMLSB n=11), while in 
a previous study in Portugal the cMLSB phenotype was three times more prevalent than 
the iMLSB (24). The number of isolates carrying the erm(TR) gene more than doubled 
the number of isolates carrying the erm(B) gene, also the opposite of what had been 
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previously reported in the country (24). This could be due to the expansion or 
disappearance of specific clones carrying these genetic elements or to the fact that in the 
previous study both invasive and non-invasive isolates were characterized (24). In 
contrast to the data reported here, several publications indicate that the erm(B) gene is 
overrepresented in serotype V isolates (9, 25, 27, 30, 61), while a higher prevalence of 
erm(TR) has only been described in Canada (17). This suggests that there are several 
distinct erythromycin resistant genetic lineages expressing serotype V that are 
differentially distributed in various geographic locations. The fact that macrolide 
resistance was significantly associated to specific PFGE-based clusters but not to 
particular serotypes suggests that increasing resistance is due in part to the limited 
expansion of resistant clones, although horizontal dissemination of genetic elements 
carrying resistance determinants may have also contributed. Considering the wide 
consensus on the importance of serotype V in erythromycin resistance, the fact that this 
serotype is overrepresented in almost all studies of GBS causing invasive infections in 
non-pregnant adults, and the diversity of resistant lineages, a detailed discrimination of 
the macrolide resistant clones from other regions may help understand the evolution and 
dynamics of erythromycin resistance in GBS. 
The nearly ubiquitous resistance to tetracycline was mostly mediated by the 
tet(M) gene, as described elsewhere (52). A small fraction of the isolates carried the 
tet(O) gene, which has been associated with bovine strains (20).  Not all erythromycin 
resistant isolates were simultaneously resistant to tetracycline, including those carrying 
the erm(B) gene, indicating that erythromycin resistance is not necessarily linked to 
tetracycline resistance and may not be encoded by the same mobile genetic elements, as 
previously suggested (16).  
Even though the tet(M) gene is spread throughout all serotypes and major PFGE 
clusters, the association between the tet(O) gene and a particular genetic lineage, as 
defined by the same PFGE cluster (G7) and sequence type (ST12), supports the clonal 
expansion of this resistance determinant. 
GBS is a significant agent of invasive disease in adults, and the high morbidity 
and mortality associated with these infections justifies the continued monitoring of this 
pathogen. While most serotypes and genetic lineages are capable of both asymptomatic 
colonization and of causing invasive disease in different age groups, their prevalence is 
not the same, suggesting that particular lineages may be better adapted to specific 
Chapter 5    
 
126
lifestyles or age groups. On the other hand, the salient role played by serotype Ia 
isolates as cause of invasive infections in both adults and neonates in the Iberian 
Peninsula, together with the high prevalence of ST24 that is rarely found elsewhere, 
suggests that lineages with enhanced invasiveness may be emerging at a regional level. 
This dynamic nature of GBS invasive isolates may prove challenging to future 
prevention strategies for these infections. 
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Summary 
The polysaccharide capsule is a major antigenic factor in Streptococcus agalactiae 
(Lancefield group B streptococcus – GBS). Previous observations suggest that exchange 
of capsular loci is likely to occur rather frequently in GBS, even though GBS is not 
known to be naturally transformable. We sought to identify and characterize putative 
capsular switching events, by means of a combination of phenotypic and genotypic 
methods, including pulsed-field gel electrophoretic profiling, multilocus sequence 
typing, and surface protein and pilus gene profiling. We show that capsular switching 
by horizontal gene transfer is not as frequent as previously suggested. Serotyping errors 
may be the main reason behind the overestimation of capsule switching, since 
phenotypic techniques are prone to errors of interpretation. The identified putative 
capsular transformants involved the acquisition of the entire capsular locus and were not 
restricted to the serotype-specific central genes, the previously suggested main 
mechanism underlying capsular switching. Our data, while questioning the frequency of 
capsular switching, provide clear evidence for in vivo capsular transformation in S. 
agalactiae, which may be of critical importance in planning future vaccination 
strategies against this pathogen. 
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Introduction 
Streptococcus agalactiae (group B streptococcus, GBS) is primarily a 
colonizing agent of the genitourinary and gastrointestinal tracts, but it is also a leading 
cause of bacterial sepsis and meningitis in neonates and is increasingly associated with 
invasive infections in adults (39). The capsular polysaccharide is a major GBS virulence 
factor and also the main target of antibody-mediated killing (11). In the last decade, 
conjugated multivalent vaccines have been developed and proved to be highly 
immunogenic, raising the possibility of the prevention of perinatal GBS disease through 
maternal immunization (38).  
Nine capsular types are recognized: Ia, Ib and II to VIII, along a new provisional 
serotype IX, recently proposed (19). Comparison of the capsular locus genes suggested 
that the structural diversity of the capsular polysaccharide is associated with the genetic 
diversity of the capsular locus, possibly driven by horizontal gene transfer (9, 24).  
Capsular serotyping has been the classical method used in epidemiological studies to 
differentiate GBS isolates, although further characterization of GBS diversity includes 
the use of a broad range of DNA-based typing methods, such as restriction fragment 
length polymorphisms (RFLP), pulsed-field gel electrophoresis (PFGE) and multilocus 
sequence typing (MLST). Both PFGE and MLST have provided new clues about the 
population structure of S. agalactiae, particularly the recognition of diverse lineages 
among serotype III that were shown to differ in virulence potential and tropism (16, 25, 
26, 31, 41). Although the distinction of lineages within a particular serotype has proved 
useful, a complete correlation between capsular type and the lineages defined by MLST 
was not found (4, 21, 22). Moreover, whole-genome comparative analysis of isolates 
expressing different serotypes showed that they sometimes share more genes than 
strains of the same serotype, suggesting a serotype-independent clustering of strains 
(43). These observations support the hypothesis that closely and divergently related 
clones may share the genes coding for a particular capsular type, suggesting that 
exchange of capsular genes in vivo may have occurred (16, 21, 22). We refer to these 
phenomena as capsular switching in vivo, recognizable by the expression of different 
serotypes and the presence of different capsular loci in otherwise undistinguishable 
isolates when sampling a set of 11 loci distributed in the genome. 
The changes at the capsular locus were proposed to be driven by the equilibrium 
between the selective pressure imposed by host immunity and conservation of a 
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particular capsular polysaccharide, as an adaptive advantage of virulent clones (4, 9, 
21). Capsular switching by homologous recombination would be facilitated by the 
organization of the locus encoding the capsular polysaccharide synthesis genes (cps), 
where the highly variable serotype determining region (cpsG-cpsK) is flanked by 
conserved genes (9, 24). This led to the suggestion that genetic exchange of the central 
part of the cps operon could be driving capsular switching (9, 22). According to Luan et 
al., who specifically addressed this issue, horizontal transfer of capsular genes occurs at 
a high level within a population without restriction to genetic background. The authors 
of that study also suggest that since only advantageous combinations of genotype-
serotype persist, these altered serotypes, due to capsular switching, are recognized at a 
lower frequency among stable clones (21). 
Capsular switching is well established in other streptococcal species such as 
Streptococcus pneumoniae, where spontaneous in vivo capsular transformation events 
were observed and characterized (28, 34). In contrast to GBS, S. pneumoniae is 
naturally transformable, and this is widely believed to be responsible for the ease with 
which this species exchanges DNA. Capsular switching may have serious impact in 
pneumococcal vaccination programs since it may provide the selective pressure for 
virulent genotypes to switch capsules and escape vaccine coverage (6), and a similar 
response could be seen with a future introduction of GBS vaccination (38). 
The aim of the present study was to evaluate the concordance between serotype 
and the clusters defined by PFGE and to further characterize any putative transformants 
to establish unequivocally that capsular switching occurs in GBS. We combined PFGE 
with the analysis of multiple genes spread across the GBS genome in order to identify 
capsular transformants and concluded that capsular switching events occur less 
frequently than previously thought. 
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Materials and Methods 
Bacterial isolates 
We studied a collection of 463 GBS isolates isolated between December 1999 
and December 2004 in 11 Portuguese hospitals. The isolates were recovered from 
neonates (invasive infections – defined by the isolation of GBS from a normally sterile 
fluid) and adults (invasive and non-invasive infections and asymptomatic colonization), 
some of which were previously characterized (12, 23, 25). Isolates were identified to the 
species level by Gram stain, colony morphology, catalase test, and the commercial latex 
agglutination technique Slidex Strepto B (bioMérieux, Marcy l'Etoile, France). 
 
Serotyping 
Capsular serotyping was done by slide agglutination using sera for types Ia, Ib 
and II to VIII (Hemolytic Streptococcus Typing antisera for Group B; Seiken, Japan), as 
previously described (12). Further confirmation of serotyping results was carried out by 
a latex agglutination assay with a GBS serotyping kit (Essum, Umeå, Sweden) 
according to the manufacturer’s instructions or by the capillary precipitation method 
(40) with type II, III, and V sera (Statens Serum Institute, Copenhagen, Denmark). 
 
Pulsed-field gel profiling and MLST 
Total bacterial DNA of the strains was isolated, digested with SmaI, and 
separated by PFGE as previously described. PFGE patterns were compared by using 
Bionumerics software (Applied Maths, Sint-Martens-Latem, Belgium) to create 
dendrograms by the unweighted pair-group method with arithmetic averages 
(UPGMA). The Dice similarity coefficient was used with optimization and position 
tolerance settings of 1.0 and 1.5, respectively. PFGE-based clusters were defined as 
isolates with ≥80% relatedness on the dendrogram (25). 
MLST was performed by sequencing seven housekeeping genes as described 
previously (16) and sequence type (ST) identification was done by using the S. 
agalactiae MLST database (http://pubmlst.org/sagalactiae). Alleles and sequence types 
not previously described were deposited at the S. agalactiae MLST database. Clonal 
complex analysis was done using the entire GBS MLST database and goeBURST (13). 
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Surface protein gene profile 
Total bacterial DNA was isolated by treatment of the cells with mutanolysin and 
boiling. A multiplex PCR assay was performed for direct identification of GBS alpha-
protein-like genes, as described elsewhere (10). This assay allowed the determination of 
the following GBS surface protein genes directly by the analysis of the amplicon size: 
the alpha-C protein gene (bca); the epsilon protein gene (eps); and rib, alp2/3 and alp4 
genes. Later, we used the sequences of the surface protein antigen genes alp2 and alp3 
deposited at Genbank to set up a similar multiplex PCR assay to differentiate these two 
genes by direct evaluation of the amplicon size. Oligonucleotide primers, their target 
sites and sequences are listed in Table 6.1. For detection of the β antigen gene (bac) a 
PCR assay was performed as described previously (27). 
 
 
TABLE 6.1 Oligonucleotide primers designed in this study 
Target Primer Gene Accession no. (position)a Sequence (5’→3’) 
Amplicon 
size (bp)b 
alp2/3-D alp2 
alp3 
AF208158 (1070)  
AF245663 (1311) CATTAACCGTCACTCCAGAGCAAC  
alp2-R alp2 AF208158 (1582) CTTCATCTGTTGACTTATCTGGATAG 513* 
alp3-R alp3 AF245663 (1637) CTTTTGGTTCGTTGCTATCCTTAAG 327* 
PI1-UP gbs80 AE009948 (632375) GGTCGTCGATGCTCTGGATTC 
PI1-DN gbs80 AE009948 (633255) GTTGCCCAGTAACAGCTTCTCC 
881 
881 
PI2a-UP gbs67 AE009948 (1417645) CTATGACACTAATGGTAGAAC 
PI2a-DN gbs67 AE009948 (1417071) CACCTGCAATAGACATCATAG 
575 
575 
PI2b-UP san_1519 AAJR01000022 (10160) ACACGACTATGCCTCCTCATG 
PI2b-DN san_1519 AAJR01000022 (10880) TCTCCTACTGGAATAATGACAG 
721 
721 
PI1_all-UP sal_0710 AAJP01000027 (23718) ACCTATGTTGCTGATTCGGCTGAAAATG 
PI1_all-DN sal_0709 AAJP01000027 (23035) TACGGACACTTTCTAGTGCCTTTGGATC 
684† 
684† 
neuB1-UP neuB EF990364 (10162) CAAGCGGTGAATATTTTACG 
neuA-DN neuA EF990364 (12958) CATTGCTTCCTTTATATGCCATG 2797 
neuB2-UP neuB EF990364 (10653) CTTGGGACAAGAAGCGCAAG  
neuC1-UP neuC EF990364 (11153) GCGTTGATTTATAATGTCCCAG  
neuC2-UP neuC EF990364 (11672) CTGATTGGTAATTCGTCTTCTGG  
neuD-UP neuD EF990364 (12133) GAAGATGGCTCAATAGATGCAG  
a
 That is, the position of primer from the 5’ end  
b *
, together with primer alp2/3-D; †, size if the isolate lacks the PI-1 islet (if this locus is present, a 16.7 Kb-
fragment would be expected). 
 
 
Pilus-associated gene profile 
The genes encoding pili in GBS are located within two distinct loci in different 
regions of the genome, designated pilus islands 1 and 2 (PI-1 and PI-2), the later 
presenting two distinct variants, PI-2a and PI-2b (35). We designed a multiplex PCR 
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targeting the sortase genes to identify the pilus islands present in each isolate by direct 
evaluation of the amplification product size. Oligonucleotide primers, their target sites, 
and sequences are listed in Table 6.1. Briefly, 1 µl of DNA template lysate prepared as 
described above was added to the PCR mixture containing 1× PCR buffer (Promega, 
Madison, WI), 200 µM deoxynucleoside triphosphates (MBI Fermentas, Vilnius, 
Lithuania), 0.5 µM primers, 1.5 mM MgCl2, and 1 U of GoTaq DNA polymerase 
(Promega) in a final volume of 50 µl. PCR conditions for amplification were as follows: 
30 cycles of 95°C for 1 min, 52°C for 1 min, and 72°C for 1 min, with a final extension 
at 72°C for 10 min in a Biometra T-gradient (Goettingen, Germany) thermocycler. The 
PCR products were analyzed by electrophoresis in a 2% (wt/vol) agarose gel.  
In order to confirm that the PI-1 negative isolates did not carry the pilus 
pathogenicity islet or parts of it, a set of primers that flanked the PI-1 locus were 
designed with the aim of amplifying the entire pilus islet. Oligonucleotide primers, their 
target sites, and sequences are listed in Table 6.1. All isolates that were negative for the 
presence of the PI-1 sortase gene were subjected to PCR with primers PI1_all-UP and 
PI1_all-DN. If the pilus locus was absent, the expected PCR product using these 
primers would be 684 bp. The PCR mixture and PCR conditions were similar to those 
described above except for the annealing temperature that was 60ºC.  
 
Capsule gene cluster RFLP analysis 
Sequence variability within a region of the cps gene cluster (cpsG-neuA) results 
in different patterns between serotypes upon enzyme digestion, allowing the 
unambiguous identification of the cps gene clusters. We performed a previously 
described PCR-based restriction fragment length polymorphism (RFLP) method 
suitable for genetic serotyping of S. agalactiae (24) to identify which cps cluster was 
present in each isolate. 
 
Southern-blot hybridization 
Chromosomal DNA fragments digested by SmaI and separated by PFGE, were 
transferred to nylon membranes (Hybond N+; Amersham, Uppsala, Sweden) by using 
the vacuum gene system (Pharmacia LKB Biotech, Uppsala, Sweden) and membranes 
were hybridized to specific DNA probes labeled with the ECL Direct Labeling System 
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(Amersham, Uppsala, Sweden). Both hybridization and labeling were performed 
according to the manufacturer’s instructions. 
Ia, Ib, and II to V serotype-specific DNA probes were generated by PCR with 
template DNA from reference strains, as previously described (3), and hybridized 
against all isolates tested. The PCR products were purified by using the High Pure PCR 
Product Purification Kit (Roche, Manheim, Germany) and labeled according to the 
manufacturer’s instructions. 
 
Sequencing of the cps locus 
Sequence analysis of the partial GBS cps gene cluster, namely, the conserved 
regions cpsD-cpsG and neuB-neuA, reveal polymorphisms that allow the identification 
of the various cps loci. A previously published method described a GBS serotype 
identification method by PCR and sequencing of the cpsD-cpsG region. In this region 
56 variable sites suitable for molecular serotyping were identified (18). For the neuB-
neuA region, we used a similar PCR and sequencing analysis approach. The 
oligonucleotide primers designed for the amplification and sequencing of this region are 
listed in Table 6.1. We aligned the sequences obtained from at least three isolates 
expressing serotypes Ia, Ib, and II to V in order to identify the variable sites 
characteristic of each serotype. Later, we analyzed the data obtained by sequencing of 
the neuB-neuA region of the isolates being tested for concordance with these 
polymorphisms. Both these methods allow the confirmation of the conventional 
capsular serotyping method and also the evaluation of the possibility of partial cps gene 
cluster transfer and recombination among isolates of different serotypes.  
 
Typing concordance and DNA sequence analysis 
Wallace coefficient (W) provides a quantitative measure of the clustering 
concordance between different typing methods (7, 30). We assessed the Wallace 
coefficient in our collection to determine the concordance between PFGE-based 
clustering and serotyping. Simpson’s index of diversity (SID) was calculated to evaluate 
the diversity found among the isolates studied (8). These calculations were performed at 
the comparing partitions website (www.comparingpartitions.info).  
Analysis of DNA sequences was done using the Vector NTI 10 (Invitrogen, 
Carlsbad, CA) and the GATA (29) software. 
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Nucleotide sequence accession number 
The sequence of the cpsG-cpsH region of strain 312754 was deposited in 
Genbank under accession GQ457335. 
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Results 
Serotyping and PFGE 
Among the 463 isolates we found 16 different PFGE clusters (≥ 5 isolates), of 
which the major five accounted for nearly 60% of the isolates (Figure 6.1). The 
remaining isolates (n=67) were included in minor PFGE groups (containing four or 
fewer isolates) or had unique profiles and were not considered for further analysis. The 
SID for the classification of the isolates in PFGE clusters was 0.901 (95% confidence 
interval, CI95% 0.887 to 0.916), indicating that the collection analyzed is very diverse. 
A few isolates were initially classified as non-typeable by serotyping because of 
positive agglutination with both types II and III sera when using sera from Denka 
Seiken. Serotyping of these isolates by the capillary precipitation method (using Statens 
Serum Institute sera) and by a latex agglutination assay using Essum Probiotics sera, 
revealed that in all cases the isolates only presented a positive reaction with serotype II 
specific serum. This phenotype was genetically confirmed by RFLP and Southern 
hybridization (the latter excluding the possibility of the strains carrying two capsular 
loci), further confirming that the correct identification was serotype II. With this in 
mind, all isolates previously classified as either serotype II or III using Denka Seiken 
sera were independently confirmed using either of the other sera and conventional 
serotyping methodologies to exclude any possibility of error. We believe these 
observations are the result of cross-reaction between type II and III sera, a possibility 
admitted in the latest literature provided by the manufacturer. This can lead to errors in 
serotyping if not further confirmed by other sera or typing methods. 
In general, serotype was associated with the overall genotype defined by PFGE. 
The Wallace coefficient (W) relating the PFGE clusters with the serotype (W=0.720, 
CI95% 0.666 to 0.775) was high, indicating that isolates grouped in the same PFGE 
cluster frequently also share the same serotype. However, some clusters were found to 
contain isolates with serotypes that were different from the most frequently found 
serotype in the cluster, suggesting that capsular switching could have occurred 
(n=27/463, 5.8%).  Confirmation of the serotype of these isolates using conventional 
serotyping methods revealed in 18 cases that the original serotype was in error. 
However, we did confirm the serotype of nine isolates (n=9/463, 1.9%) that differed 
from the most prevalent serotype in the same PFGE cluster and these cases were further 
studied (Figure 6.1).  
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FIGURE 6.1 Dendrogram analysis of the PFGE profiles of 463 GBS isolates. UPGMA and the Dice 
coefficient (indicated as percentages in the scale above the dendrogram) were used to construct the 
dendrogram. Each PFGE cluster (defined as a group of ≥5 isolates with a Dice coefficient of ≥80% in the 
dendrogram) is represented by a triangle with size proportional to the number of isolates included in the 
cluster. The clusters are identified by capital letters outside each triangle. Putative capsular transformants 
were selected based on exhibiting a serotype different from the dominant serotype of the PFGE cluster. 
M1 and M2 are two sub-lineages of the same cluster, defined at >80% similarity in the dendrogram. 
 
 
 
Every putative transformant was compared to two other isolates in the same 
PFGE cluster having the prevalent serotype of the cluster and PFGE profiles as similar 
as possible (maximum of three different bands). Each set of three isolates (the putative 
transformant and the two isolates used for comparison) was characterized for genes 
distributed across the GBS genome (Figure 6.2) and for confirmation of the genetic 
determinants of the capsular polysaccharide. 
 
 
 
 
 
 
 
 
 
 
 
 
 
MLST, surface protein gene profiling, and pilus-associated gene profiling 
In the nine sets of isolates studied the STs found (Table 6.2) were associated 
with serotypes in agreement with previous observations (17, 21, 25). With no 
exceptions, all isolates were positive for only one alpha or alpha-like protein gene and 
occasionally the isolates were also positive for the β-antigen gene (Table 6.2). None of 
the isolates tested were positive for the alp2 or alp4 genes. The isolates were also tested 
for the presence of the genetic determinants of the pilus-like structures, and all were 
found to contain at least one of the identified islands. The PI-2a variant was present in 
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FIGURE 6.2  
Genome map of S. agalactiae indicating 
loci of interest. Relative positions of 
housekeeping genes characterized in the 
MLST scheme (pheS, atr, tkt, glnA, sdhA, 
glcK and adhP), genes identified for 
surface protein gene profiling (same 
relative position for bca, alp2, alp3, alp4, 
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for pili-island profiling PI-1 and PI-2 
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and the capsular locus region are depicted. 
Numbers inside the circle represent the 
scale in megabases. 
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all isolates, whereas PI-1 was found together with PI-2a in 16 isolates and none were 
positive for the PI-2b variant (Table 6.2).  
 
Sequencing of the conserved regions of the cps locus 
All 55 single nucleotide polymorphisms and one repetitive sequence suitable for 
molecular serotyping in the cpsD-cpsG region described previously (18) were analyzed, 
and a molecular capsular type was assigned to each isolate according to this 
methodology. A similar analysis was done for the neuB-neuA region. The single 
nucleotide polymorphism patterns found were characteristic of the serotype identified 
using conventional immunological techniques for all isolates except strain 312754 in set 
S3 (Table 6.2). 
 
Southern hybridization and capsule gene cluster RFLP analysis 
The Southern blot hybridization methodology used to probe the capsular locus 
aimed at determining if a serotype-specific gene of the cps locus was present in each 
isolate and, if so, its location in the chromosome. This information was essential to 
exclude the possibility of “binary encapsulated” strains (1) or the generation of hybrid 
cps loci that could cross-react with two existing sera. We observed that all isolates 
tested presented only one capsular locus, as hybridization occurred with a single probe 
and in a single chromosomal fragment. We also observed that the positive hybridization 
fragment was of the same size in sets S1 to S5 and S7 to S8 but not for sets S6 and S9 
(Table 6.2).  In the latter cases one of the three different bands in the PFGE profiles of 
the isolates included the fragment with the capsular locus, suggesting a possible link 
between capsular transformation and the differences in PFGE profile.
  
 
TABLE 6.2 Detailed characterization of the putative transformants and other isolates from the same PFGE cluster. 
a  The capsular type compatible with the single nucleotide polymorphisms and insertions found using the methodology described in the text is indicated. 
b
 That is, the size of the fragment in the PFGE profile that presented a positive hybridization signal and the corresponding serotype identified by the  probe (see the text). 
c One fragment different from the characteristic serotype Ia RFLP-profile.
Sequencinga  
Set PFGE profile (cluster) Isolate Serotype 
MLST 
(ST) 
Surface protein 
gene profile cpsD-cpsG neuB-neuA 
RFLP 
cpsG-neuA 
Hybridization 
positive 
fragment (Kb)b 
Hybridization  
Probeb 
Pilus island  
gene profile 
S1 Identical  (G) SH366 II 24 bca II II II 450 II PI-2a 
 
 707618 Ia 24 bca Ia Ia Ia 450 Ia PI-2a 
 
 12631 Ia 24 bca Ia Ia Ia 450 Ia PI-2a 
S2 Identical (I) CN4609 Ia 10 bca + bac Ia Ia Ia 582 Ia PI-1 + PI-2a 
 
 275586 Ib 10 bca + bac Ib Ib Ib 582 Ib PI-1 + PI-2a 
 
 321927 Ib 10 bca + bac Ib Ib Ib 582 Ib PI-1 + PI-2a 
S3 Identical (G) 312754 Ib 24 bca Ia Ia Iac 436.5 Ia PI-2a 
 
 333425 Ia 24 bca Ia Ia Ia 436.5 Ia PI-2a 
 
 401936 Ia 24 bca Ia Ia Ia 436.5 Ia PI-2a 
S4 Identical (M1) 316560 III 295 rib + bac III III III 500 III PI-1 + PI-2a 
 
 768348 II 28 rib + bac II II II 500 II PI-1 + PI-2a 
 
 850409 II 28 rib + bac II II II 500 II PI-1 + PI-2a 
S5 One-band 406301 IV 2 eps IV IV IV 300 IV PI-1 + PI-2a 
 
difference 424176 V 1 alp3 V V V 300 V PI-1 + PI-2a 
 
(B) 345352 V 1 alp3 V V V 300 V PI-1 + PI-2a 
S6 Three-band 351726 IV 2 eps IV IV IV 300 IV PI-1 + PI2a 
 
difference 314460 V 2 eps V V V 339.5 V PI-1 + PI2a 
 
(C) 371990 V 2 eps V V V 339.5 V PI-1 + PI2a 
S7 Three-band 927045 V 23 eps V V V 582 V PI-2a 
 
difference 401207 Ia 23 eps Ia Ia Ia 582 Ia PI-2a 
 
(G) 314927 Ia 23 eps Ia Ia Ia 582 Ia PI-2a 
S8 Three-band 931422 V 19 eps + bac V V V 582 V PI-1 + PI-2a 
  difference 950541 III 19 rib III III III 582 III PI-1 + PI-2a 
 (P) 880372 III 19 rib III III III 582 III PI-1 + PI-2a 
S9 Three-band 2227 III 396 rib III III III 535.5 III PI-1 + PI-2a 
 difference SH436 Ia 24 bca Ia Ia Ia 500 Ia PI-2a 
 (G) 342399 Ia 24 bca Ia Ia Ia 500 Ia PI-2a 
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RFLP of the cps region was concordant with the phenotypically determined 
serotype in all isolates with the exception of isolate 312754 (phenotypically serotype 
Ib), whose pattern was different from the predicted pattern for serotype Ib isolates. In 
fact, the cps RFLP pattern was very similar to the one expected for serotype Ia isolates, 
with the exception of a single fragment (1,135 bp), which was smaller in strain 312754. 
An in silico analysis suggested that this fragment corresponded to the cpsG-cpsH 
region. Sequencing of this region showed two deletions (one of 197 bp and a smaller 
one of 6 bp) in isolate 312754 that generated a smaller fragment (932 bp instead of 
1,135 bp) in the restriction profile. The deletion resulted in the fusion of the cpsG and 
cpsH genes without compromising the reading frame, and leading to the possible 
production of a fusion protein lacking 23 amino acids of the C-terminal region of cpsG, 
9 amino acids of the N-terminal region of cpsH, and 2 amino acids close to the C-
terminal region of cpsH (Figure 6.3). 
 
 
 
 
FIGURE 6.3 Diagram representing the DNA sequence of the cpsG-cpsH region of the capsular locus of 
S. agalactiae serotypes Ia and Ib compared to that of strain 312754. The cpsG and cpsH genes are 
represented by dashed and dotted arrows, respectively. The cpsG-cpsH fusion in strain 312754 is 
predicted to generate a fusion protein since the reading frame is maintained (see the text). The fragments 
with high DNA identity are represented by black boxes, whereas lower identity fragments are represented 
by lighter shades of gray. Similar fragments are connected by lines. 
 
 
 
 
 
 
 
 
Ia 
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Discussion 
Clonal structure of the S. agalactiae population 
PFGE analysis showed a diverse population of GBS isolates with 16 different 
PFGE clusters identified (Figure 6.1). Such diversity is in agreement with the isolates 
being collected from multiple sources, in different years and age groups and associated 
with different severity of infections and colonization. Nevertheless, we observed that 
most isolates were grouped in clusters sharing the same serotype, implying an 
association between the serotype and the PFGE-based genotypes reflected in a high 
value of the Wallace coefficient and this coefficient would be even higher if we 
excluded non-typeable isolates (W=0.838, CI95% 0.804 to 0.872). Non-typeable isolates 
frequently produce small amounts of capsule polysaccharide that easily revert to fully 
encapsulated variants (36) or result from mutations or from the insertion of mobile 
genetic elements in the cps locus, leading to absent or reduced expression of the capsule 
polysaccharide due to loss of function of the proteins involved in its biosynthesis (33). 
Thus non-typeable isolates probably do not represent capsular switching events but 
carry cps loci very similar to those of other isolates in the same PFGE cluster. 
Therefore, their inclusion in the calculation of the Wallace coefficients leads to an 
artificial underestimation of the concordance between the classification in PFGE 
clusters and serotype. 
Still, in certain PFGE clusters, the presence of isolates whose serotype is 
different from the prevalent serotype in the cluster, but having similar PFGE profiles, 
suggested that capsular switching by horizontal gene transfer of the capsular genes 
could have recently occurred. The number of putative capsular transformant isolates in 
the present study was much larger than when we first analyzed the PFGE profiles 
(5.8%), and this value was in line with previous studies that addressed this issue (21). 
However, only nine isolates (2% of the total isolates) could be confirmed by a second 
round of traditional serotyping using different methods and sera. This significant 
decrease in putative capsule switching events can be explained by the fact that 
serotyping using phenotypic methods is particularly prone to errors due to user-
dependent evaluation of an agglutination reaction that relies heavily on the experience 
of the user. On the other hand, the specificity of the polyclonal sera used may also be an 
issue in particular situations, as discussed previously. In fact, a validation study to 
evaluate the quality of serotyping of S. pneumoniae, another species of the 
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Streptococcus genus, in European reference laboratories identified a 5% error rate (20). 
Similarly, our data argue that serotyping errors in S. agalactiae may be frequent and 
contribute significantly to overestimate capsular switching events in this species. 
However, studies using capsular genotyping, and therefore not subjected to these errors, 
have also found evidence of capsular switching (32). 
We used the classification in PFGE clusters as the main screening method to 
identify putative transformation events. To further identify recent capsular switching 
events, we characterized isolates with no more than three different bands in their PFGE 
profiles, which could result from a single genetic event meaning that the isolates are 
very closely related (42). For capsular switching to have occurred recently, the isolate 
with an unusual serotype must have been identical to other isolates of the same bacterial 
clone, all sharing the same genotype as defined by MLST, surface protein and pili 
island gene profile. 
 
Capsular switching 
Table 6.2 summarizes the characterization of the nine isolates identified as 
potentially resulting from capsular switching. Whereas some of the isolates had exactly 
the same genotype as the isolates they were being compared to (sets S1 and S2), other 
capsular transformants were found having different genotypic properties compared to 
additional isolates in the same PFGE cluster (sets S3 to S9). Sets S1 and S2 provide 
strong evidence for recent capsular switching since in these cases the potential 
transformants share the same genotype as defined by PFGE, sequence type, surface 
protein gene and pilus island gene profile as the comparator isolates, with the only 
difference residing in the capsular locus. 
Initially, we considered the possibility that SH366 had acquired only the type II-
specific genes cpsG-cpsK, as proposed in the literature (9, 22), and so the capsular locus 
of the putative transformant would be expected to be a hybrid between the recipient and 
the donor cps loci. For instance, strain SH366 was expected to exhibit features of both 
serotype II (recently acquired central genes cpsG-cpsK) and Ia (conserved regions of the 
operon cpsA-cpsF and cpsL-neuA). If that were so, we should find the type Ia-specific 
polymorphisms when sequencing the conserved regions of SH366 capsular locus. This 
was not the case, and the entire capsular locus of SH366 was consistent with the type II 
capsule. These observations led us to conclude that SH366 had acquired the entire 
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capsular locus coding for the type II capsule and that the recombination breakpoints are 
located outside of the capsular locus. An in silico analysis of the published GBS 
genomes showed that the regions flanking the capsular locus are extremely conserved 
among S. agalactiae isolates (data not shown); therefore, homologous recombination in 
these regions is possible independently of the overall genetic background of the isolates. 
Moreover, recent data describes the region surrounding the capsular locus as showing 
evidence of a high density of recombination events corroborating our data, while 
identifying the transfer of DNA fragments as large as 334 Kb (5). The sequence type of 
SH366 (ST24) is almost exclusively found among serotype Ia isolates (16, 21), with a 
high prevalence in Portugal (25), and accounts for one of two main lineages of serotype 
Ia (unpublished data). A similar situation was found in set S2, with strain CN4609 
possessing a cps locus entirely consistent with serotype Ia but found in a PFGE cluster 
of serotype Ib isolates, indicating the acquisition of a large chromosomal fragment 
encompassing the entire cps locus (Table 6.2). CN4609 is a representative of ST10, 
frequently found among serotype Ib isolates but previously not described in serotype Ia 
isolates (16, 21, 25), further supporting its identification as a capsular transformant. 
Taken together, these findings provide evidence of recent capsular switching events in 
SH366 and CN4609. 
In set S3, we found that strain 312754 (phenotypically identified as serotype Ib) 
presented two deletions in a cps locus that was closely related to that of serotype Ia 
(Figure 6.3). These deletions result in the loss of 23 amino acids in the cpsG gene 
product, a β-1,4-galactosyltransferase, and of 11 amino acids in the cpsH gene product, 
the capsular polymerase, with the consequent production of a 505 amino acid fusion 
protein. Nuclear magnetic resonance studies showed that the types Ia and Ib 
polysaccharides have an identical composition and differ only in the glycosidic bond of 
the galactose residue to the N-acetylglucosamine in the lateral chain – type Ia 
polysaccharide has a β(1→4) bond and type Ib polysaccharide a β(1→3) – and these 
bonds are critical for the immune specificity of both polysaccharides (15). The 
characterization of the genes that compose the capsular locus of type Ia attributed to 
each gene a specific role in assembling the capsular polysaccharide (44). The two β-1,4-
galactosyltransferases identified were encoded in the cpsG and cpsJ genes, responsible 
for the glucose-galactose bond in the polysaccharide backbone and the galactose-N-
acetylglucosamine bond of the lateral chain, respectively (44). Since this last bond is the 
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only difference between type Ia and Ib capsules, and considering that the cpsJ gene is 
not altered in 312754, it would be expectable that, in this isolate, the merging of cpsG 
and cpsH genes would result in the production of an Ia or Ia-like capsular 
polysaccharide. However, the data presented here seems to argue that cpsG would be 
responsible for the β-(1→4)-galactose-N-acetylglucosamine bond. The cps locus of 
strain 312754 is therefore closely related to that of serotype Ia isolates (Figure 6.3) not 
being clear, in the light of previous knowledge, how the deletions described above 
justify the expression of a type Ib capsule. Discrepant results between phenotypic 
serotyping and the capsular locus were described previously for a GBS isolate (19), but 
no detailed study of its capsular locus was performed. It is also possible that the 
capsular polysaccharide expressed by strain 312754 is biochemically different from 
both type Ia and Ib capsules but is somehow recognizable by the Ib polyclonal serum 
used in conventional serotyping; however, a detailed characterization of this 
polysaccharide is outside the scope of the present study. 
In sets S4-S9 the isolates express a serotype that is unique in the cluster and 
show different genetic features when compared to other isolates of the same PFGE 
cluster. These differences are shown in Table 6.2 and include MLST sequence type (sets 
S4, S5 and S9), PFGE profile (sets S5 to S9), surface protein gene profile (sets S5, S8 
and S9) and the presence of the pilus islands-associated genes (set S9). All the markers 
used to evaluate the genetic background of the isolates are distributed in an arrangement 
conserved across serotypes and spread throughout the GBS genome (Figure 6.2), 
assuring that if horizontal gene transfer occurs these should be independently 
transferred among isolates providing a good measure of the genetic background against 
which to detect capsular transformation. 
In set S4 the isolates have different sequence types (STs) and share the 
remaining features tested. ST295 and ST28 belong to the same clonal complex (CC19) 
and are double-locus variants, presenting different alleles for the genes adhP and glnA. 
Since the distance between these genes is more than 400 Kb (Figure 6.2) and each is 
even further distant from the capsular locus, it is unlikely that the event driving capsule 
switching and the acquisition of the two alleles occurred simultaneously.  This implies 
that at least three independent genetic events occurred between the putative 
transformant and its ancestors. 
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In set S5 the putative capsular transformant and the representatives of the cluster 
show differences in the PFGE profile, the MLST profile, and surface protein gene 
profile. ST1 and ST2 are single-locus variants in the same clonal complex (CC19) and 
differ only in the atr allele. The eps and alp3 genes code for epsilon and alpha-like 3 
proteins, respectively; both are members of the alpha-like surface protein family and 
mutually exclusive that have been mapped to the same genomic location. Considering 
that the surface protein and the atr gene are ~ 64 Kb apart, both of these genes could be 
transferred among isolates in the same DNA fragment. In this case, a minimum of two 
independent genetic events would have to be invoked to explain the differences 
observed, between the putative transformant and its ancestors. 
Sets S6 and S7 include isolates that share all the characteristics tested with the 
exception of the PFGE profile, that differs in three bands between the putative capsular 
transformants and the representatives of the PFGE cluster where they were found. In set 
S6 some of the detected differences in the PFGE profile involve the fragment where the 
cps locus is found, as demonstrated by Southern hybridization, suggesting that the 
capsular switching itself could be linked to the changes in the PFGE profile. A single 
genetic event, involving recombination of a large DNA fragment, could result in both 
capsular switching and a different PFGE profile. This hypothesis is supported by the 
successful incorporation of DNA fragments up to 334 Kb in S. agalactiae (5). In set S7 
the changes in the PFGE profile of the putative transformant do not involve the 
fragment containing the capsular locus, not suggesting a direct link between the changes 
in PFGE profile and cps locus, although this cannot also be formally excluded. 
In set S8 the isolates differ in their PFGE profiles by three bands and in the 
surface protein gene profiles. Again since the genomic locations for the eps or rib genes 
and the bac gene are more than 350 Kb apart and even more distant from the capsular 
locus, all of these genes should be independently transferred among the isolates. Any of 
these genetic events could also give rise to the differences observed in the PFGE 
profiles, but a minimum of three independent recombination events would still be 
needed to explain the differences between the isolates. 
Finally, set S9 comprises isolates showing very different genetic properties and 
thus unlikely to be closely related. These differences include the PFGE profile, all seven 
MLST alleles, surface protein, and the pilus island gene profiles. The grouping of these 
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isolates by PFGE seems to have been spurious, and all other evidence argues against 
capsular transformation. 
Capsular switching is thought to contribute to the rise of new serotype-genotype 
combinations, allowing evasion of immune pressure. However, the success of these new 
variants is possibly restrained by interactions between the new capsule and the original 
properties of the isolate. If immune pressure were an overwhelming selective force, we 
would expect to see the expansion of these capsule switching sub-lineages. We did 
detect in our sample a PFGE cluster that contains two sub-lineages, identified as such 
by PFGE (i.e., defined as two independent groups of isolates related at >80% similarity 
in the dendrogram), presenting different serotypes, STs, and surface proteins, 
suggesting the existence of stable related lineages (Figures 6.1 and 6.3, PFGE cluster 
M). However, after confirmation of the initial serotyping results, we found only nine 
isolates that met our initial criteria and, upon more detailed analysis, only a fraction of 
these could result from recent capsular switching events. This could be due to either a 
small rate of capsular transformation, the clearing of these variants from the population 
or a combination of both. The stability of several GBS clones, such as the hypervirulent 
ST17 clone found among serotype III isolates that is characterized by a specific 
combination of genetic markers including mobile genetic elements and virulence genes, 
that are part of the variable genome and thus not shared by all GBS (2, 4, 21), suggests 
that the rate of gene exchange in this species may be lower than that of other 
streptococci. In fact, the PFGE analysis of collections of S. agalactiae isolates shows 
fewer clones than in other streptococcal species, such as Streptococcus pyogenes (14) 
and S. pneumoniae (37), consistent with a less diverse clonal structure of the population. 
On the other hand, genomic analysis of eight fully sequenced strains of S. agalactiae, 
provided evidence for the exchange of large chromosomal fragments, hinting at a high 
rate of gene exchange through an unusual mechanism (5). 
The analysis presented here used several loci and took into account both the core 
and variable portions of the genome when analyzing GBS isolates. This approach is 
expected to allow us to identify changes in the genomic background of the 
transformants with high resolution, enabling the identification of recent capsular 
switching events. Our data suggest that serotyping errors may account for a significant 
proportion of putative capsular transformation events described previously, reinforcing 
the importance of different methods and sera or a genetic approach in confirming all 
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putative transformation events. Our analysis also provided unambiguous evidence for 
the existence of capsular transformation in GBS and indicated that the exchange of the 
entire capsular locus is more widespread than switching restricted to capsule-specific 
genes. Taken together, our data support the existence of capsular switching in GBS but 
at a lower frequency than previously suggested. 
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Group B streptococcus (GBS) is primarily a colonizing agent of the 
genitourinary and gastrointestinal tracts, yet it has long been recognized as an important 
agent of invasive disease in neonates. Implementation of screening guidelines and 
effective intrapartum antimicrobial prophylaxis (IAP) have contributed to significantly 
reduce neonatal infections in the early-onset period; however late-onset infections 
mostly remained unchanged. In Portugal, nearly all hospitals are now expected to 
follow the recommendations for prevention of perinatal GBS infections from the 
Portuguese Society of Paediatrics (2), even though no information has been issued from 
official health authorities about the implementation and effectiveness of these measures. 
Therefore, follow-up on GBS infections has been made mostly at the hospital level; 
aside from one study based on national voluntary reporting of neonatal infections (16). 
A first study addressing the prevalence of capsular types and antimicrobial 
susceptibility patterns in the largest Lisbon hospital (8), was available at the beginning 
of the studies included in this thesis, but in fact very little was known on the 
epidemiology of GBS infections in Portugal, and even less on the molecular properties 
of the isolates.  
This lack of information substantiated the importance - and main purpose of this 
thesis - that of the epidemiological characterization of the GBS isolates causing 
neonatal infections in Portugal, as well as of those responsible for an increasing number 
of invasive infections in non-pregnant adults. The availability of new molecular typing 
techniques, alongside the classical phenotypic methods contributed to the improved 
characterization of GBS populations. The analysis of the data provided by these studies 
helped determining the main GBS lineages circulating in Portugal, and put them in the 
context of the worldwide GBS population causing infections in humans, hopefully 
bringing novel insights into the population dynamics of this pathogen. 
 
GBS epidemiology in Portugal 
Overall, the GBS isolates recovered from colonization in pregnant women as 
well as those causing invasive disease in Portugal were very diverse, some having the 
capacity of occupying multiple niches and found asymptomatically colonizing the 
vagina and rectum as well as causing mild to severe infections in neonates and adults. 
While the wide range of serotype-genotype combinations found in the studies presented 
in this thesis corroborates this diversity, it is apparent that simultaneously a clonal 
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structure can be found among the GBS isolates in Portugal, since specific lineages are 
not only more frequent in the population but are also more likely to cause invasive 
infections or to be associated with particular age groups. Still the GBS diversity was not 
constant in all age groups. 
The multiplicity of genetic lineages observed in non-pregnant adults was higher 
than that found among invasive isolates from neonates, which presented with a 
substantially more clonal genetic structure. 
Accordingly, GBS invasive infections in non-pregnant adults had a broader 
spectrum of disease presentation and were more frequent in the elderly, reflecting the 
possible impact of risk factors that increase with age, such as co-morbidities and 
immune senescence. In addition, men were found to have a higher susceptibility for 
GBS disease, regardless of age. Yet the reasons behind the sex imbalance remain to be 
clarified. 
 
Serotype distribution  
As seen in most countries, even though nearly all serotypes are able to both 
colonize and cause invasive disease, the prevalence of the GBS serotypes was different 
according to disease presentation and age groups (Figure 7.1).  
 
 
FIGURE 7.1 Relative prevalence of GBS serotypes among colonizing and invasive isolates in different 
age groups in Portugal. Colonization (pregnant women), EOD (0-6 days), LOD (7-90 days), Adults (18-
64 years), Elderly (>64 years). Adapted from Chapters 2 and 5. 
 
0 
10 
20 
30 
40 
50 
60 
70 
III 
V 
II 
Ia 
 
NT 
 
Ib 
VII 
VI 
 
IV 
Colonization EOD LOD Adults Elderly 
% 
   Concluding Remarks 
165 
The comparison of the prevalence of serotypes in different human populations 
revealed some interesting findings. First, maternal colonization includes a wide range of 
serotypes, with capsular types III and V being more frequent but immediately followed 
by serotypes II and Ia. Considering that vertical transmission accounts for the majority 
of neonatal disease cases, particularly during the early-onset period, our data is in 
agreement with a maternal source of infection, with the leading serotypes colonizing 
pregnant women also being responsible for most EOD cases. Also worth mentioning is 
importance of serotype Ia among neonatal infections, that in Portugal was found to be 
associated to EOD. Among the GBS isolates recovered from LOD, serotype III was 
overwhelmingly predominant, similarly to what has been described elsewhere (15). It 
accounted for nearly two thirds of the isolates recovered in the late-onset period, and 
was frequently found in the cases of meningitis. 
While maternal GBS carriage is a prerequisite for EOD, the source for disease 
among adults is poorly understood, possibly reflecting asymptomatic colonization (20). 
Among the adult populations the distribution of the GBS serotypes was again different 
and more varied than that from neonatal invasive disease, which is consistent with a 
more diverse spectrum of disease presentations and frequent underlying medical 
conditions found in these patients. Nevertheless, serotype Ia was dominant, particularly 
among younger adults (18-64 years old), and these results reflect a geographical 
specificity, in which Portugal is clearly different from other European countries and the 
United States, where serotype V prevails among invasive infections in younger and 
elderly adults (13, 21). The reasons behind the higher prevalence of serotype Ia in these 
age groups in Portugal remain unclear, but the genetic lineages responsible for these 
infections are the same that cause invasive disease in neonates.  
Finally, other relevant information that can be drawn from Figure 7.1 is the 
number of non-typeable (NT) isolates, particularly high in the colonizing isolates and 
increasing with age among the adults. The polysaccharide capsule of GBS is an 
important virulence factor that contributes to the bacterial evasion of the innate immune 
system of the host. Consequently, the majority of the strains causing invasive infections, 
particularly in newborns, are encapsulated. The data in Figure 7.1 are consistent with 
previously reported higher prevalence of NT isolates among colonized women 
compared to neonates (7), and further supported by the low invasive disease potential 
described for the NT isolates among neonates in Portugal. The prevalence of NT 
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isolates in pregnant women as compared to the neonates suggests that these isolates are 
maybe less fit to cause disease, and the possibility exists that these isolates remain as 
colonizers throughout the adult life, thereby explaining their higher prevalence in 
infections in adults. Furthermore, it has been speculated that capsule expression may be 
regulated in response to host environment, and that non capsulated isolates can more 
easily adhere to epithelial cells, because the capsule hinders the interaction of bacterial 
surface factors with the epithelial cell receptors (17).  
In adults, particularly the elderly, it is possible that a colonization 
microenvironment particularly selects for less capsule production, thus favoring 
persistence of non-typeable GBS (18), yet it is unclear if colonization is the reservoir for 
GBS infections in adults. The diversity of underlying conditions that result from the 
natural ageing process, together with the immune senescence of the hosts, probably 
provide GBS with more opportunities to cause invasive disease regardless of the 
bacterial genetic background, including the lack of a polysaccharide capsule that is 
believed to be a major virulence factor. 
 
GBS genetic lineages 
While many studies concerning the clonal composition of the GBS population 
have identified the more significant serotypes and genetic lineages associated to 
invasive disease, still differences have been found in different countries reflecting a 
perhaps slower but dynamic nature of this pathogen, and further supporting continuous 
surveillance.  
Some major genetic lineages have been detailed in recent years, as result of the 
combinations of phenotypic methods with multiple genotyping systems. In the studies 
described in this thesis, the main lineages associated with invasive infections in 
newborns and adults were described, and found mostly to be in agreement with those 
circulating in other countries. However, additional data presented here highlight the 
importance of local dynamics, indicating that genetic evolution of GBS presents with a 
geographic structure and may depend on local factors. 
Among neonates, two main genetic lineages were responsible for invasive 
infections. In EOD cases, serotype Ia isolates were more prevalent, grouping together in 
a major PFGE cluster constituted by two genetic sub-lineages represented by ST23 and 
ST24. While ST23 is recognized as the main genetic lineage of serotype Ia, ST24 has 
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been rarely found elsewhere and an unusually high proportion of this lineage was first 
reported in the study. Among the LOD cases, serotype III was prominent. Since the 
availability of an MLST scheme for GBS, the serotype III genetic lineage ST17 has 
been described worldwide under the designation of hypervirulent clone, and associated 
to an increased capacity of causing neonatal invasive disease (12). The GBS isolates 
recovered in Portugal were no exception, mostly belonging to this genetic lineage, but 
were significantly associated with both EOD and LOD.  
Chapter 3 includes the analysis of a large collection of GBS isolates recovered 
from neonatal invasive infections in Barcelona, Spain. It represented an interesting 
study in the context of this thesis due to the opportunity to perform, under the same 
molecular typing methodology, the characterization of the a large number of invasive 
GBS isolates circulating in another geographic location, that still had enough proximity 
to eventually present analogous results.  
Indeed, the clonal structure and diversity of genetic lineages found in Barcelona 
was similar to those of Portugal, validating the comparative analysis of both studies. In 
the investigation of the GBS isolates from Barcelona, the same two major genetic 
lineages were identified among neonatal isolates; again an association between III/ST17 
and LOD and a significant proportion of serotype Ia isolates represented by ST23 and 
ST24. The main discrepancies concerned the associations between the genetic lineages 
and disease presentation, in Barcelona Ia/ST23/ST24 was not overrepresented among 
EOD and III/ST17 was only associated to LOD and not both types of disease onset. 
These differences are probably due to the methodological differences between the two 
studies (no colonizing isolates were available from Barcelona) and eventually to the 
smaller number of GBS isolates recovered in Portugal.  
Furthermore, in the serotype Ia sub-lineages, a complete association was found 
between the MLST-based sequence types and surface protein genes, with all ST23 
isolates carrying the eps gene and all ST24 isolates exclusively the bca gene, further 
discriminating both lineages. While supporting for the circulation of both sub-lineages 
in Portugal, these results also suggest that the presence of a particular Alp family 
surface protein gene is rather a clonal property than a feature of the serotype. 
 
The case report analysis of two clinical cases of meningitis in adults in Portugal 
(Chapter 4) was not part of the initial work plan composing this thesis, but rather posed 
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as an interesting opportunity to identify a possible community outbreak of GBS disease. 
The detailed investigation of the isolates responsible for these meningitis cases revealed 
a similar genetic background for the isolates as defined by their identical serotype Ib, 
PFGE profiles, ST10 and later determined surface protein gene bca. These data 
supported a common source for the GBS isolates, emphasized by the temporal and 
geographical clustering of the cases. However, despite the efforts from the Portuguese 
public health authorities, also involved in this investigation to identify the source of the 
isolates, no such result was achieved. The virulence of the bacterial strain causing these 
infections, suggested by the death of one of the patients and significant morbidity in the 
other case, in spite of appropriate diagnosis and antimicrobial therapy, reinforce the 
importance of surveillance while raising questions as to the possibility of community 
outbreaks of GBS infections of unknown sources. 
 
Chapter 5 comprised the study of the GBS isolates causing invasive disease 
among adult and elderly populations in Portugal, in which a more diverse array of 
genetic lineages were found. As opposed to the United States and most European 
countries where serotype V prevails among invasive infections in non-pregnant adults, 
in Portugal it accounted for less than 20% of the GBS isolates, and was nearly as 
frequent as serotype III. While no particular lineages of serotype III were evidenced, 
serotype V was mostly associated to two genetic lineages represented by ST1/alp3 and 
the infrequent ST2/eps. Additionally, the distinction of the serotype II genetic lineage 
ST28/rib was also proposed in this study, and suggested to have a possible tropism for 
joint infections, considering its overrepresentation among the isolates recovered from 
synovial fluid. 
Once more, a major difference between the Portuguese and other studies was the 
PFGE cluster including most serotype Ia isolates, and represented by ST23/eps and 
ST24/bca, further confirming the high prevalence of the later in Portugal. Nevertheless, 
among the serotype Ia isolates, a new lineage was found in a different PFGE cluster, 
that grouped together a set of isolates characterized by Ia/ST8/bca and serotype Ib/ST10 
and related STs all presenting the surface protein gene bca. Interestingly, ST8 had 
already been identified, but in that instance among serotype Ib isolates, in the analysis 
of the two cases of meningitis in adults (Chapter 4). Considering that ST8 and 
ST23/ST24 are unrelated STs, and that this lineage was not found in previous studies, in 
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which serotype Ia isolates presented a remarkable clonal structure in terms of the 
genetic lineages defined by both PFGE and MLST, these data suggest that this lineage 
is the result of relatively recent capsular switching events. The new serotype-genotype 
combination has probably an adaptive advantage at causing invasive infections in 
adults, and this could explain why the Ia/ST8/bca lineage was not associated with 
vaginal colonization or neonatal infections. 
Considering the results from the characterization of the GBS isolates in all age 
groups, a major finding of these studies is the geographical expansion of the 
Ia/ST24/bca sub-lineage in Portugal, further strengthened by the investigation 
performed with the Barcelona isolates, and another report from Italy (10) that suggest a 
Mediterranean dissemination.  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
FIGURE 7.2 Representative diagram of goeBURST group 2, including all isolates recovered from 
colonization and invasive disease in neonates (Chapters 2 and 3) and adults (Chapter 5). Light blue circles 
indicate STs that are not present in the collection analyzed, light brown STs are sub-founders identified 
has having more than three connections in the goeBURST diagram. The size of the circles (except the 
light blue and light brown) is proportional to the number of isolates (in a logarithmic scale). Figure 
prepared using the PHYLOVIZ software (http://goeBURST.phyloviz.net). 
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FIGURE 7.2 (continued)  
 
 
The nearly exclusive association of ST23 and eps, and of ST24 and bca, and the 
very small number of isolates with other capsular types presenting these and related STs 
(Figure 7.2), argue for a contemporary clonal expansion of a specific sub-lineage within 
some geographical boundaries.  
While the diversification of GBS populations is ongoing, continued monitoring 
of the genetic lineages responsible for GBS infections in the near future may yield 
important information for the comprehension of the population dynamics of this 
pathogen. 
 
Antimicrobial resistance 
Serotype V has long been recognized as the most frequent serotype causing 
invasive infections in non-pregnant adults in the United States and most European 
countries, to which the genetic lineage ST1/alp3 has added importance due to its 
association to macrolide resistance (19). In Portugal, erythromycin resistance was also 
more frequently among serotype V isolates, still only 40% of erythromycin resistance 
was found in this serotype, while the remaining was dispersed in most other serotypes. 
In fact, erythromycin resistance presented as a clonal property of V/ST1/alp3 instead of 
a specific feature of serotype V. The identification of another lineage of serotype V, 
ST2/eps, fully susceptible to several antimicrobials, including tetracycline, to which 
   Concluding Remarks 
171 
GBS is nearly ubiquitously resistant, may have contributed for this clonal asymmetry of 
macrolide resistance in serotype V. In Barcelona, erythromycin resistance was 
associated to serotype V (30% of resistant isolates) but also distributed in various 
serotypes. The fact that among the neonates only the lineage V/ST1/alp3 was found, but 
not the susceptible V/ST2/eps, may indicate a strong host age-dependence of this 
lineage’s ability to cause invasive disease. 
Another particular finding in the study from non-pregnant adults in Portugal was 
the high number of isolates carrying the erm(TR) macrolide resistance gene, as opposed 
to a previous report from Portugal (8), and to the study of neonatal infections from 
Barcelona, in which macrolide resistance was more frequently determined by the 
erm(B) gene. Also, most reports from other countries are generally in agreement as to 
the dominance of erm(B) gene among erythromycin resistant isolates (4, 9, 11), so again 
local factors can be contributing to the spread of particular resistance determinants. 
Moreover, although all neonatal isolates presented the cMLSB phenotype, among adults 
erythromycin resistance was similarly distributed among the cMLSB and iMLSB 
phenotypes, while in previous studies from Portugal and other countries the cMLSB 
phenotype was much more prevalent than the iMLSB (4, 8, 9).  
An origin for the spread of this resistance gene cannot be determined by a 
comparison of this and the previous Portuguese study (8), comprising invasive, non-
invasive and colonizing isolates. If on one hand, the spread of the erm genes throughout 
most serotypes and clusters suggests a multiclonal dissemination of resistance, on the 
other hand the association between erythromycin resistance and particular genetic 
lineages (such as the V/ST1/alp3) supports a clonal expansion model of resistance. 
Nevertheless, considering the general consensus on the predominance of this genetic 
lineage in macrolide resistant isolates, yet carrying either the erm(B) or erm(TR) genes, 
it is possible that they constitute two sub-lineages that are not discriminated by the 
typing methods currently used to characterize these isolates. It is possible that the 
horizontal gene transfer of the erm(TR) gene into a genetic lineage previously carrying 
the erm(B) gene could have been advantageous for the isolates causing invasive disease 
among adults in Portugal, leading to their expansion and explaining the variations 
observed within the same geographic region. 
Macrolide resistance rates in Portugal are not showing significant increasing 
trends, despite a supposed increment in macrolide use following the introduction of IAP 
Chapter 7    
172 
in recent years. Continuous surveillance of macrolide resistance will help clarify the 
mechanisms by which the dissemination of resistance occurs in GBS, and to which 
extent it depends on local genetic lineages.  
The genetic determinants responsible for tetracycline resistance were assessed 
among the GBS recovered from non-pregnant adults in Portugal and, as frequently 
reported elsewhere, tetracycline resistance was mostly mediated by the tet(M) gene. 
This gene was present in all serotypes and major PFGE and MLST-based genetic 
lineages, in agreement with a multiclonal dissemination of resistance. It was also found 
together with the erythromycin resistance erm(B), erm(TR) and mef(E) genes, however 
not all erythromycin resistant isolates were simultaneously resistant to tetracycline, not 
being apparent the association between particular erm and tet genes, already shown to 
be carried by the same transposons in GBS (19). Interestingly, the few isolates carrying 
the tet(O) gene, frequently associated to bovine strains (6), were mostly clustered in a 
single PFGE cluster including different serotypes, proposing a clonal spread for this 
genetic determinant. 
 
Capsular switching 
Typing methods are now widely used to discriminate large collections of isolates 
based on their phenotypic and genotypic characteristics, in order to determine the 
genetic relationships between strains. However, the congruence between the different 
typing methods has proved challenging in face of the diversity of phenotype-genotype 
combinations found among GBS isolates. Comparative genomics of GBS introduced the 
concept of a “pan-genome” including a regulatory core genome, plus a variable genome 
consisting mostly of strain-specific genes, with abundant mobile and foreign elements, 
supporting the hypothesis that the majority of GBS specific traits depend on intra- and 
inter-species lateral gene transfer. Furthermore, the serotype-independent clustering of 
strains provided crucial evidence for capsular switching within this species as strains 
could share the same capsular type regardless of their genetic background (22).  
The genetic heterogeneity found among GBS strains, even of the same serotype, 
proposed that the evolution of GBS is ongoing, particularly within the genes encoding 
virulence factors, including the capsular polysaccharide, due to recombination events 
leading to gene replacement or allelic exchange (3).  
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In the epidemiological studies, the absence of a complete correlation between 
serotypes and genetic the lineages defined by PFGE and MLST supported the 
hypothesis above mentioned, suggesting that capsular switching events could provide 
the explanation for the discrepancies found (5, 14). The study describe in chapter 6 
benefits from previous investigations of large collections of GBS isolates performed in 
Portugal, in which similar inconsistencies in the relation of serotypes and genotypes 
were found. This study provided unequivocal evidence for the existence of capsular 
switching in GBS. These are, however, rare events; and their high frequency postulated 
previously was probably due to an overestimation resulting from serotyping errors. The 
proposed mechanism for capsular switching was by horizontal gene transfer of the 
whole capsular locus instead of the earlier suggested genetic transfer of only the 
serotype-specific genes. 
 
Vaccines 
Development of a universal vaccine is the most promising approach to the 
prevention of GBS infections, given the potential adverse effects of IAP, as well as the 
need for effective prevention of LOD and invasive disease in non-pregnant adults.  
In the Portugal, a CPS-based vaccine against serotypes Ia, Ib, II, III, and V could 
potentially offer protection to 80-95% of the population including neonates, pregnant 
women and non-pregnant adults; however, the problem remains of pathogenic serotypes 
that are more prevalent in other parts of the world. Furthermore, NT isolates account for 
significant numbers among maternal colonization and invasive isolates in non-pregnant 
adults, and would not be covered by a polysaccharide-based vaccine formulation. The 
introduction of such a vaccine could also lead to serotype replacement as observed in S. 
pneumoniae (1), with the expansion of infrequent serotypes not included in the vaccine 
following a decrease in the infections caused by vaccine serotypes.  
Finally, it is possible that vaccination will provide selective pressure for virulent 
genotypes to switch capsules and escape vaccine induced immunity. The work 
presented in this thesis identified capsular switching events in GBS, yet proposing for 
their rare occurrence. The selective pressure imposed by a vaccine could amplify these 
events in natural populations of GBS. 
GBS surface structures other than the capsule hold promise as vaccine 
components by overcoming serotype-specificity and efficiently preventing infections. In 
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recent years, both capsule-protein conjugated and pilus-based vaccines have been 
developed, raising the possibility of prevention of both adult and perinatal disease. 
However, the PI-2a variant has been investigated in detriment of neonatally-associated 
PI-2b, and conjugate multivalent vaccines remain vague, therefore, a universal vaccine 
that could prevent all GBS disease is still elusive.  
 
Considering that colonization is a pre-requisite for disease, and that GBS usually 
resides as a commensal microorganism, asymptomatically colonizing the human host in 
either a transient, intermittent or persistent way, it is crucial to extend our knowledge on 
the natural reservoirs of GBS, particularly those of the isolates causing invasive disease 
in the neonatal late-onset period and among adults, for the appropriate management of 
the GBS infections. 
The studies presented in this thesis provided new insights into the population 
structure of GBS, emphasizing the diversity of the genetic background among different 
clinical conditions and age groups. Evidence was provided for the important role of 
recombination as a mechanism of genetic diversification in GBS. These findings, while 
contributing to a better knowledge of the global epidemiology of GBS, highlighted the 
importance of ongoing selection and local expansion of specific GBS clones, with 
significant impact on the dissemination of antimicrobial resistance or the spread of 
invasive clones into the community.  
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